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Abstract  
 
S-Adenosylmethionine (SAMe) is the principal methyl donor of the cell and is 
synthesized via an ATP-driven process by methionine adenosyltransferase (MAT) 
enzymes. It is tightly linked with cell proliferation in liver and colon cancer. In humans, 
there are three genes, MAT1A, MAT2A and MAT2B, which encode MAT enzymes. 
MAT2A and MAT2B transcribe MATα2 and MATβ enzyme subunits, respectively, with 
catalytic and regulatory roles. The MATα2β complex is expressed in nearly all tissues 
and is thought to be essential in providing the necessary SAMe flux for methylation of 
DNA and various proteins including histones. In human hepatocellular carcinoma 
MAT2A and MAT2B genes are upregulated, highlighting the importance of the MATα2β 
complex in liver disease. The individual subunits have been structurally characterized but 
the nature of the complex has remained elusive despite its existence having been 
postulated for more than 20 years and the observation that MATβ is often co-localized 
with MATα2. Though SAMe can be produced by MAT(α2)4 alone, this thesis shows that 
the kcat of the MATα2β complex is three- to four fold higher depending on the variants of 
MAT that participate in complex formation. Using X-ray crystallography and solution X-
ray scattering, the first structures are provided of this 258 kDa functional complex both 
in crystals and solution with an unexpected stoichiometry of 4α2 and 2βV2 subunits. It is 
demonstrated that the N-terminal regulates the activity of the complex and it is shown 
that complex formation takes place surprisingly via the C-terminal of MATβV2 that 
buries itself in a tunnel created at the interface of the MAT(α2)2. The structural data 
suggest a unique mechanism of regulation and provide a gateway for structure-based drug 
design in anticancer therapies. 
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Crystal structures of human MATα2 containing various bound ligands providing a 
‘structural movie’ of the catalytic steps are also presented. High to atomic-resolution 
structures reveal the structural elements of the enzyme involved in the utilization of 
substrates, methionine and adenosine, and the formation of the product SAMe.  MAT 
enzymes are also able to produce S-adenosylethionine (SAE) from substrate ethionine. 
Ethionine, an S-ethyl analogue of the amino acid methionine, is known to induce steatosis 
and pancreatitis. It is shown here that S-adenosylethionine occupies the active site in a 
manner similar to SAMe, confirming that ethionine also binds and utilizes the same 
catalytic site to form the product SAE. Through by gel filtration and small angle x-ray 
scattering (SAXS) it is shown that the catalytic MAT enzymes exist in multiple 
oligomeric populations in solution, whilst the regulatory MAT subunit, MATβ, is 
monomeric. In view of these data and recent crystallographic structures of the MAT 
enzyme complex, a rationalization of nomenclature for the MAT enzymes and their 
complexes has been produced.  
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Chapter I. Introduction  
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1.1 Introduction to SAMe 
Giulio Cantoni, in 1952, discovered S-Adenosylmethionine (SAMe) by demonstrating 
that adenosine triphosphate (ATP) and methionine were able to react to form a new 
molecule, which he identified and named SAMe. He showed that SAMe was able to 
transfer its methyl group to guanidinoacetic acid and nicotinamide to form creatine and 
N-methylnicotinamide, respectively (Cantoni 1952). Since the 1950s, SAMe has been 
extensively studied and has been implicated in thousands of different methylation 
reactions and to date SAMe competes with ATP as the most widely used enzyme substrate 
(Cantoni 1952; Loenen 2006). 
 
SAMe (Fig 1.1) emerged as the foremost donor of methyl groups in methylation reactions 
early in evolution and many molecules contain methyl groups, such as DNA, RNA, 
proteins and sugars, that have been derived from SAMe. SAMe is synthesised from ATP 
and the amino acid L-methionine in a two-step SN2 reaction where the triple phosphate 
moiety is cleaved from ATP as SAMe is being formed. SAMe is a typical sulphonium 
salt that contains a sulphur with three single covalent bonds and, therefore, an overall 
positive charge (Bentley 2005). The sulphonium ion can transfer its methyl group to a 
vast range of nucleophilic atoms through a typical SN2 substitution reaction resulting in 
the release of S-adenosyl-L-homocysteine (SAH) (Fig 1.1) (Hegazi et al. 1976; Scavetta 
et al. 2000). In methylation reactions, dependent on SAMe, the nucleophile can be a 
nitrogen atom, as in the N-methylation reaction of the amino group of glycine 
methylation; a carbon atom as in DNA methylation of C5-cytosine; an oxygen atom of a 
hydroxyl moiety; or a sulphur atom in the methylation of thiopurines (Lin et al. 2002). 
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There are two chiral centres in SAMe, a chiral carbon at the α amino position and the 
other chiral is a sulphur at the sulphonium centre, therefore, SAMe has two diastereomeric 
forms. With respect to the sulphonium ion the forms are (S,S)-SAMe and (R,S)-SAMe, 
the former is the only enzymatically synthesised form, which is used in almost all 
methylation reactions (Beaudouin et al. 1993; Bentley 2005; Cannon et al. 2002; de la 
Haba et al. 1959). Under physiological conditions (i.e pH 7.5 and 37 °C) the sulphonium 
ion of (S,S)-SAMe can racemize to form its R counterpart, which is biologically inactive 
(Hoffman 1986), and this accounts for 1.5 % and 3 % of total SAMe levels in mouse liver 
and rat brain, respectively (Beaudouin et al. 1993; Hoffman 1986). 
 
 
Figure 1.1 Structure of S-adenosyl-L-methionine and its derivatives. The Structure 
of S-adenosyl-L-methionine (SAMe), S-adenosyl-L-homocysteine (SAH) and 5’-
methylthioadenosine (MTA). S-adenosyl-L-homocysteine is formed when the methyl 
group from the sulphonium ion of SAMe is transferred. 5’-methylthioadenosine is formed 
when SAMe is spontaneously broken down into 5’-methylthioadenosine and homoserine 
lactone. The two chiral centres in SAMe are shown by blue rings. Adapted from Lu & 
Mato, 2012. 
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There are two spontaneous reactions that SAMe can undergo within the cell: the first is 
the production of 5’-methylthioadenosine (MTA) (Figure 1.1) and homoserine lactone 
through an intramolecular cleavage and the second spontaneous reaction is where the 
hydrolysis of SAMe at the glycosidic bond produces adenine and S-pentosylmethionine 
(Hoffman 1986; Wu et al. 1983). These two reactions contribute to the control of the level 
of (S,S)-SAMe within the cell and stops the accumulation of the biologically inactive 
form.  Non-mammalian systems contain certain methyltransferases  including Mht-1 (S-
methylmethionine-homocysteine methlytransferase) and Sam4 (SAMe-homocysteine 
methyltransferase) that are able to process (R,S)-SAMe and control levels of this racemic 
form (Vinci & Clarke 2007). Mammalian systems have to cope with levels of (R,S)-
SAMe through other means, as they lack homologs to Mht-1 and Sam4 (Vinci & Clarke 
2010).  
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1.2 SAMe Biosynthesis  
This production of SAMe is catalysed by the enzyme methionine adenosyltransferase 
(MAT, EC 2.5.6.1) (Kotb et al. 1997). With the exception of certain parasites and 
infectious agents, that obtain SAMe from their hosts (Merali & Clarkson 2004; Stephens 
et al. 1998), all living cells express MAT and so the mat gene is essential to sustaining 
life (Glass et al. 2006). In mammals, all cells studied to date express MAT with the 
greatest levels of expression found in the liver (Finkelstein 1990) and so not surprisingly, 
individuals with hepatic MAT deficiency present with hypermethioninemia, as 
methionine is unable to be cleared from the liver (Ubagai et al. 1995). Compared to 
control individuals that contain ~35 μM methionine, patients with hepatic MAT 
deficiency show levels of methionine of ~1300 μM (Ubagai et al. 1995). SAMe synthesis 
has been studied using MAT from E.coli and rat liver (Sanchez del Pino et al. 2000; 
Markham & Pajares 2010) and will be described in Section 1.8. SAMe is tightly linked 
to four metabolic pathways: a) transmethylation, b) transsulphuration, c) polyamine 
synthesis and d) as a mediator for radical chemical reactions.  
 
1.2.1 Transmethylation  
 
Although SAMe is made in the cytosol of all mammalian cells, it is the liver where it is 
produced the most, where half of the daily intake of methionine is metabolised, and where 
85 % of methylation reactions take place (Mato & Lu 2007; Mudd & Poole 1975). Due 
to the nature of SAMe, it is able to donate its methyl group to a vast array of acceptor 
molecules, which are all catalysed by methyl transferases and in fact there are over 200 
SAMe-dependent methyl transferase proteins (Petrossian & Clarke 2011). Methyl 
transferases transfer the methyl group from SAMe to oxygens, nitrogens, and carbon 
atoms on proteins, DNA, small molecules, lipids and carbohydrates. The main methyl 
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transferase in the liver, which accounts for 1 % of liver cytosolic protein, is glycine N-
methyltransferase (GNMT) (Lu et al. 2000; Stipanuk 2004). GNMT knockout mice  
develop hepatocellular carcinoma  and steatohepatitis, whilst human patients with genetic 
GNMT deficiency have elevated plasma methionine and SAMe levels and also develop 
liver injury and hepatomegaly (Augoustides-Savvopoulou et al. 2003; Mudd et al. 2001). 
 
SAMe-dependent methylation reactions cause the generation of SAH, which is a potent 
inhibitor of methylation reactions as its inhibition constant (Ki) is in the same micromolar 
range as the Michaelis constant (Km) of most SAMe-dependent methyl transferases 
(Chiang 1998; Chiang et al. 1996). An important metabolic gauge in controlling 
methylation reactions in vivo is the ratio between SAMe and SAH whereby an increase 
in this ratio increases the methylation capacity of the cell (Finkelstein 2007). Levels of 
SAH are regulated tightly by SAH hydrolase that through a reversible cleavage reaction 
turns SAH into homocysteine and adenosine (Figure 1.2) (Della Ragione & Pegg 1983). 
SAH synthesis is favoured over hydrolysis due to the thermodynamics of SAH hydrolase 
(Finkelstein 2007). In vivo, adenosine and homocysteine can be rapidly removed allowing 
for the hydrolysis of SAH which is an essential process to prevent the accumulation of 
SAH (Hoffman et al. 1980; Mato et al. 1997). Any impairment in homocysteine 
catabolism will lead to SAH accumulation and this results in the inhibition of methyl 
transferases. homocysteine can be remethylated in the liver by two different enzymes: 
betaine homocysteine methlytransferase, which requires betaine, and methionine 
synthase, an enzyme that requires 5-methlytetrahydrofolate which is converted to 
tetrahydrofolate once it donates its methyl group (Figure 1.2). 5-methlytetrahydrofolate 
production is catalysed by methylenetetrahydrofolate reductase  that converts 5,10-
methlytetrahydrofolate  to 5- methlytetrahydrofolate.  
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1.2.2 Transsulphuration  
 
Homocysteine can also be processed into cysteine via the transulphuration pathway that 
links SAMe synthesis to cysteine production (Figure 1.2). Here, cystathionine β-synthase 
converts homocysteine to cystathionine before cystathionase converts it into cysteine in 
a two-step enzymatic process and both reactions require vitamin B6 (Figure 1.2). Cysteine 
is an important precursor for the formation of glutathione, which is a powerful 
antioxidant. In the liver the transsulphuration pathway is highly active highlighting SAMe 
as an important precursor for glutathione (Lu 2009). Betaine homocysteine 
methlytransferase expression is limited to liver and kidney whilst both MAT and 
methionine synthase enzymes, which are important as SAMe inhibits 
methylenetetrahydrofolate reductase and activates cystathionine β-synthase, are 
expressed ubiquitously (Mato et al. 1997; Prudova et al. 2006). This allows the level of 
SAMe to control the flow of homocysteine processing, whether it is remethylated or if it 
is funnelled into the transsulphuraton pathway when levels of homocysteine are high. 
Mice which have methylenetetrahydrofolate reductase or betaine homocysteine 
methlytransferase deficiencies have increased levels of homocysteine and SAH and 
reduced SAMe (Finkelstein 2006). 
8 
 
 
Figure 1.2. Methionine metabolism. Methionine adenosyltransferase (MAT) catalyses 
the conversion of methionine and ATP into SAMe. In transmethylation reactions, SAMe 
donates its methyl group to a large variety of acceptor molecules (X) in reactions 
catalysed by methyl transferases (MTs). SAMe-dependent methylation reactions yield 
SAMe as a by-product. SAMe cellular content is regulated by the enzyme SAH hydrolase 
which in a reversible reaction cleaves SAH into adenosine and homocysteine (Hcy). 
Remethylation of homocysteine to form methionine occurs by two enzymes: methionine 
synthase (MS), which requires normal levels of folate and vitamin B12 and betaine 
homocysteine methyltransferase (BHMT), which requires betaine. MS-catalysed 
homocysteine remethylation requires 5-methyltetrahydrofolate (5-MTHF), which is 
derived from 5,10-methylenetetrahydrofolate (5,10-MTHF) in a reaction catalysed by 
methylenetetrahydrofolate reductase (MTHFR). 5-MTHF is then converted to 
tetrahydrofolate (THF), as it donates its methyl group and THF is converted to 5,10-
MTHF and this completes the folate cycle. The transsulphuration pathway links SAMe 
to cysteine biosynthesis. Homocysteine is converted to cysteine via a two-step enzymatic 
process catalysed firstly by cystathionine-β-synthase (CBS) and then cystathionase 
(CSE), both requiring vitamin B6. α-Ketobutyrate, the other product of cystathionine 
cleavage, is further metabolised by the mitochondria through the Kreb’s cycle. 
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1.2.3 Polyamine synthesis  
 
SAMe is also involved in the synthesis of polyamines which are low-molecular weight 
molecules that are positively charged and ubiquitously found in all living cells (Perez-
Leal & Merali 2012). Many biological processes, including transcription, translation, cell 
growth and apoptosis, require polyamines highlighting their crucial role within the cell. 
In order to produce polyamines from SAMe, SAMe must first be decarboxylated by 
SAMe decarboxylase to produce decarboxylated SAMe. Spermidine and spermine are 
the predominant polyamines in mammalian cells and are produced by the sequential 
addition of aminopropyl groups to decarboxylated SAMe using the enzymes spermine 
synthase and spermidine synthase. These reactions produce 5’-methylthioadenosine as a 
by-product (Fig. 1.1), which interestingly is able to inhibit both spermine synthase and 
spermidine synthase with a Ki of 0.3 μM and 2-10 μM, respectively (Hibasami et al. 1980; 
Pajula et al. 1979; Pajula & Raina 1979; Raina et al. 1982). Fortunately for the cell this 
inhibition has little effect as 5’-methylthioadenosine is rapidly metabolised, through the 
methionine salvage pathway, which enables SAMe to be regenerated (Pegg & Williams-
Ashman 1969). Here, 5’-methylthioadenosine is cleaved to give rise to adenine and 5-
methylthioribose-1-phosphate by the enzyme 5’-methylthioadenosine phosphorylase and 
the latter product is further processed into methionine, which can be used by MAT 
enzymes to give SAMe (Figure 1.3). 
 
1.2.4 SAMe radical reactions  
 
Another function of SAMe is that it is able to mediate radical chemical reactions in 
organisms that are grown anaerobically (Knappe & Schmitt 1976). SAMe mediates 
radical chemical reactions for over 2800 radical enzymes that contain a [4Fe-4S] cluster, 
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which SAMe binds to and this results in a reductive cleavage that generates [4Fe-4S]-
methionine and 5’-deoxy-adenosyl 5’-radical (Figure 1.3) (Frey et al. 2008). The latter 
molecule is able to remove a hydrogen atom from proteins, RNA, DNA or small 
molecules initiating a radical mechanism (Frey et al. 2008). An example of a SAMe 
radical enzyme is the interferon-inducible antiviral protein, viperin, whose expression is 
used as a predictive response in the treatment of chronic hepatitis C infection (Sarasin-
Filipowicz et al. 2008). 
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Figure 1.3. Polyamine synthesis, methionine salvage pathway, and SAMe radical 
reactions. To synthesise polyamines, SAMe is decarboxylated, by the enzyme SAMe 
decarboxylase, to form decarboxylated SAMe (dcSAMe). Common polyamines in 
mammalian cells are spermidine (SPD) and spermine (SPM). These polyamines are made 
by sequential addition of aminopropyl groups from dcSAMe, giving rise to 5’-
methylthioadenosine (MTA) as a by-product. SPD synthase (SPDS) catalyses the transfer 
of the first aminopropyl group from dcSAMe to putrescine to form SPD and MTA. SPM 
synthase (SPMS) catalyses the transfer of the second aminopropyl group to SPD to form 
SPM and a second molecule of MTA. MTA is metabolised through the methionine 
salvage pathway to regenerate SAMe. In this pathway cleavage of MTA by the enzyme 
MTA phosphorylase (MTAP) occurs producing adenine and 5-methylthioribose-1-
phosphate, which is further metabolised to methionine and adenine to AMP. SAMe may 
be also converted to 5’-deoxyadenosyl 5’-radical by SAMe radical enzymes (SRE) which 
have a CX3CX2C motif forming a characteristic [4Fe-4S] cluster. This [4Fe-4S] cluster 
binds SAMe catalysing its reductive cleavage to generate [4Fe-4S]-methionine and a 5’-
deoxyadenosyl 5’-radical. 
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1.3 Effect of SAMe in the cell 
An effect that SAMe has within the cell is that it regulates cellular proliferation. Using 
models of partial hepatectomy, mechanisms of how levels of SAMe induces cellular 
pathways for the regeneration of the liver have been studied and elucidated. The effect 
SAMe has on proliferation is cell specific, for example during lymphocyte activation 
intracellular levels of SAMe increase five-fold (Halim et al. 1999) and this is related to 
the need of polyamines for the activation of lymphocytes. In liver, this is not the case and 
levels of SAMe reflect the state of cell, whether it is proliferating or quiescent and thus 
having low or high levels of SAMe respectively (Martínez-Chantar et al. 2003; Cai et al. 
1998). During partial hepatectomy, the hepatic SAMe level dramatically drops, which 
coincides with induction of early response genes and DNA synthesis (Huang et al. 1998). 
The MAT1A knock out mouse model, displays increased basal hepatocyte proliferation, 
but impaired regeneration following partial hepatectomy (Chen et al. 2004).  
 
The molecular mechanisms of how SAMe inhibits growth in hepatocytes has been 
deduced. SAMe inhibits both hepatocyte growth factor, which is a mitogenic growth 
factor essential for liver generation (Latasa et al. 2001) and leptin (Ramani et al. 2008). 
Both hepatocyte growth factor and leptin have been shown to be needed for liver cell 
proliferation by activating MAT2A transcription (Latasa et al. 2001; Pañeda et al. 2002; 
Ramani et al. 2008). In order for the mitogenic effects of hepatocyte growth factor to take 
effect, hepatic parenchymal cells need to be primed to be able to react to hepatocyte 
growth factor which is accomplished by tumour necrosis factor (TNF)-α and interleukin-
6 (Cressman et al. 1996; Yamada et al. 1997). Both TNF-α and interleukin-6 are 
inflammatory cytokines that promote the activation of STAT-3, NFκB, activator protein 
1 and CCAAT/enhancer binding protein β, which leads to the activation of genes in 
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hepatocytes and subsequent DNA synthesis and cell proliferation (Varela-Rey et al. 
2011). 
 
One of the genes that is upregulated is inducible nitric oxide synthase (iNOS) and 
increased levels of nitric oxide is essential for liver repair and for mice lacking this 
enzyme they display impaired liver regeneration (Rai et al. 1998) and interestingly, 
hepatocyte growth factor requires iNOS activity and a drop in the levels of SAMe to 
function (García-Trevijano et al. 2002). Moreover, nitric oxide is a specific inhibitor of 
MATα1 but not MATα2 and is able to nitrosylate residues causing the inactivation of 
MATα1 (Lu & Mato 2012). Taken together these observations paint a picture whereby 
following an attack on the liver, such as a partial hepatectomy, an influx of inflammatory 
cytokines induces the expression of iNOS and allows for the increased production of nitric 
oxide. The elevated levels of nitric oxide cause the inactivation of MATα1 facilitating a 
fall in SAMe and the knock-on effect of releasing inhibition of growth factors. Lower 
levels of SAMe causes reduction in the methylation and activation of phosphatase 2A, 
which reduces the dephosphorylation and deactivation of serine/threonine kinase 11 and 
AMP-activated protein kinase that are kinases stimulated by hepatocyte growth factor 
(Vázquez et al. 2010).  This is supported by the MAT1A knock out mouse phenotype that 
does not display decreased SAMe levels following partial hepatectomy and which are 
resistant to the mitogenic effects of HGF (Chen et al. 2004). 
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1.4 Methionine adenosyltransferases-Overview of genes and proteins. 
 
In mammals there are two genes, MAT1A and MAT2A, which produce the catalytic MAT 
proteins, MATα1 and MATα2 (Mudd 1962). The MAT1A gene encodes a 395 amino acid 
catalytic subunit (MATα1) that shares a 84 % sequence homology with MATα2 (Kotb et 
al. 1997) and is predominantly expressed in the adult liver only (Gil et al. 1996) within 
parenchymal cells, liver endothelial, hepatocytes and Kupffer cells (Shimizu-Saito et al. 
1997). MATα1 can exist in two functional forms, as a dimer (MATIII) or a tetramer 
(MATI) (Kotb et al. 1997). The MAT2A gene encodes a 395 amino acid catalytic subunit 
(MATα2) expressed in all extrahepatic tissue including erythrocytes, lymphocytes, 
kidney, brain, and fetal liver and is expressed in very low levels in the liver of adults 
(Kotb et al. 1997; Mato et al. 1997; Kotb & Kredich 1985; Gil et al. 1996). Using phenyl 
sepharose columns the protein products of MAT1A and MAT2A were separated with 
different hydrophobic characteristics into three peaks which were named MATI, MATII 
and MATIII for the order of elution (Sullivan & Hoffman 1983).  
 
MAT promoters have been cloned sequenced and studied giving insights into expression 
patterns of these genes (Hiroki et al. 1997; LeGros et al. 2001; Alvarez et al. 1997; Mao 
et al. 1998; Zeng et al. 2000). In the developing liver MAT1A expression increases 
progressively during gestation and, after birth, it increases 10-fold and peaks at 10 days. 
A slight decrease occurs after 10 days to a level that is maintained for the adult life (Gil 
et al. 1996). On the other hand, MAT2A expression decreases towards birth and continues 
to do so postnatally until minimal levels are reached in the adult (Gil et al. 1996). Under 
normal cellular conditions MATα2 does not contribute notably to the metabolism of 
hepatic methionine compared to MATα1. The developmental pattern of MAT enzymes 
is closely related to both albumin and α-fetoprotein for hepatocyte differentiation (Gil et 
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al. 1996) and expression of MAT1A can be used as a marker of liver differentiation (Mato 
et al. 1997). The MAT1A promoter contains two CpG sites that in are hypermethylated in 
extrahepatic tissue and in fetal liver and this becomes unmethylated, allowing 
transcription in adult liver (Torres, López-Rodas, et al. 2000; Torres, Avila, et al. 2000). 
Furthermore, histones that are associated with MAT1A promoter in the liver are acetylated 
~15 fold higher than those in the kidney (Torres, Avila, et al. 2000). Looking at the 
promoter for MAT2A in different cell types no differences were found between that of the 
liver, where low levels of expression are observed, and other tissues where the gene is 
transcribed, suggesting that methylation of MAT2A promoters seems to be uniform 
regardless of tissue type (M. Avila et al. 2000). During hepatocellular carcinoma the 
human MAT2A promoter becomes hypomethylated and this allows for increased 
expression (Latasa et al. 2001). 
 
The MAT2B gene encodes four isoforms MATβV1, MATβV2, MATβV2a and 
MATβV2b with the first two being the dominant ones. MATβV1 and MATβV2 share 
very high sequence identity, but differ in their number of N-terminal residues (Yang et 
al. 2008). MATβV2a and MATβV2b are expressed at very low levels compared to 
MATβV2 and have not been studied in detail. The two dominant forms are differentially 
expressed in normal tissues with MATβV1 expressed in prostate, lung, fetal liver, brain, 
thyroid and the adrenal gland, which is opposed to MATβV2 that is expressed in skeletal 
muscle and heart. Both isoforms are expressed in the kidney and thymus (Yang et al. 
2008). MATα2 and MATβ are able to interact to form the MATαβ complexes and binding 
of the regulatory subunit, MATβ, regulates the activity of MATα2 by lowering the Ki for 
SAMe and the Km for methionine (Halim et al. 1999; LeGros et al. 2000). The oligomeric 
form of these MATαβ complexes remains in question and several groups have tried to 
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work out the composition of the complexes. Two models, a tetrameric (MAT(α2β)2) 
(Kotb & Kredich 1985; Mitsui et al. 1988; Langkamp-henken et al. 1994) and trimeric 
(MAT(α2)2βV1) (González et al. 2012) assemblies have been proposed. For this thesis 
the nomenclature shown in Figure 1.4 will be used to describe MAT proteins. 
 
Figure 1.4. Nomenclature of mammalian MATs. A. The mammalian genes MAT1A, 
MAT2A and MAT2B encode the catalytic subunits MAT1, MAT2 and the regulatory 
subunit MAT respectively. MAT1 and MAT2 subunits can be organised as dimers 
and tetramers. On the other hand, MAT2B encodes for four isoforms, MATV1, 
MATV2, MATV2a, MATV2b. B. Proposed model of MATαβ complexes. 
Experimental evidence from Gonzalez et al. 2012 suggested that a MATαβ complex is 
composed of two MATα2 and one MATβV1. 
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1.5 Post translational modifications of MATs. 
 
Estimates of MATα1 subunit size, as determined by SDS-PAGE indicated a molecular 
weight of 48 kDa (Cabrero et al. 1988), which was slightly larger than the predicted 
weight from sequence of 45 kDa. This observation led to the suggestion that MATα1 is 
modified post-translationally and further analysis of the MATα1 sequence revealed 
phosphorylation sites for several kinases, including PKC, which has been explored in 
vitro (Pajares et al. 1994). MATα2 was purified from human chronic lymphocytic 
leukemia cells to apparent homogeneity, but showed three bands on SDS-PAGE, at sizes 
of 53 kDa, 51 kDa and 38 kDa with the latter corresponding to MATβ (Kotb & Kredich 
1985) giving further evidence that MAT proteins are subjected to post translational 
modification.  
 
Nitric oxide and reactive oxygen species (ROS) are able to inactivate MATα1 through 
either the S-nitrosylation or oxidation of Cys120.  A single MATα1 monomer contains 
10 cysteine residues and mutagenesis studies have revealed that replacing cysteine with 
serine (C120S) yields a MATα1 that cannot be deactivated by NO or ROS (Avila et al. 
1997; Sánchez-Góngora et al. 1997). Cys120 is one of the residues that makes up the 
gating loop, the flexible loop that facilitates access to the active site, and modification of 
this single cysteine residue is sufficient to inactivate MATα1 (Pérez-Mato et al. 1999; 
Sánchez-Góngora et al. 1997). MATα2 contains a glycine residue at position 120 rather 
than a cysteine and is not effected by NO or ROS. Basic and acidic residues (Asp354, 
Arg356 and Arg362), surround Cys120 and reduce the acid dissociation constant (pKa) 
of the thiol group belonging to cysteine enabling it to become  more nucleophilic (Stamler 
et al. 1997) that can be S-nitrosylated. Modifications of these surrounding residues 
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reduces the ability of nitric oxide to S-nitrosylate MATα1 (Pérez Mato et al. 2001), and 
these residues are conserved in MATα2. Mutating glycine 120 to a cysteine causes 
MATα2 to become sensitive to nitric oxide and ROS induced inhibition (Castro et al. 
1999). 
 
Aligning multiple sequences of MATs from bacteria, yeast, plants, flies, mouse, rat and 
humans reveals that the Cys120 is a feature of liver specific enzymes whilst other tissues 
favour different amino acids and in particular, glycine. Inactivation of MATα1 by nitric 
oxide or ROS can be reversed by glutathione (Avila et al. 1997; Sánchez-Góngora et al. 
1997; Corrales et al. 1999), at millimolar concentrations which differ depending on the 
oligomeric form of MATα1 (MAT(α1)4= 3 mM, MAT(α1)4= 25 mM).   Normal hepatic 
glutathione levels are between 5-10 mM which may contribute to the selective loss of 
MAT(α1)4 in liver diseases (Corrales et al. 1990). When glutathione synthase is inhibited 
a reduction in the SAMe level and increased MATα1 activation is observed (Corrales et 
al. 1999). Taken together these mechanisms of MAT regulation may be the cause of 
hepatic MATα1 inactivation, in conditions of oxidative stress, such as septic shock, liver 
cirrhosis and hepatitis B or in conditions of increased nitric oxide synthesis like during 
hypoxia and liver regeneration (Mato et al. 1997; Avila et al. 1997; Avila et al. 1998; 
Martin-Duce et al. 1988; Lu et al. 2000). It has been shown that MATα1 can be 
phosphorylated by protein kinase C (PKC) but this modification does not change the 
kinetic properties of MATα1 and the role of this phosphorylation in the regulation of 
MAT remains unclear (Pajares et al. 1994). Whether MATα2 is regulated by 
phosphorylation is unknown.  
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In recent years, it has been speculated that MAT proteins provide a continuous source of 
nuclear SAMe, as it has been reported that both MATα1 and MATα2 can be located in 
the nucleus (Reytor et al. 2009; Katoh et al. 2011). To support this further, accumulation 
of MATα1 in the nucleus coincides with higher levels of histone H3K27 trimethylation, 
which is a known epigenetic gene repression mechanism (Reytor et al. 2009). MATβ 
variants are also localised to the nucleus and can stabilise proteins such as HuR, the RNA 
binding protein. Katoh et al reported that MATαβ complex resides in the nucleus where 
it serves as a transcriptional corepressor complex with MafK and that this complex 
provides SAMe needed for methylation of DNA and histones, participating in chromatin 
based regulation.  
 
It has been shown that, in liver cancer, MATα2 can be acetylated and directed for 
degradation by ubiquitylation. This occurs when folate levels are insufficient enabling 
P300 to acetylate MATα2 at Lys81, which in turn promotes UBR4-mediated 
ubiquitylation, leading to its proteasomal degradation and reduced cell growth. 
Conversely, when folate levels are sufficient MATα2 is stabilised by deacetylation via 
HDAC3 which inhibits ubiquitylation and in turn allows MATα2 to accumulate and 
enhances tumour growth (Yang et al. 2015). 
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1.6 MAT associated diseases. 
 
The changes in both MAT activity and expression have been linked through numerous 
studies, to many types of disease. These changes correspond to altered levels of SAMe 
and, therefore, affect the many reactions and pathways that this molecule is involved in. 
Given this, a direct relationship between MAT and the development of a disease can be 
tricky to establish. One of the most well established MAT related diseases is in cancers 
such as hepatocellular carcinoma and colon cancer. Cancer is a major cause of death in 
the first world whose basis depends on both environmental and genetic factors that cause 
anomalous cell growth through dysregulation of the cell cycle. Furthermore, a property 
of human cancer cells is that they depend on exogenous methionine for growth whereas 
in a healthy cell homocysteine is metabolised (Halpern et al. 1974). Studying the 
methionine cycle has revealed roles in carcinogenesis of several diseases and the MAT 
family of proteins plays a role in driving the development of hepatocellular carcinoma.  
 
Data from several studies indicates that a reduction in MAT1A mRNA, protein and 
activity (Simile et al. 2005; Huang et al. 1999; Liang et al. 2005; Okada et al. 1979) 
coincides with the increase in the same parameters in MAT2A (Huang et al. 1999; 
Horikawa et al. 1993; Liau et al. 1979). Other studies have shown that different types of 
tumour cell lines and tumours (Liau et al. 1979; Abe & Tsukada 1981) have shown rapid 
growth, increased levels of MATα2, decreased MATα1 and moreover, this expression 
pattern has been characterised in liver diseases such as HCC where the expression patterns 
of MAT proteins reverts back to a fetal form (Table 1.1).  
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Table 1.1. Summary of MAT expression in liver in healthy and disease states (Mato & 
Lu 2007).  
MAT 
gene 
Protein  Isoform Expression pattern in 
healthy adult liver  
Expression during HCC 
MAT1A MATα1 MAT(α1)2 High Low 
  MAT(α1)4 High Low 
MAT2A MATα2 MAT(α2)2 Low High 
  MAT(α2)4 Low High 
MAT2B MATβ MATβV1 Low High 
  MATβV2 Low High 
  MATβV2a Low Low 
  MATβV2b Low Low 
 
Global hypomethylation seems to be a common property of several diseases where 
MAT1A expression and SAMe levels are altered (Yang et al. 2001). The role of MAT 
proteins in HCC has been studied for many years and the role that SAMe plays in cancer 
development was confirmed when the MAT1A knockout mouse (Martínez-Chantar et al. 
2002) showed that a chronic deficiency in SAMe lead to the spontaneous appearance of 
HCC. Interestingly, treatment with SAMe has been shown to be efficient in treating HCC 
(Garcea et al. 1989) as it inhibits the mitogenic effect of HGF by blocking NFκB 
activation of cytokine-stimulated hepatocytes (Majano et al. 2001). If antisense MAT2A 
RNA is used in normal or MAT2A overexpressing hepatoma cells the result is cell death 
(Cai et al. 1998). The expression of the regulatory subunit MATβ provides a growth 
advantage to human hepatoma cells, and the expression of these proteins is common in 
cancer and readily associated with hepatic dysfunction (Martínez-Chantar et al. 2003).  
 
Ethanol plays an interesting role in the development of liver disease. Combining a high 
fat diet and intragastric feeding of ethanol in rats increases the mRNA levels of both 
MAT1A and MAT2A, but only the protein levels of MATα2 rose noticeably (Lu et al. 
2000). Ethanol induction of MAT2A is accomplished by the stimulation of TNF-α, which 
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causes NFκB and AP-1 to bind to the MAT2A promoter (Yang et al. 2001). A reduction 
in the level of SAMe has been observed during the ethanol feeding of rats, baboons, 
micropigs and in patients who suffer from ethanol hepatitis (Lu et al. 2000; Villanueva & 
Halsted 2004; Lieber et al. 1990; Lee et al. 2004). However a reduction in SAMe does 
not always translate to same level of reduction in SAH and differences in the levels of 
SAH have been observed between these models. Overall there is a net reduction in the 
SAMe/SAH ratio that correlates with a decrease in global DNA methylation whilst there 
is an increase in both c-Myc expression and genome-wide DNA strand breaks (Lu et al. 
2000). 
 
Alcoholic liver cirrhosis can be a precursor for liver cancer and samples from alcoholic 
hepatitis and cirrhotic patients saw a reduction in levels of MAT1A RNA but no induction 
of MAT2A (M Avila et al. 2000; Lee et al. 2004). Samples from cirrhotic patients (84 %) 
showed expression of MATβ, but the effect of this protein has not been explored 
(Martínez-Chantar et al. 2003). Liver damage due to both short and long term ethanol 
consumption has been linked to a reduced supply of oxygen to the liver and such sustained 
hypoxia induces the down regulation of MAT1A expression in both liver cirrhosis and 
long term ethanol consumption (Arteel et al. 1997; Ji et al. 1982; Tsukamoto & Xi 1989). 
This damage may be irreversible as methylation reactions and glutathione-dependent 
detoxification capacities are impaired and also by changing levels of glutathione and nitic 
oxide which can activate or deactivate MATα1, respectively (Avila et al. 1998; Corrales 
et al. 1999). 
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Transmethylation pathways have roles in several neurodegenerative conditions such as 
Parkinson’s and Alzheimer’s disease (Gomes Trolin et al. 1995; Gomes Trolin 1998; 
Surtees et al. 1991; Cheng et al. 1997) and also in psychiatric disorders such as dementia 
and schizophrenia (Regland et al. 1995). Studies in mice, monkeys and pigs have linked 
the development of myelopathies, ataxia, subacute combined degeneration of the spinal 
cord and peripheral neuropathy to defects in MAT (Lee et al. 1992; Scott 1992; Scott et 
al. 1994). Although an association with MATs and Parkinson’s diseases exist no link 
between the levels of SAMe and/or SAH with the duration or age of Parkinson’s has been 
described. There are elevated levels of MAT in erythrocytes of patients who suffer from 
Parkinson’s and schizophrenia but they also have lower levels of SAMe and SAH in the 
blood (Cheng et al. 1997; Smythies 2012). 
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1.7 Structural basis of MAT proteins. 
MAT enzymes are an exceptionally well conserved family of enzymes found throughout 
all walks of life and comparing sequences from E.coli, Mycoplasma genitalium, 
Saccharomyces cerevisiae, Arabidopsis thaliana, mouse, rat and human highlights their 
similarity (Mato et al. 1997). E.coli and human MAT share a 59 % sequence identity 
(Alvarez et al. 1991). 
 
Crystal structures of various MAT enzymes have been published for rat MATα1 
(González et al. 2000), E.coli MAT (eMAT) (Komoto et al. 2004; Fu et al. 1996; 
Takusagawa et al. 1996) and human MATα1 and MATα2 (Shafqat et al. 2013). Due to 
the high sequence identity, the overall topology is the same for each protein. A MAT 
monomer consists of three repeats of beta-alpha-beta-alpha-beta secondary structures, 
which are related to each other by pseudo threefold symmetry (Fig. 1.5A) and each 
monomer contains three domains: N-terminal, central and C-terminal domains. Pairs of 
subunits form dimers and each dimer forms a tight complex that creates two active sites 
using residues from each monomer (Fig 1.5B). MAT dimers can oligomerise to form a 
tetrameric state at right angles to their central tip (Fig 1.5C). The hydrophobic interface 
between MAT monomers is much greater than the polar interface between pairs of dimers 
forming the tetramer. A common feature of catalytic MAT proteins is that they share a 
disordered loop segment that becomes well-ordered on the binding of substrate or 
products, which was termed the gating loop. This loop was proposed to act as a flexible 
gate allowing access to the active site and this notion has been supported by kinetic and 
spectroscopic studies (Taylor et al. 1996; Taylor et al. 2002). 
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Figure 1.5. Structural organisation of MAT proteins. A. A monomer of MATα1 
(PDB=2OBV) with the gating loop highlighted in red. B. MAT(α1)2 in slate and dark red 
showing the formation of the active enzyme. Two active sites are created upon the 
dimerisation of MAT monomers taking residues from each monomer. The product SAMe 
can be seen as orange sticks. C. MAT(α1)4 forms from two MAT dimers. Both dimer and 
tetramer are functional enzymes, whilst the monomeric form is not functional as it 
contains no complete active site.  
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The structurally unrelated regulatory subunit MAT has two domains: a core Rossmann-
like domain and a second extension domain (Fig 1.6A). The Rossman-like domain 
consists of a seven-stranded β-sheet that is sandwiched between six α-helices and it 
contains conserved signature sequences common for a short-chain 
dehydrogenase/reductase. These include, a co-factor binding domain rich in glycine 
residues (G35ATG38LLG41) and a catalytic triad important for substrate activation 
(S136…Y159GKTK163) (Oppermann et al. 2003; Shafqat et al. 2013). The second extension 
domain contains α-helices and double-stranded β-sheet that makes up a nicotinamide 
adenine dinucleotide phosphate (NADP) binding site consisting of the conserved 
GxxGxxG motif. The adenosyl phosphate end of NADP is anchored to MATβ by the L1 
loop that contains a sequence that confers specificity for NADP over nicotinamide 
adenine dinucleotide (NAD) in many short-chain dehydrogenase/reductases  (G59xRR62) 
(Fig 1.6B). Gly59 provides the space for the phosphate moiety whilst Arg62 supports the 
phosphate oxygen’s through hydrogen bonding (Shafqat et al. 2013).   
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Figure 1.6. Crystal structure of MATβ. A. MATβ has two domains: The Rossmann 
domain in teal and the extension domain in bronze. The L1 loop, a loop needed to anchor 
NADP, is highlighted in red and a molecule of NADP can be seen as sticks. B. A closer 
view of NADP binding shows the G59xRR62 motif in red which confers specificity of 
NADP, whilst in purple the residues Y159GKTK163 are shown as sticks and these are 
important for substrate activation.  
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1.8 Enzymatic reaction of MAT  
SAMe synthesis follows an SN2 catalytic mechanism (Parry et al. 1982; Markham et al. 
1987) where the reaction is initiated through a nucleophilic attack by the sulphur atom of 
methionine on the C5’ atom of ATP which produces the intermediate triple phosphate 
(PPPi). The hydrolysis of the triple phosphate into pyrophosphate (PPi) and 
orthophosphate (Pi) occurs prior to the release of all three products, (SAMe, PPi and Pi) 
from the enzyme (Fig 1.7).  
 
Figure 1.7. Schematic of SAMe synthesis. Methionine (MET) and ATP react together 
to produce SAMe and a triple phosphate (PPPi) which is then broken down into 
pyrophosphate (PPi) and orthophosphate (Pi). SAMe synthesis follows an SN2 catalytic 
mechanism which is initiated through a nucleophilic attack by the sulphur atom of 
methionine on the C5’ atom of ATP. This produces the intermediate triple phosphate that 
is broken down into pyrophosphate and orthophosphate.  
 
Komoto et al (2004) proposed a detailed mechanism of actions based on several structures 
of eMAT. The substrates ATP (here AMP-PNP) and methionine enter the active site and 
the flexible gating loop becomes well-ordered closing the active site. The NE2 of His14 
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forms a hydrogen bond with O5′ of AMP-PNP (O5′-NE2=2.85 Å), and the ND1 of His14 
is surrounded by the two amide groups of Asp16 and Lys17 within hydrogen bond 
distance (ND1-N[Asp16]=3.05 Å, ND1-N[Lys17]=3.69 Å) (Fig 1.8A). The imidazole ring 
of His14 can be polarized so that the proton on NE2 is readily released to O5′ of ATP (Fig 
1.8B). The C5′-O5′ bond cleavage occurs following a molecular vibration allowing the 
amide groups of Asp16 and Lys17 to form strong hydrogen bonds with ND1 of His14. 
This leads to a series of electron movements taking place (Fig 1.8C) resulting in the 
cleavage of the ATP C5′-O5′ bond forming the triple phosphate  coproduct (Fig 1.8D). 
The negatively charged ND1 of His14 is stabilised by the surrounding basic main chain 
amide groups of Asp16 and Lys17.  
 
The positively polarized C5′ moves toward the electron-rich SD atom of the bound 
methionine by changing the ribose ring conformation from C4′-exo to C3′-endo. A 
nucleophilic attack on the C5′ to form SAM and displace triple phosphate occurs due to 
the SD atom. It must be noted that the C5′-O5′ bond cleavage and the C5′-SD bond 
formation occurs in a concerted manner, consistent with a SN2 reaction. This proposed 
catalytic mechanism is supported with previous mutational studies which showed when 
H14N mutation was down a >1000-fold reduction in Vmax was observed. The Vmax of the 
mutant K165M only diminished by 2.5-fold, indicating that interactions with Lys165 are 
less important in catalysis (Taylor & Markham 2000). SAMe in crystal structures have 
an S-configuration at the SD atom, and the naturally occurring SAMe has the S-
configuration as well (Cornforth et al. 1977; Stolowitz & Minch 1981), supporting the 
proposed catalytic mechanism. The triple phosphate is then proposed to be broken down 
into pyro and orthophosphate providing the energy to dislodge the gating loop and 
facilitate product release. The mechanism of hydrolysis of the triple phosphate 
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intermediate appears to be similar to other metal ion dependent ATPases and 
phosphatases. However, it still remains a question which water is activated to react with 
the triple phosphate and thus split the polyphosphate chain into PPi and Pi (Markham & 
Pajares 2010). 
 
Figure 1.8. Proposed catalytic mechanism for SAMe formation. Curved arrows 
indicate the movements of electron pairs. Possible polar interactions are illustrated by 
dotted lines. The “+” and “-” indicate positive and negative charges, respectively. 
Although the mechanism is illustrated in a sequential fashion for clarity, the C5′-O5′ bond 
cleavage and the C5′-SD bond formation occur in a concerted manner, i.e., the proposed 
SAM formation is a SN2 reaction. Figure taken from Komoto et al 2004.  
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It has been shown that MAT enzymes do not just metabolise methionine, but depending 
on species, can process many methionine analogues (Wang et al. 2014). Ethionine, an S-
ethly analogue of the amino acid methionine, is known to induce steatosis and pancreatitis 
in rat (Rao et al. 1982). MAT enzymes are able to produce S-adenosylethionine (SAE) 
from ethionine (Smith & Salmon 1965), which in turn acts as a competitor of methionine 
and as a result, insufficient levels of SAMe is produced within the cell causing disruption 
of SAMe-dependent processes such as nicotinamide catabolism (Skordi et al. 2007). SAE 
can be used to ethylate targets by donating its ethyl group in direct competition with 
methylation, which results in abnormal alkylation of nucleic acids (Orenstein & Marsh 
1968). 
 
 
1.9 Aim of this research project  
As HCC development is strongly associated with the increased expression of both 
MATα2 and MATβ providing a proliferative advantage for the cell, the aim of this PhD 
thesis is to determine the interface interaction between MATα2 and MATβ at the 
molecular level by solving the structure of the MATαβ complex using X-ray 
crystallography. Once the structure has been solved interaction interfaces between these 
molecules will be studied and then structure based mutants that would change the nature 
of the wild-type interactions will be designed.  This will allow for the identification of the 
key residues needed to maintain the complexes.  
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Chapter II. An introduction to crystallography and 
the theory of x-ray diffraction.  
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2.1 An introduction to protein crystallography 
Macromolecular X-ray crystallography is one of the most utilised techniques available to 
determine the three-dimensional structure of proteins and nucleic acids. There are a large 
number of books that cover the subject of protein crystallography so in this thesis an 
overview of protein crystallisation and the analysis of X-ray diffraction experiments will 
be given (Drenth 2007; Rupp 2009; Rhodes 2006).  
 
Of the stages of solving the structure of a protein, protein crystallisation is the least 
understood part and remains, fundamentally, a trial and error process. The crystallisation 
process is an empiric method that depends on several physicochemical parameters that 
are not yet completely understood. The presence of impurities and other unknown factors 
plays a role in the formation of protein crystals. In general the purer the protein, i.e. the 
higher the homogeneity, the increased likelihood of a crystal growing and also obtaining 
crystals that diffract to a higher resolution. For this reason the requirement of protein 
purity is more stringent for a crystallographer than those of a biochemist who would be 
happy, for example with a purity of an enzyme that retains a catalytic activity despite high 
impurities.   
 
2.2 Crystallisation of a protein 
Crystallisation of protein involves several steps and requires bringing the macromolecule 
to supersaturation. The protein is dissolved in a solvent, usually a water-buffer solution 
of an organic solvent, before being precipitated by an organic compound or salt. The 
protein mixture must be brought to supersaturation whereby small aggregates, termed 
protein nuclei, are grown. The nuclei spontaneously form at a high level of 
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supersaturation which allows for the growth of crystals to occour. For optimal crystal 
growth once the protein nuclei has formed a reduction in the supersaturation is needed in 
order to produce larger single crystals suitable to x-ray diffraction (Fig. 2.1). If the protein 
or precipitant concentrations are too high amorphous precipitation forms whilst if the 
solution is too undersaturated, the drop can be devoid and clear of all precipitation. In 
these scenarios the likelihood of crystal formation is extremely minimal (Dessau & Modis 
2011; Chayen & Saridakis 2008).  
 
Figure 2.1 Overview of crystal growth. Initially the protein concentration is too low for 
crystal formation and lies in the undersaturation zone [1]. As the protein concentration 
increases, the solution becomes supersaturated and nucleation can occur [2]. As protein 
is used to form nuclei the protein concentration in the drop decreases allowing for the 
growth of the crystals [3]. If the protein becomes too concentrated it enters the 
precipitation zone where it precipitates out of solution.  
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2.3 Methods of protein crystallisation   
The vapour diffusion method is one of the most widely used techniques for protein 
crystallisation where a mixture of protein/precipitant is placed placed on a siliconised 
cover slip. The drop is allowed to equilibrate in a closed vessel containing a high 
concentrated precipitant reservoir which causes the concentration of the protein to be 
gradually increased by diffusion.  Volatile species, including water or organic molecules, 
diffuse from the drop to the reservoir until the concentration of precipitant is the same in 
both the drop and reservoir. There are two variations of the vapour diffusion method 
depending on the way the protein/precipitant drop is placed: hanging drop and sitting drop 
(Fig. 2.2), but both follow the same principles. During this progress, protein nuclei begin 
to form as the drop enters into a super-saturation state, surpassing an energetic barrier, 
due to diffusion causing the gradual increase in protein concentration. 
 
Figure 2.2. Vapour diffusion methods for crystallisation. Hanging drop (left) and 
sitting drop (right) methods contain a reservoir solution (blue) and protein/solution mix 
(red). Diffusion occur between the reservoir and the drop concentrating the protein within 
the drop allowing for supersaturation to be reached.  
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2.4 Crystallisation screening 
In general, the search for suitable crystallisation conditions is done in two steps. First, is 
to use the wide range of commercially available crystallisation screen which contains a 
wide range of precipitant and buffer solutions to identify hits. The second step is to take 
the most promising conditions and vary the conditions that the crystals originally formed 
in changing the concentration of the protein and/or precipitant, pH, temperature or change 
the presence of additives such as cations, anions, organic compounds and detergents. The 
need to optimise an initial hit allows for the growth of better diffracting crystals.  
 
2.5 Crystal lattices and symmetry  
A crystal is a solid composed of atoms arranged in an orderly repeated way. Any crystal, 
organic or inorganic, is made up of unit cells, which can be considered as the ordered-
translational repeat along three dimensional space. The unit cell itself is defined by three 
axis (a, b and c) and by three angles (α, β and γ) and the geometric arrangement of the 
axis and angles gives rise to the seven crystal systems: Triclinic, monoclinic, 
orthorhombic, trigonal, hexagonal, tetragonal and cubic. Regardless of which system the 
crystal is formed by each unit cell contains a smaller motif called the asymmetric unit 
(Fig 2.3). The asymmetric unit is defined by a combination of 32 point group symmetry 
operations, 14 Bravais lattices (or lattice translations), several rotational operations and 
screw axis symmetry operations. There are a total of 230 space groups, but for proteins, 
which are chiral molecules, only rotational and screw symmetry operations are allowed 
limiting the number of point groups to 11 and the total number of space groups to 65.  
Unlike salt crystals which have low solvent content and strong electrostatic bonds, protein 
crystal interactions use hydrogen bonding and as a result have increased fragility. 
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Figure 2.3. Formation of the asymmetric unit. The asymmetric unit green arrow sits 
within the unit cell after crystal symmetry has been applied (black dot) to give rise to a 
new orientation of the asymmetric unit (orange arrow). The entire crystal is made up of 
many repeats of the unit cell.  
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2.6 X-ray radiation 
X-ray radiation, produced from an X-ray generator, is monochromatic. An X-ray 
generator contains a vacuum tube known as the X-ray tube which houses within it a metal 
filament that is heated to produce electrons. These electrons are then accelerated in 
vacuum by a high electric field (20-60 kV) towards a metal target called the anode. The 
anode collects the electrons and is typically made out of copper which allows for heat, 
generated by the collision to evacuate. When electrons collide with the target, 1 % of the 
resulting energy is emitted as X-rays whilst the remaining energy is dissipated as heat.  
 
In synchrotron radiation sources, electrons that are produced from an electron gun are 
accelerated in a linear accelerator (linac) before being transmitted to a circular accelerator, 
known as a booster synchrotron, where they are accelerated further to reach an energy 
level of 6 GeV. These highly relativistic electrons are then stored in a storage ring which 
allows them to travel along a circular path at a constant energy, for many hours. The 
electrons are moving at speeds close to that of light within the storage ring and when their 
paths are altered by a magnetic field, through devices such as wiggler magnets, undulators 
and wave length shifters, they emit X-rays.  
 
2.7 X-ray structure analysis    
When a wavefront of X-rays interacts with a sample it will either be transmitted, in which 
case it continues along its original direction, or it will interact with an atom and the 
electrons in that atom will re-emit that X-ray radiation, normally without changing the 
wavelength, as a spherical wavefront.  All the atoms in the path of the X-ray beam scatter 
X-rays and peaks form when scattered X-rays, constructively interfere. Constructive 
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interference occurs when two X-ray waves, with phases separated by an integer number 
of wavelengths, add to make a new wave which has a larger amplitude. When two parallel 
X-rays from a coherent source scatter from two adjacent planes their path difference must 
be an integer number of wavelengths for constructive interference to occur (Fig 2.4). For 
systems which are not ordered, most of these scattered waves interfere destructively and 
results in lower scattered intensities. However, in ordered systems, such as in crystalline 
structures the scattered waves interfere constructively as the atoms are placed in a periodic 
and defined pattern.  
 
The noble laureates, William and Lawrence Bragg defined the diffraction by crystal 
lattices in 1913 (Bragg & Bragg 1913). They found that the co-operative scattering of X-
rays could only occour when the X-ray, of wavelength λ, is incident onto the surface of a 
crystal, and the angle of incidence, θ, will reflect back with a same angle of scattering, θ. 
When this occurs and, when the path difference, d is equal to an integer, n, of 
wavelengths, constructive interferences occurs. (Equation 1, Figure 2.4).  
𝑛𝜆 = 2𝑑 sin 𝜃 
Equation 1.  
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Figure 2.4. Graphical representation of Bragg’s law. Constructive interference 
between two diffracted rays (green lines) only occurs if the path length difference (d) 
between them corresponds to a multiple of the wavelength, λ. 
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2.8 Calculating electron density  
A waveform can be represented using a combination of both the sine and cosine 
components of the wave producing a complex number [cos 2π (hx) + i sin 2π (hx)] which 
in turn can be expressed as an exponential, e2πi(hx). The exponential contains the frequency 
of the wave (h), an imaginary component (i) and is equal to the phase (αh). In terms of 
amplitude (F), regardless how complicated a wave is it can be defined by the sum of the 
simpler wave functions: 
𝑓(𝑥) = ∑ 𝐹ℎ
𝑛
ℎ=0
𝑒2𝜋𝑖(ℎ𝑥) 
Equation 2. 
In order to solve the structure of a protein using x-ray crystallography a specific function 
that calculates the three-dimensional electron density of the molecules or ρ(x,y,z) must be 
determined. To accomplish this the contribution of the frequencies (h,k,l) from waves 
scattering in different directions of space (x,y,z) must be considered to account for the 
three dimensional sum of waves (Equation 3).  
𝑓(𝑥, 𝑦, 𝑧) = ∑ ∑ ∑ 𝐹ℎ 𝑒
2𝜋𝑖(ℎ𝑥+𝑘𝑦+𝑙𝑧)
𝑙𝑘ℎ
 
Equation 3.  
 
For any function, f(x), there is another reciprocal function called the Fourier transform, 
F(h), which instead of terms of time (x) it is expressed in terms of frequency (h). A Fourier 
transform can be applied to a sum of waves or Fourier series to obtain the contributions 
of the different waves (Equation 4), which is an approximation that relates the information 
in a diffraction pattern (reciprocal space) with the contents in the unit cell (real space).  
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𝐹(ℎ, 𝑘, 𝑙) = ∭ 𝑓(𝑥, 𝑦, 𝑧)𝑒2𝜋𝑖(ℎ𝑥+𝑘𝑦+𝑙𝑧)  𝑑𝑥 𝑑𝑦  𝑑𝑧
𝑥𝑦𝑧
 
Equation 4.  
Reflections, which make up the diffraction pattern, are generated by an x-ray wave that 
impacts the detector and each reflection represents an arriving wave that is the 
constructive sum of the waves diffracted by all scatterers in the unit cell. Therefore every 
atom in the unit cell contributes to every reflection in the diffraction pattern.  The atomic 
structure factor, fhkl, (Equation 5) is the contribution of one atom to the reflection (h,k,l) 
and the Fourier series or sum that describes the specific wave is called the structure factor 
of the reflection or Fhkl (Equation 6). For every atomic structure factor the scattering 
factor of a particular atom fhkl has to be considered as a sphere of electron density. 
Therefore, the Fhkl is considered the Fourier transform of the electron density, p(x,y,z) and 
vice versa (Equation 6). 
 
𝑓ℎ𝑘𝑙 = 𝑓𝑗𝑒
2𝜋𝑖(ℎ𝑥𝑗𝑘𝑦𝑗𝑙𝑧𝑗) 
Equation 5. 
𝐹ℎ𝑘𝑙 = ∭ 𝑝(𝑥, 𝑦, 𝑧)𝑒
2𝜋𝑖(ℎ𝑥+𝑘𝑦+𝑙𝑧)  𝑑𝑥 𝑑𝑦  𝑑𝑧
𝑥𝑦𝑧
 
Equation 6 
 
To summarise, an x-ray diffraction pattern contains a set of intensities that are associated 
with structural information called structure factors, Fhkl and by using the Fourier 
44 
 
transform the electron density, p(x,y,z), can be related to each point in the crystal and 
whose structure factor correspond to each reflection (h,k,l) in the diffraction pattern.  
 
2.9 Indexing, integration and scaling 
Once a data set from a crystal has been obtained, which has different angular reflective 
snapshots, data processing can occur. Firstly, each reflection gets Miller indexes (h,k,l) 
assigned to it and a list of possible lattices is suggested. In order to analyse the data the 
correct lattice must be chosen so intense processing of the unit cell parameters and crystal 
mosaicity is done to select the lattice. The next step evaluates the intensities of the 
reflections in a process called integration. Here, a long list of indexed reflections 
containing their individual intensities I(h,k,l) and the standard error statistics σI(h,k,l) are 
defined. The huge amount of data here needs to be reduced, which is achieved by 
combining partial identical reflections from multiple frames collected at different angles 
and normalising the data onto an absolute scale; this is scaling.  
 
Equation 6 relates the reflections that are collected with the electron density in the crystal 
and this requires not only the modules of the structure factor, |Fhkl|, but the phase α(h,k,l) 
of the wave. Unfortunately, the data from the reflections does not provide direct 
information about the phase of the wave, but only information pertaining to the structure 
factor modules, calculated from the reflection intensities. This pitfall of x-ray 
crystallography is known as the phase problem and several different methodologies have 
been developed to solve it, allowing for the calculation of the electron density and, finally, 
resolve the structure. In this thesis molecular replacement was used to overcome the phase 
problem.  
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2.10 Molecular replacement  
Molecular replacement is the process of solving the phase problem for an unknown 
structure by placing the atomic model for a related, known structure in the unit cell of the 
unknown structure in such a way as to best reproduce the observed structure factors. The 
known model, once placed, may be used to calculate phases which, in combination with 
the observed structure factors for the unknown structure, allows for the model to be rebuilt 
and refined and a model to be generated. To do this a calculation involving a six 
dimensional search over all possible orientations and translations of the known model in 
the unit cell of the unknown structure has to occur. The six dimensional search is split 
into two parts. The first part is a three dimensional search over all possible rotations to 
determine the orientation. After this is done, another 3 dimensional search occurs over all 
possible translations to work out the position of the orientated model.  
 
Using the search model diffraction data are generated, with a large P1 unit cell and this is 
termed Fc. The Patterson map is calculated for both the observed crystal data and the 
model (Pobs and Pc). The Patterson map represents all atom-atom vectors, translated to the 
origin including the vectors within the molecule and vectors between symmetry-related 
molecules (Fig. 2.5). The Pc is rotated against the Pobs to find the rotation matrix with the 
maximum correlation and from this the structure factors are recalculated (Fmodel) for a P1 
unit cell of the same cell dimensions as the crystal unit cell. This rotated model is then 
translated to every position in the crystal unit cell and also accounts for the models related 
by space group symmetry to obtain the Fcalc. The R-factor between Fobs and Fcalc is 
determined and if this less than 50 % then the solution is correct. 
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Figure 2.5. Schematic of the rotation function of molecular replacement. Patterson 
maps are generated for both the target data and the search model. A rotation matrix is 
applied to the search model patterson to align it with the target Patterson.  
  
47 
 
In summary, molecular replacement can be thought of as two parts, a rotation function 
and a translation function. The schematic in Fig 2.6 shows that in order to obtain the 
solution for the target molecule, A’, the search molecule, A, must be rotated by the 
rotation matrix, [R], before a translational vector is applied, T (Fig 2.6).  
 
 
Figure 2.6. A simple view of Molecular replacement. Firstly the search model, A, is 
rotated by the rotation matrix [R], followed by a translation, T, to give the solution of the 
target molecule A’. The movement of the search model to the target model is given by 
the equation A’=A[R]+T. 
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2.11 Refinement and validation 
Once a solution has been produced from molecular replacement the model has to be 
refined and evaluated for inaccuracies. When refining stereochemical parameters bond 
distance, bond angle and side chain rotamers are taken into account. The Ramachandran 
plot evaluates the Φ and Ψ angles of the peptide bonds within the molecule allowing for 
the identification of improper main chain rotations. Other molecules such as water, 
compounds and ions that were present during the protein purification or the crystallisation 
may also be present in the structure and must be built into the density. All atoms within 
the model must be checked for interatomic distances to ensure that the molecules are not 
too far or too near from other atoms. R-value is the measure of the quality of the atomic 
model obtained from the crystallographic data. When solving the structure of a protein, 
you build an atomic model and then calculate a simulated diffraction pattern based on that 
model. The R-value measures how well the simulated diffraction pattern matches the 
experimentally-observed diffraction pattern. A random set of atoms will give an R-value 
of about 63 %, whereas a perfect fit would have a value of 0 %. Values are resolution 
dependent and for a 2 Å structure a typical R-value would be about 20 %.  Some bias can 
come from the starting model, which could affect the R-value so another parameter, R-
free, is used in combination with R-value. When calculating the R-free and before 
refinement begins, about 10% of the experimental observations are removed from the 
data set and the remaining 90 % is used for model refinement. The calculated R-free value 
looks at how well the model predicts the 10% that were not used in refinement. For an 
ideal model, that is not over-interpreting the data, the R-free will be similar to the R-value 
and typically, it is 3-5 % higher than the R-factor (Kleywegt & Jones 1997). Validation 
of protein structures can be achieved through the online sever MolProbity (Davis et al. 
2007), which provides a summary of any errors in stereochemistry or interatomic clashes. 
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Chapter III. Small angle x-ray scattering  
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3.1 Overview of Small angle x-ray scattering 
Small angle x-ray scattering (SAXS) is a powerful structural biology technique that is 
used to investigate the oligomeric state of proteins and macromolecular complexes. It can 
also be used to quantitatively characterised kinetic reactions and assess the flexibility of 
intrinsically unfolded proteins(Koch et al. 2003; Putnam et al. 2007). SAXS shares both 
similarities and differences with x-ray crystallography, both are based on the elastic 
scattering of photons by molecules. For a crystal, where the macromolecules are regularly 
positioned the scattering waves interfere and produce diffraction patterns which can yield 
high resolution structures. For SAXS, the molecules are free to move and have random 
orientations within the solution, which allows for the magnitudes of the interatomic 
distances to be calculated and a low resolution shape of the molecules in solution to be 
reconstructed.  
 
3.2 Developments in SAXS  
An advancement in SAXS technology is the combination of SAXS with size exclusion 
chromatography (SEC), which allows for the separation of different populations of a 
protein. This is particularly useful ensuring that a protein sample is monodispersed and 
homogeneous before data are collected, and also allows for the separation of different 
oligomeric states. The SAXS-SEC method has been set up in the SWING beamline at the 
Soleil synchrotron, France. The beamline couples data collection with a high performance 
liquid chromatography (HPLC) (David & Pérez 2009). 
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3.3 SAXS theory 
Scattered photons are collected on a 2D detector but as the scattering is isotropic, meaning 
that the x-rays scatter with equal efficiency into all possible direction, the images 
collected are radially averaged to obtain the scattered intensity, I, as a function of the 
momentum transfer s: 
𝑠 =
4𝜋 sin 𝜃
𝜆
 
Equation 9 
The wavelength here is represented by λ of the incident beam, and θ is half the angle 
between the incident beam and the scattered radiation.  From Braggs law (Equation 1), 
distance probed is inversely proportional to the momentum transfer.  
 
Figure 3.1. Schematic of a small angle x-ray scattering experiment. An X-ray beam 
passes through the sample and is diffracted which is recorded on the detector.   
 
During a SAXS experiment, scattering data are collected for both the dissolved particles 
and the buffer that the particles are dissolved in separately and later the latter is subtracted 
from the former. The signal difference between these two data sets is proportional to the 
number of particles in the solution and also it is proportional to the difference in the 
electron density between the particle p(r) and the solvent ps. Unfortunately, for biological 
systems the biological molecules contain light atoms such that the particle density is only 
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slightly higher than that of the buffer. To overcome this SAXS instrumentation has been 
optimized to have the lowest possible background.  For a monodisperse system of 
identical particles that are non-interacting, the corrected background scattering intensity 
I(s) is proportional to the scattering from a single particle that is averaged over all possible 
orientations. This can be expressed as:  
𝐼(𝑠) = 〈I(s)〉𝛺 = 〈𝐴(𝑠)𝐴
∗(𝑠)〉𝛺 
Equation 10 
Here, the scattering amplitude A(s) is a Fourier transformation of the excess scattering 
length and the solid angle in the reciprocal space of the scattering vector is denoted by Ω.  
 
3.4 Overall particle characterisation 
The Guinier approximation is a fast method of providing information on size, oligomeric 
state, interactions and overall quality of the data. The Guinier analysis (Guinier 1939) is 
the most straightforward method to determine both the radius of gyration, Rg, and the 
forward scattering I(0). For a monodisperse system the Guinier equation:  
𝐼(𝑠) = 𝐼(0) ∙ exp (−
1
3
𝑅𝑔
2𝑠2) 
Equation 11 
The approximation can be used to calculate both parameters and for a monodisperse 
sample the gradient of the line and very small s values gives the Rg, and the intercept with 
the ordinate yields the intensity of forward scattering. The radius of gyration of a 
macromolecule is defined as the root mean squared distance of scattering particles that 
are weighted about its centre of mass and can be used to infer differences in the 
compactness between proteins. The linearity of the plot provides an indicator to sample 
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quality as a non-linear plot may show poor buffer subtraction, interparticle interaction or 
polydisperisty. The region that is linear is only such for a small region. Calculating the 
scattering at zero angle I(0), which once normalised to the solute concentration, enables 
an estimate of molecular mass to be calculated as I(0) is proportional to the molecular 
mass.  
 
Another way to calculate the molecular weight is to use the Porod volume (Porod 1982). 
This volume is the hydrated volume of the molecule and can be calculated if a uniform 
electron density is assumed. The Porod volume can be calculated from the Porod 
invariant, Q: 
𝑄 = ∫ 𝑠2
∞
0
𝐼(𝑠) ∙ 𝑑𝑠 
Equation 12 
𝑉𝑝 = 2𝜋
2  𝐼(0)/𝑄 
Equation 13  
Using Equation 13 the volume of the protein can be calculated for which the molecular 
weight is in kilodaltons, and this value is typically 0.6 times the Porod volume. Porod 
calculated that Q is the direct product of excess electron scattering of the particle and 
regardless of the x-ray wavelength, data should have the same constant with the same 
sample at the same concentration. 
 
The P(r) function or pair-distance distribution function describes the paired-set of all 
distances between points within an object. In SAXS, the P(r) function is used to describe 
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the paired-set of distances between all of the electrons within the macromolecular 
structure. From this, the maximum distance between two particles can be calculated, Dmax, 
which gives the largest length of the particle. The P(r) is related to I(s) by the integral:  
𝐼(𝑠) = ∫ 𝑃(𝑟)
𝑠𝑖𝑛 𝑠 ∙ 𝑟
sin 𝑠 ∙ 𝑟
𝐷𝑚𝑎𝑥
0
𝑑𝑟 
Equation 14 
 
3.5 Ab Initio modelling  
Ab initio modelling methods allow one to build three-dimensional, low resolution models 
from 1 D scattering profile. There are a number of programs that can be used within the 
ATSAS suite (Petoukhov et al. 2012) that are able to do this, but for this thesis DAMMIN 
and DAMMIF were used (Petoukhov et al. 2012). DAMMIN used an algorithm that 
represents the shape of the particle using densely packed beads in a constrained search 
volume. The sphere usually has the diameter of the Dmax previously calculated, and using 
a simulated annealing algorithm the beads are moved  from a random configuration to an 
optimum configuration that minimises the difference between the collected scattering 
data and predicted scattering pattern from the model (Svergun 1999). Ab initio methods 
do not provide unique solutions and if you run the programme multiple times, numerous 
model will be generated. Thus, multiple runs of DAMMIN can be performed, which 
produce many models. These models can be aligned using the programme SUPCOMB, 
which identifies the most typical model in the ensemble and aligns them (Kozin & 
Svergun 2001). The aligned models can be constructed into a single averaged shape, 
conserving the most persistent features using the programme Damaver, which can be used 
to average all the models.  
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DAMMIF is a faster version of DAMMIN that uses an unconstrained volume that is able 
to grow during the simulated annealing if needed, which overcomes effects caused by a 
slight underestimation of Dmax (Franke & Svergun 2009). DAMMIF also incorporates 
other programmes including Damaver and SUPCOMB which is automated and allows 
for multiple runs of DAMMIN, aligned, scored and averaged before a final model is 
produced. A limitation of these two methods is that they make the assumption of a 
uniform electron density within the particle, which limits the resolution of the bead model. 
So, this means that the scattering curve can only be fitted to a restricted range (s = 0.3 Å-
1) (Blanchet & Svergun 2013). Another programme, Crysol, can be used to compare the 
1D scattering curve of a data collection to a known structure by generating a SAXS 
intensity profiles from atomic coordinates while considering the hydration shell 
surrounding the target sample (Barberato et al. 1995).  
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Chapter IV. Materials and Methods.  
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4.1 Materials   
4.1.1 Bacterial strains 
 
Strains that were used in this work are summarised in Table 4.1 below. For expression of 
MATα1, MATα2 and MATβV2 in all vectors, BL21 (DE3) cells were used whilst for 
MATβV1 BL21 (HC41) were used for expression.  DH5α and XL1-Blue were used for 
routine cloning and mutagenesis work.  
Table 4.1 Bacterial strains used in this work 
Name Supplier  Genotype  
BL21 (DE3)  Novagen E. coli B F- dcm ompT hsdS(rB- mB-) gal λ(DE3) 
BL21 (HC41) Lucigen  E.coli F ompT hsdS B (rB -mB-) gal dcm (DE3) 
DH5α  E. coli ∆(lacZYA–argF)U169 deoR recA1 endA1 
hsdR17(rK
+, mK
+) supE44 λ– thi-1 gyrA96 relA1 F- 
proAB+ lac1qZ ∆ M15 ssf::Tn5 [Kmr] 
XL1-Blue Stragene 
corp.  
E. coli recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 
lac [F ́proAB lacIq Z∆M15 Tn10 (Tetr)] 
  
 
4.1.2 Bacterial culture 
 
Growth of bacterial strains was achieved using Lysogeny broth (LB) medium for all 
proteins. Ten mL overnight cultures were grown in 50 mL falcon tubes in the presence of 
antibiotics, either ampicillin at 100 μg/mL or kanamycin at 50 μg/mL. Cultures were 
grown at 37 °C at 250 rpm. 
4.1.3 DNAs 
 
MAT1 and MAT2 (pNIC vector) constructs were kindly provided by structural 
genomic consortium, Oxford and the MATV1 and MATV2 constructs were from the 
laboratory of Dr Shelly Lu (University of California Los Angeles). MATV1 construct 
was subcloned into the pHIS2 parallel vector. MAT2, MATV1 and MATV2 was also 
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subcloned into pET-28M-SUMO3-GP vector. GIT1 DNA was purchased from addgene 
(Plasmid #15226).  
 
4.1.4 Plasmids 
 
Plasmids containing oligo(Histidine) or oligo(Sumo) tags were used. These vectors 
contained multiple restriction sites and a sequence encoding a protease cut site which 
allows the cleavage of the tag sequences. Information regarding this can be found in Table 
4.2.  
Table 4.2. Summary of Plasmids used in this work 
Full Name Abbreviated 
Name  
Size 
(bp) 
Cleavage  Resistance  Source 
pET-28M-
SUMO3-GP 
pET_SUMO 6268 SENP2 Kanamycin  EMBL  
pET-28a(+) pET28 5396 Thrombin Kanamycin Addgene 
pHIS2 
parallel 
His-Par 7207 TEV Ampicillin (Sheffield et al. 1999) 
pNIC28-
Bsa4 
pNIC 5353 TEV Kanamycin Structural genomics 
consortium  
pEGFP-GIT1 pEGFP 6900 - Kanamycin  Addgene 
 
4.1.5 Oligonucleotides  
 
The oligonucleotides used in this work are listed below in Table 4.3. Primers were 
designed based on DNA sequences of interest and checked for secondary structure using 
the multiple primer analyser from Life Technologies. 
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Table 4.3. Oligonucleotides used for cloning of recombinant plasmids and mutagenesis. Primer names describe the primer type (forward or reverse). 
Restriction site (RS) indicates sites used for cloning. 
Name Vector Restriction 
Site (RS)  
Oligonucleotide sequence 
MATβV1W320Stop Forward His_Par  GGAATCAAAGAATCACTTTAGCCTTTCCTCATTGACAAG 
MATβV1W320Stop Rev His_Par  CTTGTCAATGAGGAAAGGCTAAAGTGATTCTTTGATTCC 
MATβV2W309Stop Forward Pet28  GGAATCAAAGAATCACTTTAGCCTTTCCTCATTGACAAG 
MATβV2W309Stop Reverse Pet28  CTTGTCAATGAGGAAAGGCTAAAGTGATTCTTTGATTCC 
MATα2Δ19 Forward pET_SUMO Age1 TTTTTACCGGTGGATTCACCTCAGAGTCGGTCGGGGAA 
MATα2Δ19 Reverse pET_SUMO XhoI TTTTTCTCGAGTCAATATTTAAGCTTCTTGGGCACTTCCC 
MATβΔ16 Forward His_Par  TTTTTCCATGGGACTCTCTATACACTTTGTTCCCGGG 
MATβΔ16 Reverse His_Par  TTTTTCTCGAGCTAATGAAAGACCGTTTG 
MATα2D134A Forward PNIC  CATTGGTGCTGGAGCCCAGGGCTTAATG 
MATα2D134A Reverse PNIC  CATTAAGCCCTGGGCTCCAGCACCAATG 
MATα1C120A Forward PNIC  CAGATATTGCCCAGGCCGTCCATCTGGAC 
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MATα1C120A Reverse PNIC  GTCCAGATGGACGGCCTGGGCAATATCTG 
MATα1C120G Forward PNIC  CAGATATTGCCCAGGCCGTCCATCTGGAC 
MATα1C120G Reverse PNIC  GTCCAGATGGACGCCCTGGGCAATATCTG 
MATβR328/317stop Forward His_Par/Pet28  CATTGACAAGAGATGGTGACAAACGGTCTTTC 
MATβR328/317stop Reverse His_Par/Pet28  GAAAGACCGTTTGTCACCATCTCTTGTCAATG 
MATβT330/319stop Forward His_Par/Pet28  GACAAGAGATGGAGACAATAGGTCTTTCATTAGCTCG 
MATβT330/319stop Reverse His_Par/Pet28  CGAGCTAATGAAAGACCTATTGTCTCCATCTCTTGTC 
MATβH331/322stop Forward His_Par/Pet28  GGAGACAAACGGTCTTTTAATAGCTCGAGCACCACC 
MATβH331/322 stop Reverse His_Par/Pet28  GGTGGTGCTCGAGCTATTAAAAGACCGTTTGTCTCC 
MATα2SUMO Forward pET_SUMO Age1 TTTTTACCGGTGGAATGAACGGACAGCTCAACGGC 
MATα2SUMO Reverse pET_SUMO XhoI TTTTTCTCGAGTCAATATTTAAGCTTCTTGGGCACTTCCC 
MATβV1SUMO Forward pET_SUMO Age1 TTTTTACCGGTGGAATGGTGGGGCGGGAGAAAGAGCT 
MATβV1SUMO Reverse pET_SUMO XhoI TTTTTCTCGAGTCACTAATGAAAGACCGTTTGTCTCCATCTCTTG 
MATβV2SUMO Forward pET_SUMO Age1 TTTTTACCGGTGGAATGCCTGAAATGCCAGAGGACATGGAG 
MATβV2SUMO Reverse pET_SUMO XhoI TTTTTCTCGAGTCACTAATGAAAGACCGTTTGTCTCCATCTCTTG 
GIT1 Forward pET_SUMO XhoI TTTTTACCGGTGGAATGTCCCGAAAGGGGCCGCGAGCG 
GIT1 Reverse pET_SUMO Not1 TTTTTGCGGCCGCTCACTGCTTCTTCTCTCGGGTGGTGATGGTGACC 
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4.2 Methods  
4.2.1 DNA amplification   
 
Polymerase chain reaction (PCR) was used to amplify DNA sequences was achieved by 
the using Phusion® High-Fidelity DNA polymerase (NEB) and primers specified in 
Table 4.4. Reaction mixture consisted of the following: 
Table 4.4. Composition of PCR reaction. 
 Volume (μL) 
Template DNA ( 1 µg) 1 
Forward primer 10 mM 2 
Reverse primer 10 mM  2 
dNTP  0.5 
Phusion buffer 5 
Phusion enzyme  0.5 
DMSO  1.5 
ddH20 12.5 
 
4.2.2 Agarose gel electrophoresis  
 
Amplified DNA fragments and plasmid DNA were analysed by 1.5 % (w/v) agarose gel 
electrophoresis. Agarose D1 Low electroendosmosis was dissolved in TAE (Tris-acetate-
EDTA) 1x buffer and 0.25 µg/ml SYBR® Safe DNA gel stain was added to the solution. 
DNA samples were mixed with the loading buffer (Thermo) in a 5:1 (v/v) ratio and 
GeneRuler™ 1 kb DNA ladder (Thermo) was used as molecular weight marker. 
Electrophoresis was run in TAE 1x buffer. 
4.2.3 Colony PCR 
  
The presence of the recombinant plasmids was detected using colony PCR. One colony 
was suspended into a tube containing Master Mix reaction (Thermo): 
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Table 4.5. Composition of colony PCR  
 Volume (μL) 
Master Mix 10 
Forward primer 10 mM 0.5 
Reverse primer 10 mM  0.5 
Water 9 
 
This was then subjected to PCR following using the following protocol: 
Table 4.6. PCR cycling conditions for amplification of MATα2, MATβV1 and MATβV2 
sequences. 
 Stage  Temperature (⁰C) Time (s) 
 Initial Denaturation  95 600 
 
25 cycles 
Denaturation 95 30 
Annealing  50-58* 30 
Elongation  72 60 
 Final Elongation  72 600 
*Annealing temperature varied depending on melting temperature of primers that were 
used.  
 
The success of the ligation process was determined by a band appearing with the size of 
the inserted DNA after being run on agarose gel electrophoresis  
4.2.4 Transformations 
 
DNA was either transformed into XL1Blue or DH5α strains. Fifty µl of competent cells 
was mixed with 50 ng of DNA for 30 min on ice. Then, the mixture was subjected to a 
heatshock at 42 °C for 45 s. After 5 min incubation on ice, 800 µl of LB medium was 
added and cells were incubated at 37 °C for 1 hour. Transformed cells were spread on an 
agar plate supplemented with the appropriate antibiotic (ampicillin at 100 μg/mL or 
kanamycin at 50 μg/mL) and incubated overnight at 37 °C. 
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4.2.5 DNA sequencing  
 
DNA sequencing of the recombinant plasmids was performed by the DNA Sequencing 
Service of the Centro Nacional de Investigaciones Oncológicas (CNIO, Madrid) and 
compared to the expected sequence using ClustalW server (Thompson et al. 1994). For 
pET28 vectors standard primers were used for sequencing as provided by CNIO, but for 
other vectors sequencing primers were designed and produced (Life Tech), and can be 
found in table 4.7. 
Table 4.7. List of sequencing primers from 5’-3’  
Name Sequence  
pNIC_forward  TGTGAGCGGATAACAATTCC 
pNIC_reverse  AGCAGCCAACTCAGCTTCC 
pET_Sumo_forward GAGGACACCATCGACGTGTT 
pET_Sumo_reverse TTCACTTGTAGAGCTCGTCCAT 
His_parallel_forward CGTCCGGCGTAGAGGATCG 
His_parallel_reverse  CTCAAGACCCGTTTAGAGGC 
 
4.2.6 Site-directed mutagenesis  
 
Point mutation mutants of MAT proteins were produced using site-directed mutagenesis 
and reaction mix is shown in Table 4.4. Forward and reverse primers are summarised in 
Table 4.3. Phusion® High-Fidelity DNA Polymerase (NEB) PCR protocol was followed. 
PCR products were subjected to Dpn1 (NEB) digest to remove template DNA for 2 hours 
at 37 °C then 20 mins at 80 °C before PCR product was transformed into DH5α cells and 
plated on antibiotic selective agar plates and incubated overnight at 37 °C. 
 
4.2.7 Cloning of MATα2, MATβV1 and MATβV2 genes into pETSUMO 
 
MATα2, MATβV1 and MATβV2 DNA were amplified by polymerase chain reaction 
(PCR) using primers MATα2SUMO Forward & Reverse, MATβV1SUMO Forward & 
Reverse and MATβV2SUMO Forward & Reverse (Table 4.3) with conditions described 
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in Table 4.8. MATα2_PNIC, MATβV1_HisParallel and MATβV2_pET28+ vectors were 
used as template DNA and followed the following cycling conditions: 
Table 4.8. PCR cycling conditions for amplification of MATα2, MATβV1 and 
MATβV2 sequences used in cloning.  
 Stage  Temperature (⁰C) Time (s) 
Initial Denaturation  95 120 
 
25 cycles 
Denaturation 95 10 
Annealing  61 30 
Elongation  72 30 
 Final Elongation  72 600 
 
 
Amplified DNA was cleaned using Wizard® SV Gel and PCR Clean-Up System 
(Promega).  pET_SUMO vector and Amplified DNA sequences were digested overnight 
at 37 ⁰C using AgeI and XhoI (NEB) restriction enzymes. Digested pET_SUMO vector 
was cleaned and dephosphorylated for 1 hour at 37 ⁰C using Antarctic Phosphatase 
(NEB).  Fragment MATα2 (1185 bp), MATβV1 (1002 bp) and MATβV2 (969 bp) and 
digested pET_SUMO (5516 bp) were extracted from a 1x TAE agarose gel after 
electrophoresis at 100 V for 50 minutes in 1 x TAE buffer followed by purification using 
the Wizard® SV Gel and PCR Clean-Up System. Purified amplified DNA was ligated 
for 1 hour at 22 ⁰C into AgeI-XhoI digested pET_SUMO vector using T4 DNA ligase 
(Fermentos), transformed into DH5α strain E.coli, plated on to agar media with added 
kanamycin (50 μg/mL) and left at 37 ⁰C overnight.  Colony PCR was used to test for the 
presence of the desired insert using the pET_SUMO_forward and pET_SUMO_reverse 
sequencing primers and PCR master mix (Thermo). The following PCR cycling 
conditions were used (Table 4.9): 
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Table 4.9. Colony PCR cycling conditions for amplification of MATα2, MATβV1 and 
MATβV2 sequences 
 Stage  Temperature (⁰C) Time (s) 
 Initial Denaturation  95 120 
 
30 cycles 
Denaturation 95 30 
Annealing  50 30 
Elongation  72 60 
 Final Elongation  72 600 
 
Samples were run on a 1x TAE agarose gel at 100 V for 50 minutes in 1 x TAE buffer. 
Colonies containing the MATα2, MATβV1 and MATβV2 DNA were grown overnight 
in selective LB media at 37 ⁰C and plasmids were extracted by Wizard SV Minipreps 
DNA Purification System (Promega). DNA was sent to and sequenced by CNIO.  
 
4.2.8 Cloning of GIT1 into pETSUMO vector 
 
Human GIT1 gene was purchased from Addgene (15526) in the pEGFP vector. Cloning 
of GIT1 into pETSUMO vector was the same as stated in section 4.2.7, but with the use 
of GIT1_forward and GIT1_reverse as the primers and the vector, pETSUMO, and 
amplified insert were digested using the restriction enzymes Xho1 and Not1. 
 
4.2.9 Production of TEV protease  
 
TEV expression was carried out in E. coli BL21 (DE3). Cells were grown in LB medium 
at 37 °C to A600= 0.6-0.8 at which protein expression was induced by the addition of 1 
mM isopropyl β-D-1 IPTG (GoldBio), at 20 °C overnight. Cultures were centrifuged at 
6000x g for 20 minutes at 4 °C and the pellet was taken and was flash frozen using liquid 
nitrogen before being stored at -80 °C. Purification of TEV protein was carried out 
following the protocol of Alsarraf et al (Alsarraf et al. 2011).  
67 
 
 
4.2.10 Production of SENP2 Protease 
  
The expression of SENP2 was the same as TEV protease (section 4,2,9). Cell pellets were 
lysed at 4°C using high-pressure homogenisation at 27 Kpsi (Constant System, Ltd, UK) 
in lysis buffer (20 mM Tris-HCl pH 8.0, 1 mM β-mercaptoethanol (β-ME), 350 mM 
NaCl, 10 mM imidazole, 10 μg/ml DNAse,  20 μg/ml lysozyme) and the cell homogenate 
was clarified by centrifugation at 20,000x g for 40 minutes. Clarified supernatant was 
loaded into nickel resin equilibrated with lysis buffer. Column was washed with lysis 
buffer and then by wash buffer (20 mM Tris-HCl pH 8.0, 350 mM NaCl, 1 mM β-ME, 
and 20 mM imidazole). Proteins were eluted with the elution buffer (20 mM Tris-HCl pH 
8.0, 350 mM NaCl, 1 mM β-ME, and 400 mM imidazole). SENP2 was then loaded into 
an ion-exchange chromatography column, HiTrap Q HP column (GE Healthcare), that 
was pre-equilibrated with 20 mM Tris-HCl pH 8.0, 50 mM NaCl, 1 mM β-ME, then the 
purification was performed using an isocratic gradient from 0.05 M to 1 M NaCl. 
Fractions containing SENP2 were collected and 10 % (v/v) glycerol was added before 
protein was flash frozen at -80 °C. 
 
4.2.11 Purification of MAT1, MAT2 (pNIC vector), MATV1 (His-Parallel) and 
MATV2 (pET28) 
 
The expression of MATV1 was carried out in E. coli BL21 (HC41) and the expression 
of other three proteins in E. coli BL21 (DE3) strain. Cells were grown in LB medium at 
37 °C to A600= 0.6-0.8 at which protein expression was induced by the addition of 1 mM 
isopropyl β-D-1 IPTG (GoldBio), at 20 °C overnight. Cultures were centrifuged at 6000x 
g for 20 minutes at 4 °C and the pellet was taken and flash frozen using liquid nitrogen 
before being stored at -80 °C. 
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Cell pellets were lysed at 4°C using high-pressure homogenization at 27 Kpsi (Constant 
System, Ltd, UK) in lysis buffer (500 mM NaCl, 5% (v/v) glycerol, 5 mM Imidazole, 10 
mM β-ME) and cell homogenate was clarified by centrifugation at 20,000x g for 40 
minutes. Clarified supernatant was loaded into nickel resin equilibrated with lysis buffer. 
Column was washed with lysis buffer and then by wash buffer (500 mM NaCl, 5% (v/v) 
glycerol,  30 mM Imidazole and 10 mM β-ME). Proteins were eluted with the elution 
buffer (500 mM NaCl, 250 mM Imidazol, 10mM β-ME) and the Histag was then cleaved 
from MAT2, MAT1 and MATV1 by incubation overnight with tobacco etch virus 
(TEV) protease and with thrombin in the case of MATV2. MAT2, MAT1 and 
MATV2 were then loaded into an ion-exchange chromatography column, HiTrap Q HP 
(GE Healthcare), and MATV1 in a HiTrap S HP, that were pre-equilibrated with Buffer 
A (20 mM Tris-HCl pH 8.0, 50 mM NaCl, 5 mM β-ME), then the purification was 
performed using an isocratic gradient from 0.05 M to 1 M NaCl. Selected fractions of 
MAT2 and MAT1 were then concentrated and loaded onto a HiLoad 16/60 Superdex 
200 gel filtration column (GE Healthcare) and fractions of MATV2 and MATV1 were 
loaded onto HiLoad 16/60 Superdex 75. Finally, fractions containing pure protein were 
pooled and stored at -80 ºC. Buffer used in each purification step was 25 mM HEPES pH 
7.5 unless otherwise states. 
 
4.2.12 Purification of MAT2, MATV1 and MATV2 (pET_SUMO) 
 
The expression, induction, lysis of cell pellets and affinity chromatography of the 
pET_SUMO constructs was the same as described above. After the protein was eluted 
from the nickel resin, 100 μg/mL SENP2 enzyme was added and the protein was left at 
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room temperature for one hour with agitation before further overnight incubation at 4 ⁰C 
and dialyzed into 25 mM HEPES pH 7.5, 50 mM NaCl and 10 mM β-ME. Proteins were 
then loaded into an ion-exchange chromatography column, HiTrap Q HP column (GE 
Healthcare), that was pre-equilibrated with Buffer A (25 mM HEPES pH 7.5, 25 mM 
NaCl, 5 mM β-ME), then the purification was performed using an isocratic gradient from 
0.05 M to 1 M NaCl. Selected fractions of MAT2 and MAT1 were then concentrated 
and loaded into a HiLoad 16/60 Superdex 200 Gel Filtration column (GE Healthcare) and 
fractions of MATV2 and MATV1 into HiLoad 16/60 Superdex 75. Finally, fractions 
containing pure protein were pooled and stored at -80 ºC.  
 
4.2.13 Assembly of MAT protein complexes  
 
In order to assemble the complexes, either MATα1 or MATα2 were incubated together 
with MATβV1 or MATβV2 for 1 hour at 4 ⁰C in 50 mM HEPES buffer pH 7.5 containing 
10 mM MgCl2, 50 mM KCl, ± 300–500 mM NADP. The complex was then loaded onto 
a Superdex 200 10/300 column and eluted with buffer consisting of 200 mM NaCl, 25 
mM HEPES pH 7.5, 1 mM MgCl2, 5mM KCl, 1 mM TCEP [tris(2-
carboxyethyl)phosphine]. Concentrations of MAT protein varied to form the MATαβ 
complexes,, but were always in a ratio of MATα:MATβ protein of 1:2.  
 
4.2.14 Purification of GIT1 proteins 
 
Growth, induction expression, centrifugation, lysis and nickel affinity chromatography of 
GIT1 and GIT1 mutants was the same as described in section 4.2.12. GIT1 proteins were 
incubated with 100 μg/mL SENP2 for 1 hour at room temperature before further 
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incubation overnight at 4 °C. Proteins were then loaded into an ion-exchange 
chromatography column, HiTrap Q HP (GE Healthcare) that was pre-equilibrated with 
Buffer A (25 mM Tris pH 8.0, 50 mM NaCl, 10 mM β-ME), then the purification was 
performed using an isocratic gradient from 0.05 M to 1 M NaCl. Selected fractions of 
GIT1_R413stop were then concentrated and loaded into a HiLoad 16/60 Superdex 200 
gel filtration column (GE Healthcare).   
 
4.2.15 Polyacrylamide gel electrophoresis (PAGE) 
 
Analysis of the proteins was done by sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) in 10-12% (w/v) acrylamide gels. Samples were mixed with 
Laemmli loading buffer 2x (Bio-Rad) supplemented with 10 mM β-ME and heated at 90 
°C for 10 min. Broad range (Bio-Rad) pre-stained standard was used as a molecular 
weight markers. Electrophoresis was carried out at 150 V with standard running buffer 
(0.025 M Tris, 0.192M glycine, 0.1% (w/v) SDS, pH 7.5).  
4.2.16 Native-PAGE  
 
NativePAGE™ Novex® 4-16 % Bis-Tris gels were purchased from Invitrogen and the 
protocol used was the same as the one described by the manufacturer.  
 
4.2.17 Staining of gels 
  
Gels were stained for 1 hour in a solution containing 0.1% (w/v) Coomassie Brilliant Blue 
R-250, 40 % (v/v) methanol and 10 % (v/v) glacial acetic acid before background staining 
was eliminated by washing with 40 % (v/v) methanol 10 % (v/v) glacial acid solution. 
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4.2.18 Activity assays  
 
Stock solutions of MATα2, MAT(α2)4(βV1)2 and MAT(α2)4(βV2)2 were diluted in 
dilution buffer ( 10 mM HEPES pH 7.5, 500 mM NaCl, 5% (v/v) glycerol and 0.5 mM 
TCEP) to concentrations of 250 nM, 125 nM and 62.5 nM, respectively. The reaction 
buffer consisted of 25 mM HEPES pH 7.5, 5 mM MgCl2, 5 mM KCl. The methionine 
solutions (25-1000 μM) were prepared in dilution buffer.  For measurements with NADP, 
stock 0.5 mM NADP, prepared in water was added to the reaction buffer.  
 
Reactions were started and final concentrations were achieved upon the addition of 40 µL 
5 mM ATP, diluted in dilution buffer. Each sample was  pre-incubated for 15 minutes 
with methionine and reaction buffer prior to the addition of ATP. Final concentrations of 
proteins were 50 nM, 25 nM and 12.5 nM for MATα2, MAT(α2)4(βV1)2 and 
MAT(α2)4(βV2)2 respectively. The reaction mixtures were thermostated and agitated (37 
°C, 1400 rpm). After 10 minutes the reactions were quenched with 75 % (v/v) acetonitrile 
and 1.2 % (v/v) formic acid in water. To ensure all reactions had been stopped, samples 
were shaken (4 °C, 1400 rpm) before centrifugation (14,000 rpm) and transferred to 96-
well plates for ultra-pure liquid chromatography mass spectrometry (UPLC-MS) analysis 
(Van Liempd et al. 2013).  
 
Samples were injected into an ACQUITY UPLC system in a randomised order and the 
detection and quantification of SAMe and methionine was carried out. Briefly, upon 
injection, polar metabolites bind to the UPLC-column and then are eluted in order of 
increasing polarity. Elutes are subjected to time of flight mass spectroscopy to determine 
identity. Ten point calibration curves with exponentially spaced concentrations were used 
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for quantification of samples. The rate of SAMe formation was calculated (fmole/s/nmol 
MAT) for each substrate concentration. Prism 4.0 (www.graphpad.com) software was 
used to fit the enzyme kinetic data with the Michaealis-Menten equation in order to obtain 
values for kcat, Vmax and Km.  
 
4.2.19 Differential scanning fluorimetry (DSF) 
  
MATα2 was purified as described in section 4.2.11. Differential scanning fluorimetry was 
performed in a 96-well PCR plate using an Mx3005p RT (real-time)-PCR machine 
(Stratagene). Each well (25 µl) consisted of MATα2 protein (0.2-1.2 mg/mL) diluted in 
25 mM HEPES pH 7.5, 5 mM MgCl2, 5 mM KCl (section 4.2.18) and Sypro Orange 
(Invitrogen). Wells also contained added compounds including SAMe (1-10 mM), PEG 
600 (2.5-20 % (w/v), and imidazole (1-100 mM). Fluorescence intensities were measured 
from 25 °C to 96 °C with a ramp rate of 1° C/min. Sypro Orange dye (Invitrogen) was 
diluted as described in the Invitrogen thermal stability assay protocol. For the analysis of 
the data, each of the melting curves was normalized. This was done by taking the 
minimum value of each curve and subtracting it from all the points on that curve followed 
by dividing the melting curve by its maximum value. This normalization enables each 
melting curve to be compared to each other. The first derivative of the melting curve was 
calculated which is used to give the melting temperature. The melting temperature is the 
temperature that corresponds to the maximum point on of the first derivative curve (Sun 
et al. 2015).    
 
4.2.20 Circular Dichroism  
 
Circular dichroism data were recorded on a J-815 circular dichroism spectrometer (Jasco, 
UK) equipped with thermoelectric temperature control. Samples of MATβV1 and 
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MATβV2 and the mutant variants were diluted to 1-5 μM in 0.1 M phosphate buffer pH 
7.0 and placed in a 2-mm cell. All circular dichroism  wavelength scans were performed 
at a constant temperature of 25 ºC between 200 and 280 nm with a scanning speed of 50 
nm ∕ min and a data pitch of 1 nm. Data analysis was done using Origin and JASCO 
Spectra Manager integrated software. Raw data were converted to Ellipticity*10-3 (deg 
cm2 dmol-1) using Microsoft Excel. 
 
4.2.21 Isothermal titration calorimetry (ITC) 
  
In order to examine the association constant (Ka) of MATαβ complexes, MATα2, 
MATα1, MATβV1, MATβV2 and any MATmutant variants were buffer-exchanged by 
gel filtration on a Superdex 200 10/300 GL column equilibrated with 200 mM NaCl, 
20 mM HEPES pH 7.5 buffer before ITC analysis. Subsequently, MATβ isoforms and 
mutants were injected into MATα2 or MATα1 solution in aliquots of 10 or 20 µl, 
respectively. The concentration of MAT proteins were: MATα2=10.0 μM, 
MATβV1=51.2 μM, MATβV2=36.5 μM, MATβV1Δ320 and MATβV2Δ309= 100 μM. 
For reactions using MATα1, 45.1 M of MATα1 and 236.8 M of MATβV1 or MATβV2 
were used. To verify the interaction of NADP with different MATβ isoforms, each 
protein was buffer-exchanged by gel filtration on a Superdex 200 10/300 GL column 
equilibrated in 5 mM MgCl2, 5 mM KCl, 20 mM HEPES pH 7.5, 200 mM NaCl before 
ITC analysis. NADP was also diluted in the same buffer. NADP was injected into 
MATβV2 in aliquots of 15 µl and into MATβV1 in aliquots of 10 µl. For measurements 
with NADP, proteins were buffer exchanged into 200 mM NaCl, 20 mM HEPES pH 7.5. 
The concentration of MAT proteins were: MATβV1=29.8 μM, MATβV2=30.0 μM, 
MAT(α2)4(βV2)2=10.2 μM. 500 μM NADP was titrated against the MATβ proteins 
whilst 155 μM NADP was titrated against the MAT(α2)4(βV2)2 complex. All ITC 
74 
 
measurements were carried out at 25 °C on a VP-ITC Microcalorimeter (MicroCal/GE 
Healthcare). The ITC data were processed using Origin software (OriginLab Corp., 
USA).  
 
4.2.22 Crystallisation and data collection 
 
Crystals of the MAT(α2)4(βV2)2 complex appeared at 25 °C within 1–2 days in drops 
containing 2 µl MAT(α2)4(βV2)2 complex at 5.8 mg ml-1 mixed with 1 µl precipitant 
solution of 100 mM MES/imidazole buffer pH 6.5, 10% (v/v) ethylene glycol, 20% (w/v) 
PEG 8000. Before crystallization the MAT(α2)4(βV2)2 complex was incubated with its 
product SAMe (1 mM), or its substrate ATP (1 mM) or AMP-PNP (250 µM) and MET 
(1 mM). These compounds were added to the precipitant and cryo solution. Cryo solution 
consisted of well condition with 20 % (v/v) ethylene glycol.  
For structures described in chapter 6 that contained only MATα2, MATα2 and 
MATβV2H323stop proteins were incubated together for 1 h at 4 ⁰C in 50 mM HEPES 
buffer pH 7.5, 10 mM MgCl2, 50 mM KCl, 100 µM AMP-PNP (Sigma), 10 mM DTT 
with either 10 mM methionine (Sigma) or 10 mM ethionine (Sigma). Each of these two 
complexes was then loaded onto a Superdex 200 10/300 column (GE Healthcare) and 
eluted using 25 mM HEPES pH 7.5, 200 mM NaCl, 1 mM MgCl2, 5 mM KCl 1 mM 
TCEP.  Before crystallization the MAT(α2)4(βV2H323stop)2, that was subjected to gel 
filtration with AMP-PNP and methionine was  incubated with AMP-PNP (250 µM) or 
selenium-methionine (250 µM) and these resulted in the crystals 
SAMe+ADO+MET+PPNP bound and PPNP bound, respectively. Crystallization of 
MAT(α2)4(βV2H323stop)2, that was subjected to gel filtration with AMP-PNP and 
ethionine was incubated with ethionine (250 µM) and  resulted in the SAE bound 
structure. For all crystallisation, protein concentration was 5.8 mg/mL. 
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SAMe+ADO+MET+PPNP bound and PPNP bound crystals appeared at 25 ⁰C within 2-
3 days in drops containing 1 µL of 0.1 M HEPES pH 7.5, 30 % (w/v) PEG 600 with 1 µL 
of MATα2. For SAE, crystals appeared at 18 ⁰C within 3-4 days in drops containing 800 
nL of 0.1 M Imidazole pH 7.0, 50 % (w/v) MPD with 800 nL of MATα2. Crystals were 
cryoprotected in the reservoir solution and flash frozen in liquid nitrogen and for the SAE 
bound crystal, 20 % (v/v) ethylene glycol was added for the cryoprotectant. 
 
Different data sets were collected at the PROXIMA1, XALOC, BM29, I04 and I24 
beamlines at SOLEIL (St Aubin, France), ALBA (Barcelona, Spain), ESRF (Grenoble) 
and Diamond (Oxford, England) synchrotron centres. Data reduction was carried out with 
the HKL-2000 (Otwinowski & Minor 1997) and XDS programs (Kabsch 2010). The 
phases were calculated with Phaser (McCoy et al. 2007) using MATα2 (PDB entry 2P02) 
and MATβ (PDB entry 2YDX, (Shafqat et al. 2013) as search models for molecular 
replacement. Model building and refinement were performed using Coot (Emsley & 
Cowtan 2004) PHENIX (Adams et al. 2010) and REFMAC (Murshudov et al. 2011). 
Data collection and refinement statistics are in table 6.3. 
 
4.2.23 Small angle X-ray scattering data collection and processing 
 
MAT(α2)4(βV2)2  and MAT(α2)4(βVΔ16)2  complexes was assembled as described in 
section 4.2.13 before SAXS data were collected on the SWING beamline at the SOLEIL 
synchrotron, using the HPLC-integrated SAXS setup (David & Pérez 2009) with a two-
dimensional AVIEX CCD detector over an angular range qmin = 0.01 Å
-1 to qmax = 0.5 Å
-
1. 80 µl of the MAT(α2)4(βV2)2 or the MAT(α2)4(βVΔ16)2  complex at 5 mg/ml was 
loaded onto a pre-equilibrated Shodex KW-402.5-4F 150 kDa SEC column, 250 frames 
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of SAXS data were taken over the course of protein elution. MATα1, MATα2 and 
GIT1_R413stop, proteins were buffer-exchanged using a Superdex 200 10/300 column 
into 25 mM HEPES pH 7.5, 200 mM NaCl, 1 mM DTT and addition of 5 % (v/v) glycerol 
before being concentrated to 7.7 mg/mL, 8.7 mg/mL and 10 mg/mL for MATα1, MATα2 
and GIT1_R413stop respectively. Data averaging and reduction, which included 
preliminary calculations of Rg and I(0) were carried out with the Foxtrot suite, developed 
at SOLEIL for the SWING beamline. Further analyses were performed with the ATSAS 
suite (Petoukhov et al. 2012) this included Primus (Konarev et al. 2003) for determination 
of radius of gyration, which fulfilled the condition qR(g)<1.3. Particle distance 
distribution function p(r) analysis was carried out with GNOM refining the Dmax value 
based on the Guinier (Rg) values. In order to generate an ab initio model twenty runs of 
DAMMIN (Svergun 1999) were performed without the use of symmetry restraints, and 
after averaging and filtering a model was produced. SUPCOMB (Kozin & Svergun 2001) 
was used to compare ab initio model with crystallographic data whilst CRYSOL 
(Barberato et al. 1995) compared the 1D scattering cure with the theoretical scatter of the 
MAT(α2)4(βV2)2 complex.  
 
Static SAXS data sets were collected at BM29 at ESRF at 5.5 mg/mL and 3.0 mg/mL for 
MATβV1 whilst MATβV2 was collected at 6.0 mg/mL and 3.0 mg/mL. For data 
collections with NADP, MATβ proteins were incubated with NADP for 1 hour before gel 
filtration was used to remove excess NADP. Samples were then concentrated and frozen. 
MATβV1+NADP data sets were collected at 2.0 mg/mL and 6.0 mg/mL whilst 
MATβV2+NADP were collected at 3.0 mg/mL and 6.0 mg/mL. Data averaging, 
reduction and merging of different concentrations were carried out using Primus 
(Konarev et al. 2003) Data collection was carried out at 20 °C. Further analyses were 
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performed with the ATSAS suite (Petoukhov et al. 2012) and ScÅtter. Molecular weights 
were determined using SAXS MoW (Fischer et al. 2009). 
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Chapter V. Structural and biochemical analysis of 
MATα2β complexes.  
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5.1 Results  
5.1.1 Production of MATα & MATβ proteins.  
 
In order to obtain protein with a high enough purity for crystallisation multiple 
chromatography methods were needed to purify MATα2, MATβV1 and MATβV2 which 
is described in section 4.2.11. MATα2 eluted from a Hitrap Q HP column with a 
maximum conductivity at ~25 mS/cm (Fig 5.1A). The predicted isoelectric point  of 
MATβV1 is 6.9, yet it did not bind to a Q HP column despite having a isoelectric point 
lower the pH of the buffer (pH 7.5) so a S HP column was used and this was found to 
bind MATβV1 (Fig 5.1B), which eluted at ~17 mS/cm. MATβV2 bound a Q HP column 
and was eluted from this at ~21 mS/cm (Fig 5.1C). All three proteins, after gel filtration, 
gave good purity as shown by SDS-PAGE (Fig 5.1D-F) and showed a good agreement 
with predicted molecular weight. Purification of MATα2, MATβV1 and MATβV2 
produced different yields of purified protein. MATα2 gave 5 mg/L, MATβV1 gave 1.4 
mg/L and MATβV2 produced 2.5 mg/L.  
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Figure 5.1 Purification of MATα2, MATβV1 and MATβV2. A. Q HP ion-exchange 
elution profile of MATα2 showing absorbance at 280 nm in blue. B. Gel filtration profile 
(blue) and the SDS-PAGE of purified MATα2 from fractions of the elution (12.5-17.5 
mL). C. S HP ion-exchange spectrum of MATβV1 showing absorbance at 280 nm in 
blue. D. Gel filtration profile (green) and the SDS-PAGE of purified MATβV1 from 
fractions of the elution (14.0-18.0 mL). E. S HP ion-exchange spectrum of MATβV2 
showing absorbance at 280 nm in blue. F. Gel filtration profile (red) and the SDS-PAGE 
of purified MATβV2 from fractions of the elution (14.0-18.0 mL). All panels show 
absorbance at 280 nm which was used as an indication of  the presence of protein. A 
Superdex 200 10/300 column was used for gel filtration. 
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5.1.2 MATαβ complex formation and characterisation. 
 
Upon incubating MATα2 with either MATβV1 or MATβV2 for 1 hour the formation of 
the MATαβ complexes; MAT(α2)4(βV1)2 (green) and MAT(α2)4(βV2)2 (red) were 
observed (Fig 5.2A). Gel filtration elution peaks of both complexes were at a different 
volume (12.0 mL) to that of MATα2 (13.5 mL) suggesting a larger molecular weight. 
Fractions of both complexes were run on SDS-PAGE and showed that both proteins were 
present in the fractions (Fig 5.2B) and also on native-PAGE which showed the complexes 
have a much larger molecular weight than either of the subunits alone (Fig 5.2C). The 
molecular weight of the complexes according to native-PAGE corresponded to ~130 kDa. 
Initially, to make the MATαβ complexes equal ratios of MATα2 to MATβ were incubated 
together, which resulted in two peaks appearing on gel filtration, one corresponding to 
the complex at ~12.0 mL whilst the other peak, which appeared around ~15.0 mL was 
MATβ. The ratio of MATα2:MATβ was then changed to 2:1 and this caused the second 
peak, MATβ, to disappear leaving the complex peak only.   
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Figure 5.2. Formation of the MATαβ complexes. Purified MATα2 protein was 
incubated with either purified MATβV1 or MATβV2 (section 4.2.11) before being 
injected into a Superdex 200 10/300 column (section 4.2.13). A. Gel filtration profiles of 
250 μM MATα2 (blue) and MATαβ complexes (green & red). MAT(α2)4(βV2)1 consisted 
of 140 μM MATα2 and 70 μM of MATβV1. MAT(α2)4(βV2)2 consisted of 100 μM 
MATα2 and 50 μM of MATβV2. The shift in the MATαβ complexes, shown by a lower 
elution volume, suggests that the MATαβ complexes had a greater molecular size 
compared to MATα2. Absorbance was measured at 280 nm which was used as an 
indication of the presence of protein. B. SDS-PAGE of selected fractions from the elution 
of MAT(α2)4(βV2)2 showing that MAT(α2)4(βV2)2 complexes contain two proteins. C. 
Native-PAGE showing that MATαβ complexes have a greater molecular weight (~147 
kDa) than individual proteins (MATα2= ~45 kDa, MATβV2= ~66 kDa). Arrows indicate 
specific proteins and/or protein complexes. 
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5.1.3 Crystallisation and data collection, processing of MAT(α2)4(βV2)2. 
 
For crystallisation, both MAT2V1 and MAT2V2 were concentrated to 10 mg/mL 
and the PCTTM PreCrystallization test was done, which caused heavy precipitation of the 
protein. As a result, the concentration of the complexes was reduced to 6 mg/mL and the 
PCTTM PreCrystallization test was done again and this concentration was found suitable 
for crystallisation trials. Numerous commercial screens were used in 96 well screening 
plates which allowed for two drops to be set per condition, one for MAT2V1 and the 
other for MAT2V2. After 2-3 days crystals appeared at 18 °C in a 100:100 nL drop 
(Fig 5.3A) in 0.1 M MES/imidazole pH 7.5, 20 %  (w/v) PEG 8000, 10 % (v/v) ethylene 
glycol and 0.1 M carboxylic acid mix (Na-formate; NH4-acetate; Na
3-citrate; NaK-
tartrate (racemic); Na-oxamate) for the MATαβV2 complex.  
 
These crystals were taken to a synchrotron source (section 4.2.22) for testing and 
diffracted to 8.5 Å (Fig 5.3B) revealing that they were protein crystals but they did not 
diffract to a suitable resolution to solve the structure. Matthews’s coefficient was 
calculated based on cell dimensions of the crystal (Table 5.1) and gave a probable solution 
size of 258 kDa. Refinement screens were set up in order to grow bigger crystals and 
involved screening around the initial hit by varying the components of the screen, 
changing the temperature, size of drop and ratio of protein to well condition. Varying the 
amount of PEG 6000 or changing this for another PEG variant resulted in no crystal 
growth or greater precipitation. Larger crystals were able to be attained at 25 °C in a 2:1 
μL drop of protein to well condition (Fig 5.3C). Before these crystals were tested a range 
of cryo protective solution were tested, on the home X-ray source at CIC bioGUNE, for 
which 20 % (v/v) additional ethylene glycol was selected. These crystals showed varied 
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morphology and often a cracked appearance was seen (Fig 5.3D), which caused 
diffraction with poorly defined spots. For crystals which contained a non-cracked 
morphology several data sets were collected ranging from 2.35-3.3 Å. To note no crystals 
of MATαβV1 complex were ever seen. 
 
Table 5.1. Calculation of Matthews coefficient from a crystal of MAT(α2)4(βV2)2 that 
diffracted to 8.5 Å.  
Model Prob (N) 
for 
resolution  
Prob (N) 
overall 
Matthews 
coefficient  
Solvent 
content (%)  
Molecular 
weight (kDa)  
1 0.015 0.016 4.930 75.100 129.000 
2 0.981 0.980 2.470 50.100 258.000 
3 0.005 0.005 1.640 25.200 387.000 
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Figure 5.3. Protein crystals of MAT(α2)4(βV2)2. A. Initial screening hit from Morpheus 
crystal screen (Molecular Dimensions) at 18 °C with 200:200 nL protein: well condition 
size drop.. B. Protein crystal in loop from initial hit (30 μm by 10 μm). C. Refinement 
screen produced larger MAT(α2)4(βV2)2 crystals of drop size 1:1 μL protein: well 
condition at 25 °C. The refinement screen condition was 100 mM MES/imidazole buffer 
pH 6.5, 10% (v/v) ethylene glycol, 20% (v/v) PEG 8000. D. Larger crystals (100 μm by 
30 μm) often gave a different morphology with a cracked appearance taken during data 
collection at PROXIMA1, SOLEIL. 
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5.1.4 Structural determination of the MATαβV2 complex. 
 
Using molecular replacement with structures of MATα2 and MATβ (2P02 and 2YDX) 
(Shafqat et al. 2013) the crystal structure of MATαβ could be solved. Several 
crystallographic structures of the 258 kDa MAT2V2 complex were solved with 
different ligands of resolutions ranging from 2.35 to 3.3 Å, which all revealed that the 
complex consists of a 185 kDa MAT2 tetramer, flanked by two MATV2 subunits of 
36.5 kDa each (Fig 5.4) giving the MAT(α2)4(βV2)2 complex. The complex has four 
active sites located at the interface of the MAT2 dimers, two which contain ligands 
bound within the active site and two which do not contain ligands. The N-terminus of all 
four subunits of the MATα2 tetramer were disordered for residues 1-15. Also, the two 
MATα2 monomers which had empty active sites showed no density for the ‘gating loop’ 
(residues 113-131). The flexibility of this loop induces two different conformations of the 
catalytic subunit: opened and closed. The loop is disordered in the open conformation 
causing the entrance to the active site to be opened. The entrance to the active site is 
blocked in the closed conformation and the gating loop becomes well ordered.  Each 
MATβV2 interacts with MATα2 through their C-terminal region flanking the tetrameric 
catalytic core between tunnels created by the N-domain and central domain of two 
MATα2 monomers. In addition, the N-terminal loop (residues 1-13) of both MATβV2 in 
the complex, which are orientated to the same side as the open active sites, are disordered. 
The Proteins, Interfaces, Structures and Assemblies (PISA) server was used to calculate 
if the hexameric, MAT(α2)4(βV2)2, was the most energetically stable form (Table 5.2). 
The hexamer is more energetically stable (ΔGint= -62 kcal/mol) then a trimeric 
MAT(α2)2(βV2)2 (ΔGint= -26.3 kcal/mol). Refinement statistics of the MAT(α2)4(βV2)2 
structures can be found in Table 5.3.  
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Figure 5.4. Structure of MAT(α2)4(βV2)2 complex. A. Crystallographic structure of 
MAT(α2)4(βV2)2 complex (protein data bank accession number 4NDN). Two MATα2 
monomers with visible gating loops are coloured in slate whereas the other two MATα2 
monomers are coloured in red forming a central tetramer. MATβV2 monomers are 
coloured in green with the first visible residues at the N-terminal in orange. The reaction 
product (SAMe) is represented by spheres. 
 
Table 5.2 Analysis of protein interface of MAT(α2)4(βV2)2 complex ranked in order of 
stability of quaternary structures as determined by Proteins, Interfaces, Structures and 
Assemblies (PISA) server. ΔGint represents the standard free energy of binding and ΔGdiss 
is the standard free energy of dissociation. Chains A-D are MATα2 and Chains E-F are 
MATβV2. 
Rank Composition  Chains  Stable ΔGint 
(kcal/mol) 
ΔGdiss 
(kcal/mol) 
1 (α2)4(β)2 ABCDEF Yes -62.0 1.1 
2 (α2)2(β)1  ABF Yes -26.8 1.4 
3 (α2)2(β)1   CDE Yes -27.8 1.0 
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Table 5.3. Data collection and refinement statistics of MAT(α2)4(βV2)2 crystals. *Highest 
resolution shell is shown in parenthesis. 
 SAMe-bound  ADO-bound PPNP-bound 
Data collection 
Wavelength 0.98 0.978 0.979 
Detector Pilatus 6M Pilatus 6M Pilatus 6M 
Space group P212121 P212121 P212121 
Cell dimensions 
    a, b, c (Å) 72.44, 115.72, 
298.45 
72.09, 116.57, 299.48 72.14, 122.18, 298.42 
Resolution (Å)  50-2.6 (2.69-2.6) * 108.63-3.3 (3.48-3.3) * 50-2.35 (2.43-2.35) * 
 Rmerge (%)   14.4   (59.4) 13.9 (49.4) 10.1 (70.4) 
I/I  10.12 (1.75)   6.8 (2.7) 17.3 (1.6) 
Completeness (%)  98.7  (90.1) 99.9 (99.9) 98.0 (83.2) 
Redundancy  5.6     (4.5)   3.3  (3.5) 7.5 (5.2) 
Refinement 
Resolution (Å) 2.6 3.3 2.35 
No. reflections 76590 38907 108283 
Rwork/ Rfree 21.8/27.9 17.6/26.0 21.1/25.1 
No. atoms    
    Protein 15061 16370 16463 
    Ligand/ion 54 / 1 38 / 1 54 / 4 
    Water 108    37 498 
B-factors (Å2) 
    Protein 76.64 71.19 58.4 
 Ligand/ions SAMe / Mg 
68.16 / 60.62 
ADO / Mg 
97.95/49.14 
SAMe /PNPP /Mg 
47.73 / 63.48 /39.57 
   Waters 56.13    30.67 48.39 
Ramachandran Statistics 
Residues in  
Preferred Regions 
1920 (94%) 1863 (90%) 2001 (96%) 
Residues in  
Allowed regions 
108 (5%) 185 (9%) 76 (4%) 
Outliers 10(0.5%) 20 (1%) 8 (0.38%) 
R.m.s deviations 
    Bond lengths (Å)  0.006 0.008 0.005 
    Bond angles (º) 1.091 1.265 1.026 
 
 
  
89 
 
5.1.5 Comparison of ligand bound MAT(α2)4(βV2)2 structures.  
 
In order to probe the catalytic reaction of MAT(α2)4(βV2)2 complex different ligands 
were pre incubated with the complex before crystallisation.  After incubation of 
MAT(α2)4(βV2)2 complex, with its product SAMe, its substrate MET, ATP or AMP-PNP 
(non-hydrolysing ATP analog), the presence of SAMe, adenosine  or PPNP were clearly 
observed in different crystals at the active site (Fig 5.5A-C) as supported by the 
corresponding omit maps (Fig 5.5D-F). In all of the structures the adenine group makes 
a π-π stacking with Phe250 of MATα2, supporting the hypothesis that the substrate (ATP) 
and product (SAMe) can occupy the active site in similar orientations. The adenine group 
of adenosine and SAMe is stabilised by hydrogen bonding between OH of Ser247 side 
chain and the main chain oxygen of Arg249. Gln113 forms a hydrogen bond with its NE2 
to the terminal oxygen of SAMe. The structures show that two of the four active sites are 
occupied by SAMe or adenosine whereas the other two are empty thus providing details 
of structural differences that accompany SAMe formation by comparison of empty and 
occupied sites.  
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Figure 5.5. Active site comparison of MAT(α2)4(βV2)2 crystals. MATα2 monomer 
with visible gating loop is coloured in slate whereas MATα2 monomer with disordered 
loops is coloured in red. Important hydrogen bonds are shown as dotted lines. A. Stick 
representation of the bound product, SAMe, at the active site. B. Crystal co-crystallised 
and soaked with only ATP shows adenosine molecule and PO4 at the active site, as a 
result of the ATPase and tripolphosphatase activity of MATα2. C. Crystal co-crystallised 
and soaked with ANPPNP and methionine shows SAMe and PPNP.  D. Omit (Fo-Fc) 
electron density map and stick representation of bound molecule, the map is contoured at 
the 2.5 σ level around the SAMe molecule E. around the adenosine  molecule and F. 
around SAMe and PPNP. Details of MATαβ complex crystallisation are in section 4.2.21.  
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A comparison of SAMe-bound MAT(α2)4(βV2)2 complex with SAMe-bound MAT(α2)4 
(PDB:2P02) (Shafqat et al. 2013) shows that in the absence of MAT(βV2)2 the four active 
sites of MAT(α2)4 are in a closed conformation (Fig 5.6A). The complex formation with 
MAT(βV2)2, causes an asymmetry in MAT(α2)4, in which two sites are found in an open 
state while the other two are in closed conformation. In the absence of SAMe, the apo-
structures exhibit no density for the gating loop indicating its flexible nature (Fig 5.6B). 
However in MAT(α2)4(βV2)2 the open active sites show two additional flexible loops, 
near the inserted MATβV2 C-terminus (Fig 5.6C).  
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Figure 5.6. Comparison of MAT(α2)4(βV2)2 complex with MAT(α2)4. A. 
Superposition of SAMe-bound MAT(α2)4 (PDB:2P02 in blue) and SAMe-bound 
MAT(α2)4 (slate, red) from the complex MAT(α2)4(βV2)2. In the closed state both 
structures are similar. B. Superposition of apo-MAT(2)2 from Burkholderia 
pseudomallei (PDB:3IML in pink) with the SAMe-bound MAT(α2)2 (PDB:2P02 in blue), 
in the absence of SAMe only the gating loop is disordered. C. Superposition of SAMe-
bound MAT(α2)2 (PDB:2P02 in blue) with MAT(α2)2 after MATβV2 binding, the open 
state in this case show two additional flexible loops, near the inserted MATβV2 C-
terminus. 
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5.1.6 Small angle x-ray scattering of MATα2β complexes. 
 
The oligomeric state of the crystallographic structure of MAT(α2)4(βV2)2 is different to 
the suggested tetrameric form [MAT(α2)2(β)2] (Kotb & Kredich 1985) or the recently 
proposed model in which MATαβ was assumed to be a trimer [MAT(α2)2(β)1] (González 
et al. 2012). In order to conﬁrm that the crystallographic oligomer is representative of the 
solution state and is thus physiologically relevant, small-angle X-ray scattering (SAXS) 
experiments using the HPLC-integrated SAXS set-up at the SOLEIL synchrotron were 
performed. The scattering curve of the complex in solution obtained by SAXS is in 
agreement with the theoretical curve calculated from our 2.35 Å crystal structure (X2 = 
3.2) (Fig. 5.7A), conﬁrming that the MATα2β complex in solution does indeed have the 
same composition and overall conformation as observed in our crystal structures, i.e. 
MAT(α2)4(βV2)2 (Fig. 5.7B).  Statistics for SAXS modelling can be found in Table 5.4. 
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Figure 5.7. Conformation of oligomeric state of MAT(α2)4(βV2)2. A. Small-angle X-
ray scattering of MAT(α2)4(βV2)2 complex (5.0 mg/mL), with the experimental spectrum 
(blue)  shown with a simulated fit (red) obtained from the crystal structure (qmax = 0.30 
Å-1). The radius of gyration, Rg=50.1  0.05 Å, was estimated from the low angle 
scattering region by a Guinier plot (15-39). The distance distribution function, P(r), with 
maximum linear dimension Dmax = 187 Å. B. The ab initio shape reconstruction of 
MAT(α2)4(βV2)2 by DAMMIN using P1 symmetry, showing a good agreement between 
the predicted molecular shape (light green mesh) and the crystal structure (Rg=50.7) 
(cartoon), after alignment by SUPCOMB (NSD=0.93). The MAT(α2)4(βV2)2 consists of 
a tetramer of MATα2 proteins displayed in slate and red flanked by two MATβV2 
proteins shown in orange. The figure was generated using Pymol (Schrödinger, LLC 
2010). 
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As the Chi squared value of the predicted scattering of the MAT(α2)4(βV2)2 structure 
versus the 1D scattering data that was collected was considered to be slightly high, which 
was attributed to the flexibility of the MATβV2 N-terminus, a mutant of MATβV1 was 
created which lacked the first 16 residues (MATβΔ16). This mutant was used to assemble 
the MAT(α2)4(βΔ16)2 complex and then used to perform SAXS experiments.  Comparing 
the experimental data to the docked model (4NDN) gave a closer likeness, given by a 
lower X2 value (1.7), than the wild type MAT(α2)4(βV2)2 complex (Fig 5.8A). Maximum 
particle size (Dmax) of MAT(α2)4(βΔ16)2 (18.7 nm) is simialar to the Dmax calculated from 
the crystallographic model (19.6 nm) (Fig 5.8B). The solution scattering of the  
MAT(α2)4(βΔ16)2  complex, again suggests that it has the same composition and overall 
conformation as observed in the MAT(α2)4(βV2)2 crystal structure (Fig 5.8C). 
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Figure 5.8 Solution scattering of MAT(α2)4(βV1Δ16)2. A. Small-angle X-ray scattering 
of MAT(α2)4(βVΔ16)2 complex (5.0 mg/mL), with experimental spectrum (blue) is 
shown with a simulated fit (red) obtained from the crystal structure (qmax = 0.30 Å
-1). The 
radius of gyration, Rg=53.34 ± 0.15 Å, was estimated from the low angle scattering region 
by a Guinier plot (25-35). B. The distance distribution function, P(r), with maximum 
linear dimension Dmax = 18.70 nm. C.  The ab initio shape reconstruction of 
MAT(α2)4(βV1Δ16)2 by DAMMIN using P1 symmetry, showing a good agreement 
between the predicted molecular shape (light green mesh) and the crystal structure 
(Rg=50.70) (cartoon), after alignment by SUPCOMB (NSD=0.93). The MAT(α2)4(βV2)2 
consists of a tetramer of MATα2 proteins displayed in slate and red flanked by two 
MATβV2 proteins shown in orange. The figure was generated using Pymol (Schrödinger, 
LLC 2010). 
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Table 5.4. Summary of small angle X-ray scattering (SAXS) processing of 
MAT(2)4(V2)2 and MAT(2)4(V116)2. 
SAXS Process MAT(2)4(V2)2 MAT(2)4(V116)2 
Guinier 
q range (Å-1) 0-0.3  0-0.3 
Guinier range 15-39 24-35 
Rg (Å) 50.1  0.05  53.34 ± 0.15 
P(r) 
Maximum particle distance (Dmax) (nm) 18.70 18.67 
I(0) 144.2 ± 8.424x10-3 175.83 ± 8.79x10-2 
Porod volume ( nm3) 310.51 341.65 
Dammin 
Number of runs  10 10 
Maxium q (Å-1) 0.3 0.3 
Dammin refinement 
Chi squared (X2) 1.45 1.5 
Crysol (4NDN.pdb) 
Chi squared (X2) 3.208 1.720 
Supcomb   
Normalized spatial discrepancy (NSD) 0.931 0.922 
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5.1.7 Stabilisation of MATβ binding with the MAT(α2)2 cavity. 
 
One of the key findings from determining the structure of the MAT(α2)4(βV2)2 complex 
is how MATβ interacts with MATα2. The structure reveals that MATβV2 interacts with 
MAT2 through the insertion of the C-terminal tail of the beta subunit into a cavity 
created at the interface of the MAT2 dimer (Fig 5.9A). Residues Lys315 to His323 of 
MATβV2 establish extensive hydrophobic and polar interactions with side chains of both 
MAT2 monomers. A list of interactions can be found in Table 5.5 highlighting all the 
hydrogen bonding between MATα2, MATβ and waters. In the complex, the usually 
disordered tail of the MATV2 C-terminal folds into a helical structure, and within 
MAT(2)2 binding cavity the interaction generates a dilation of the cleft without any 
change in the orientation of the side chains consistent with a ‘lock & key’ mechanism. 
Comparing MATβ crystallised in the absence of MATα2 (2YDY) with MATβ from the 
MAT(α2)4(βV2)2 complex shows that only a small structural rearrangement in the C-
terminus occurs to facilitate binding and that the majority of the MATβ structure remains 
unchanged (Fig 5.9B).  
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Figure 5.9 MATβV2 C-terminal interactions with MATα2. A. Each MATβV2 subunit 
interacts with the core by inserting its C-terminus (green) in a tunnel created at the 
interface between two MATα2 subunits (slate, red). The residues involved in the 
interaction are in stick representation (hydrogen bonds in black dotted lines). B. 
Superposition of MAT (PDB: 2YDY) in blue with MATV2 from the complex with 
MATα2 (green). The black arrow indicates the conformational change of the unfolded C-
terminal loop. 
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Table 5.5. List of hydrogen bonding stabilising the interaction of MATβ with MATα2. 
MATβV2 
Residue 
Atom Interacting 
partner 
Interacting 
Residue 
Interacting 
Atom 
Distance 
(Å) 
Lys315 O MATβ Trp317 N 3.26 
 O MATβ Arg318 N 2.88 
Arg316 N MATβ Leu312 O 2.93 
 N MATβ Ile313 O 3.26 
 O MATβ Arg318 N 3.25 
 NH1 MATβ Asp191 OD1 2.65 
 NH1 MATβ Phe311 O 2.87 
 NH2 MATβ Asp191 OD1 3.14 
Tyr317 N MATβ Ile313 O 3.14 
Arg318 O Water   3.01 
 O MATβ Thr320 N 2.84 
 OE1 Water   2.76 
 NE2 MATα2 Arg192 O 3.07 
 NE2 MATα2 Gly336 O 2.99 
 NE2 MATβ Pro310 O 2.99 
Thr320 OG1 MATβ Phe322 O 2.68 
 O MATα2 Arg313 NH2 2.77 
Val321 O MATα2 Arg313 NH1 3.00 
 O MATα2 Arg313 NH2 3.20 
Phe322 N Water   2.96 
 O Water   3.08 
His323 N Water   3.21 
 ND1 Water   3.07 
 NE2 MATα2 Gly273 O 2.80 
 O MATα2 Arg313 NH2 2.35 
 O Water   2.84 
 OXT MATα2 Arg313 NH2 3.27 
 OXT MATα2 Tyr335 OH 2.99 
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5.1.8 Validation of C-terminal interaction site. 
 
To establish that the C-terminal tail is indeed the key region of the interaction a truncated 
mutants lacking the last 15 residues at the C-terminus in both variants of MAT, 
MATV1 and MATV2 were generated. These deletions precluded the assembly of the 
complex in solution (Fig 5.10A). Also, these deletions maintained the secondary structure 
as in the wild type MATβ isoforms, as confirmed by Circular Dichroism (CD) spectra 
(Fig 5.10B). The circular dichroism spectra of MATβV1ΔW320 is different from the 
other circular dichroism spectrums suggesting, although the MATβV1ΔW320 is folded, 
that it is different from the wild type protein. The interaction was also confirmed with the 
use of ITC, which showed that wild type MATβ isoforms interact with MATα2, but the 
mutant isoforms, MATβV1ΔW320 and MATβV2ΔW309 produced no heat release when 
titrated against MATα2 and, therefore, did not interact (Fig 5.11, Table 5.6). Taken 
together, these data show that MATβV1 and MATV2 interact with MAT(2)2 through 
the insertion of the C-terminal tail of the beta subunit. The ITC also supported the ratio 
of MATα2:MATβ being 2:1 which is consistent with the crystal structure, gel filtration 
and SAXS experiments.  
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Figure 5.10 Conformation of MATβV2 C-terminal interaction with MATα2. A. Gel 
filtration profiles for MATα2+MATβV2W309 (black), MATβV2W309 (light green) 
and MAT(α2)4 in blue. 100 μM of MATα2 and 50 μM of MATβV2Δ309 were used in 
complex formation, whilst 100 μM of MATα2 and 50 μM of MATβV2 were used as 
controls. Absorbance at 280 nm was used to measure for the presence of proteins. For 
complex formation MAT2 was incubated with both MAT variants prior to being 
loaded on a Superdex 200 10/300 column (section 4.2.13). B. Circular dichroism spectra 
of MATV1 (green), MATV2 (orange), MATV1320 (red), MATV2309 (violet) 
and MATV116 (blue). Proteins were diluted to 1-5 μM in 0.1 M phosphate buffer pH 
7.0. Comparison between the circular dichroism spectra of the wild type and the mutants 
shows that the secondary structure is conserved after the deletion of the C-terminus 
(MATV1320 and MATV2309) or the N-terminus (MATV116). Data is 
displayed as ellipticity*10-3 (section 4.2.20).  
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Figure 5.11. Interaction MATα2 and MATβ. A. Isothermal titration calorimetry of 
MAT2 with MATV2 showing the interaction of these two proteins. The top graphs 
represent the differential heat released during the titration of MATβV2W309 or 
MATV2 with MAT2. The bottom graphs represent the fitted binding isotherms. B. As 
in A Isothermal titration calorimetry of MAT2 with MATβV1W320 or MATV1. 
Proteins were buffer exchanged into 200 mM NaCl, 20 mM HEPES pH 7.5. The 
concentration of MAT proteins were: MATα2=10.0 μM, MATβV1=51.2 μM, MATβV2= 
36.5 μM, MATβV1Δ320 and MATβV2Δ309= 100 μM. 
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 Table 5.6. Thermodynamic parameters of MAT complex formation. Ka is calculated 
from as 1/Kd and is the binding constant (M
-1). The Kd represents the affinity of the 
reaction (M). H binding enthalpy of the interaction in kcal/mol. N is the stoichiometry 
indicating the ratio of the injected macromolecule-cell macromolecule binding.   
   
 MATV2   MAT2 MATV1   MAT2 
[] 36.5M    10M 51.2M   10M 
Ka(M
-1) (1.14  0.17) X 108 (2.90  0.82) X 107 
Kd(M) (8.77  1.34) X 10-9 (3.44  0.98) X10-8 
H kcal/mol -2.28 X104  188.4 -2.37 X104  367.6 
N 0.44   0.001 0.44  0.004 
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5.1.9 MATβ binding motif in MATαβ complexes. 
 
To narrow down the interaction site further a more extensive mutational analysis of the 
MATβ C-terminus was conducted. Several different MATβ constructs were made by 
introducing stop codon mutations in different positions in the C-terminus of MATβ. Six 
mutants were produced and purified (section 4.2.6, 4.2.11. & table 4.3): MATβV1ΔR329, 
MATβV1ΔT331, MATβV1ΔH334, MATβV2ΔR318, MATβV2ΔT320, and 
MATβV2ΔH323. These were then incubated with MATα2 and passed through gel 
filtration to evaluate formation of the complexes. The gel filtration experiments showed 
that the minimum motif required for the formation of MAT(α2)4(βV2)2 complex 
comprises of four residues at the end of the C-terminal of MATβV2 
(THR320VAL321PHE322HIS323). This was also the same for MATα2βV1 complex which 
also had an absence of the complex peak when MATα2 was incubated with 
MATβV1T331stop (THR331VAL332PHE333HIS334) (Fig 5.13). The deletion of the 
terminal histidine residue was insufficient to preclude the formation of the complex with 
either MATβV1 or MATβV2. 
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Figure 5.12. Mutational analysis into MATβ binding of MATα2. Gel filtration 
spectrums of various C-terminal beta mutants mixed with MATα2 for 1 hour prior to gel 
filtration on a Superdex 200 10/300 in 25 mM HEPES pH 7.5, 200 mM NaCl, 1 mM 
MgCl2, 5 mM KCl, 1 mM TCEP (section 4.2.13).  For complex formation, 100 μM of 
MATα proteins and 50 μM of MATβ were used. A. Mutant MATβV1 mutants showed 
that deleting the last four residues (MATβV1T331stop) is enough to prevent MATαβ 
complex formation. B. As in A, but using MATβ2 mutants. Absorbance was measured at 
280 nm which was used as an indication of the presence of protein.  
107 
 
5.1.10 Rotation of MATβ bound to MATα2. 
 
Interestingly, the tunnel created at the interface of the MAT2 dimer has a symmetry that 
allows two possible conformations of the C-terminal MATβV2. In both orientations the 
MATβV2 tail is stabilised by hydrogen bonds and hydrophobic interactions of the same 
residues of the opposing MATα2 dimer (Fig 5.13A). The interchangeability of these two 
orientations could allow certain rotational flexibility of the MATβV2 subunit enabling 
MATβ to interact with MATα2 on both sides of the dimer and both active sites. To note 
the N-terminal of MATβV2 face the direction of the MATα2 active site and are at a 
suitable distance that the disordered MATβV2 terminus could interact with the empty 
active site. At a first glance it did not seem that MATβ was close to the active site of 
MATα2, but upon examination of the interaction MATβV2, His323 interacts with Gly273 
that is part of a loop that is directly connected to the MATα2 active site (Fig 5.13B). 
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Figure 5.13. Close view of the tunnel created at the interface of the MAT2 dimer. 
A. Stick representation of the MAT2 residues at the dimer interface, side chains 
involved in the interaction with MATV2 (chain_E in green) are coloured in cyan, the 
symmetry residues are shown in magenta. Side chains that are involved in the interaction 
with MATV2 (chain_F in green) are coloured in magenta, the symmetry residues are 
shown in cyan. Note that between the conformation represented in A and B there is a 
twofold symmetry. B. Cartoon representation of the MAT2 monomer from the 
MAT(α2)4(βV2)2 complex (4NDN), showing the loop that connects the active site with 
the buried tail of MATV2 that is highlighted in yellow. The MATβ C-terminal is shown 
in green. 
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5.1.11 Enzymatic activity of MATαβ complexes. 
 
The observation that the MATβV2 N-terminus is close to the active site of MATα2 raises 
the question of whether the N-terminus of MATβ could regulate the gating loop of 
MATα2 and affect the kinetic activity of MATα2. If this was the case, the presence of 
MATβ should affect their enzymatic activities and also differences should be observed 
between isoforms of MATβ due to the varying lengths of the N-terminus of MATα2βV1 
and MATα2βV2. Thus, the activity of MATα2, MAT(α2)4(βV1)2, MAT(α2)4(βV2)2 and 
MAT(α2)4(βV116)2 complexes were compared. Ideal conditions for the assay were set 
up whereby the concentration of protein was tested to ensure that substrate would remain 
in excess by the end of the reaction. Different buffers were tested to see if the MATα2 
could produce SAMe and it was found that in HEPES pH 7.5, PIPES pH 7.5 and PBS pH 
7.5 SAMe could be formed (Fig 5.14A-C). When 10 mM DTT was added to the reaction 
buffer SAMe formation dropped. As the proteins were purified in HEPES pH 7.5 it was 
decided to use this buffer to perform the experiment (Fig 5.14D).  
110 
 
 
Figure 5.14. The effect of different reaction buffers on the formation of SAMe by 
MATα2. 100 nM of MATα2 was pre-incubated with 25 mM buffer (HEPES, PIPES, 
PIPES and DTT, or PBS), 5 mM KCl, and 5 mM MgCl2.To start the reaction 200 μM 
methionine was added and reactions were quenched with 75 % (v/v) acetonitrile and 1.2 
% (v/v) formic acid in water over a 10 min course. SAMe formation was quantified using 
UPLC-MS/MS (Van Liempd et al. 2013). A. HEPES pH 7,5. B. PIPES pH 7.5. C. PBS 
pH 7.5. D. PIPES pH 7.5 +DTT. 
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Notably, the presence of either MATβV1 or MATβV2 increased the kcat of MAT(α2)4 4 
or 3 times respectively without altering the Km for methionine. Additionally, the kcat of 
MAT(α2)4 was 30 % higher in presence of MATβV1 than with MATβV2, thus 
emphasising that differences at the N-terminus affect the activity of MAT(α2)4. 
Furthermore, the utilisation of the MAT(α2)4(βV116)2 complex, in which MATβ has 
the shortest N-terminus, enabled it to be possible to see if the activity of this complex 
would return to the same level as in MAT(α2)4 alone. The MAT(α2)4(βV116)2 complex 
also has the lowest kcat of the complexes which was still higher than the catalytic subunit 
alone (Fig 5.15, Table 5.7). Therefore, increasing the N-terminal length correlates with 
an increase in kcat of the complex activity, confirming the role of N-terminal in the 
regulation of the activity.  It also suggests that presence of MATβ has a positive effect on 
the activity of MAT(α2)4 and this must be due to the C-terminal interaction. 
 
As a result of the cloning process several extra residues we added to the N-termini of 
MATβV1 and MATβV2. In order to rule out that these residues were causing the 
observed kinetic differences the MAT proteins, MATα2, MATβV1 and MATβV2 were 
sub cloned (section 4.2.7) into the PET_SUMO vector system which produced proteins 
with no extra residues. The same trend was observed with these proteins as with those 
produced in the other vector system when the kinetic tests were performed.  
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Figure 5.15 Kinetic reactions of MATα2 and it’s complexes. ATP was added to 
MAT(α2)4, MAT(α2)4(βV116)2, MAT(α2)4(βV2)2 and MAT(α2)4(βV1)2 pre-incubated 
with 5 μM to 200 μM of methionine then SAMe formation was quantified using UPLC-
MS/MS (section 4.2.20). It shows that the kcat of MAT2 complexes are higher 
depending on the variant of MAT. Triplicate data points were collected and are 
displayed as circles. MAT(α2)4 as red circles, MAT(α2)4(βV116)2 as black circles 
MAT(α2)4(βV2)2 as green circles and MAT(α2)4(βV1)2 as blue circles. SAMe formation 
is displayed as pmol/s/nmol of protein.  
 
Table 5.7. Kinetic properties of MATα2β complexes as determined by kinetic assay 
(section 4.2.18 & fig 5.15). kcat is the turnover number and Km is defined as substrate 
concentration at half the maximum velocity. 
 MAT(α2)4 MAT(α2)4(βV1Δ16)2 MAT(α2)4(βV2)2 MAT(α2)4(βV1)2 
kcat 295. ± 23.7 688. ± 38.4 859 ± 57.1 1300 ± 47.8 
Km 53.8 ± 10.5 84.8 ± 9.93 42.5 ± 7.38 53.5 ± 4.79 
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5.1.12 Investigation into the effect that NADP has on MAT proteins. 
 
Previously, it has been shown that NADP binds tightly to a conserved glycine-rich 
GXXGXXG motif (G24ATG27LLG30) at the N-terminal domain of MATβ (Shafqat et al. 
2013). Mutants lacking residues involved in NADP binding of the β subunit have been 
shown to be able to form a complex with MATα2 supporting the idea that NADP is not 
needed to form the complex (González et al. 2012). In our case, co-crystallisation and 
soaking experiments with an excess of NADP yielded crystals of the MAT(α2)4(βV2)2 
complex without NADP. Also, incubating the proteins with NADP prior to gel filtration 
did not yield a shift in the elution profile or produced MATαβ crystals that contained 
NADP (Fig 5.16A). No observable effect was seen on Native PAGE with bands for either 
MAT subunit or MAT(α2)4(βV2)2 complex in the presence or absence of NADP (Fig 
5.16B). This observation prompted us to evaluate whether NADP could interact in 
solution with the preformed complex. Using the kinetic assay that was set up the effect 
of NADP was examined on the activity of MAT(α2)4(βV1)2 and showed that the kcat in 
the presence and absence of NADP was not significantly different (Fig 5.16C, Table 5.8).  
 
Table 5.8. Kinetic parameters of MAT(α2)4(βV1)2 ± NADP as determined by kinetic 
assay (section 4.2.18 & fig 5.16). kcat is the turnover number and Km is defined as 
substrate concentration at half the maximum velocity. 
 
 
 
 
 MAT(α2)4(βV1)2 MAT(α2)4(βV1)2+NADP 
kcat 2190 ± 145 1770±150 
Km 60.2±9.10 50.3± 10.6 
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Figure 5.16. The effect of NADP on MATα2. A. Gel filtration of MAT(α2)4(βV2)2 
((MATα2 200 μM and MATβV2 100 μM), complex with (blue) and without (magenta) 
NADP incubation (250 μM) and Native-PAGE of MAT subunits and MAT(α2)4(βV2)2 
complex with and without NADP (section 4.2.13). B. Native PAGE of MATα2 MATβV2 
and MAT(α2)4(βV2)2 complex in the presence and absence of 250 μM NADP. C. ATP 
was added to MAT(α2)4(βV1)2 ± NADP pre-incubated with 5 μM to 200 μM of 
methionine before SAMe formation was quantified using UPLC-MS/MS (Van Liempd et 
al. 2013) (section 4.2.18). It shows that the kcat of MAT(α2)4(βV1)2 in the presence and 
absence of NADP are not significantly different. 
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ITC experiments confirmed that though NADP binds to both MATβ isoforms (Fig 5.17A-
B) no interaction could be observed with the MAT(α2)4(βV2)2 complex (Fig 5.17C, Table 
5.9). To note, NADP binds MATβ isoforms; MATβV1 and MATβV2 with very similar 
affinity and in a ratio of one NADP molecule to one MATβ. The overall structure of 
MATβV2 within the MAT(α2)4(βV2)2 complex has no significant structural changes as 
compared with the NADP-bound MATβ structure (RSMD=0.42 Å). The position of 
residues that are involved in NADP binding, such as Phe49, Arg51, Ser125 and Trp148, 
do not differ in the presence of MATα2 (Fig 5.18A). Modelling NADP in the active site 
of MATβV2 within the MAT(α2)4(βV2)2 complex shows that NADP could interact with 
MATβV2 (Fig 5.18B).  Furthermore, the observation that MAT(α2)4 does not block the 
binding pocket, suggests that the NADP could bind to MAT(α2)4(βV2)2 complex (Fig 
5.18C).  
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Figure 5.17. Interaction of MATα2β complexes with NADP. A,B. Isothermal titration 
calorimetry of MATβV2, MATβV1 and MAT(α2)4(βV2)2 complex with NADP. The top 
graphs represent the differential heat released during the titration of NADP with the 
different MAT subunits, the bottom graphs represent the fitted binding isotherms. 
Proteins were buffer exchanged into 200 mM NaCl, 20 mM HEPES pH 7.5. The 
concentration of MAT proteins were: MATβV1=29.8 μM, MATβV2=30.0 μM, 
MAT(α2)4(βV2)2=10.2 μM. 500 μM NADP was titrated against the MATβ proteins 
whilst 155 μM NADP was titrated against the MAT(α2)4(βV2)2 complex. 
 
Table 5.9. Thermodynamic parameters of NADP binding to MAT isoforms from ITC 
experiments. Ka is calculated by taking 1/Kd and is the binding constant (M
-1). The Kd 
represents the affinity of the reaction (M). H binding enthalpy of the interaction. N is 
the stoichiometry indicating the ratio of the injected ligand-cell macromolecule binding.   
 NADP  MATV2 NADP  MATV1 NADP MAT(2)4(V2)2 
[]   500M   30.0M   500M   29.8M 155M 10.2M 
Ka(M
-1) (1.12  0.130) X105 (1.17  0.220) X105 -- 
Kd(M) (8.93  1.07) X 10-6 (8.55  1.60) X10-6  -- 
H 2780 117 1870  128 -- 
N 0.850  0.0260 1.23  0.0600 -- 
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Figure 5.18. NADP binding site. A. Superposition of the NADP-bound MATβ structure 
(PDB: 2YDX in blue) over MATβV2 as it is in the MAT(α2)4(βV2)2 complex (in green). 
Residues directly involved in the interaction with NADP are labelled and shown as sticks. 
B. Surface representation of the model of a NADP molecule within the binding pocket of 
MATβV2 from the MAT(α2)4(βV2)2 complex showing that interaction of MATβ with 
MATα2 does not prevent NADP from binding. C. The MAT(α2)4(βV2)2 complex shown 
as the MAT(α2)4 (in red and slate) and MATβV2 in green which  does not block the 
access of NADP to MATβV2 (in green). 
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5.1.13. The effect of resveratrol binding to the MATαβ complex. 
 
Resveratol, a molecule found in the crystal structure of MATβ (2YDX), was able to 
interact with MATβ, as reported so by Shafqat et al, so we wanted to test whether this 
molecule had any influence of the MATαβ complex. When resveratrol was titrated against 
the MAT(α2)4(βV2)2 no interaction was seen (Fig 5.19A) and further to this gel filtration 
experiments revealed no shift in the elution volume of the protein with and without 
resveratrol, which supported that resveratrol does not interact with the MATαβ complexes 
(Fig 5.19B).  
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Figure 5.19. Interaction of MAT complexes with resveratrol. A. Isothermal 
titration calorimetry of MAT(2)4(V2)2 complex with resveratrol. The top graphs 
represent the differential heat released during the titration of resveratrol to 
MAT(2)4(V2)2 complex. 500 μM of resveratrol was titrated against 150 μM of the 
MAT(α2)4(βV2)2 complex. The bottom graphs represent the fitted binding isotherms. 
B. Chromatograms of the gel filtration performed after the incubation of MATV1 
(violet), MATV2 (red) with resveratrol before addition of MAT2, the 
chromatograms shows that resveratrol does not influence MAT2 complexes 
formation as they eluted at the same volume of MAT(2)4(V2)2 complex without 
resveratrol (green).  
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5.2 Discussion 
 
Initially when trying to form the MATαβ complexes a ratio of 1:1 MATα2:MATβ was 
used which resulted in the formation of the complexes, but also a second peak, 
corresponding to the elution profile of MATβ (~16 mL) was present. The literature at the 
time suggested that MATαβ complexes were a tetramer of two MATα2 to two MATβ 
[MAT(α2)2(β)2] (Kotb & Kredich 1985). This prompted the revaluation of the oligomeric 
state of the MATαβ complexes, so using ITC it was observed that MATα2 interacts with 
MATβ in a 2:1 ratio (Fig 5.11), which was consistent with the model proposed by 
(González et al. 2012) (MAT(α2)2(β)1) and what was seen using gel filtration upon 
changing the ratio of MATα2: MATβ to 2:1. The initial hit for MAT(α2)4(βV2)2 did not 
allow for solving the structure, but did give insights into the oligomeric state as Matthews 
coeffcient analysis suggested a molecule of 258 kDa, which would be akin to size of a 
hexamer (Table 5.1). This predicition also had 50 % solvent content within the crystal, 
which  is around the average for most protein crystals. Once the crystallographic 
strucuture was solved (2.35-3.3 Å) it revealed the complex to be a hexamer (Fig 5.4).  
 
A pitfall of crystallography is that structure, resolved through this technique, may not 
represent the real biological interface and therefore not represent what is happening in 
solution. The contact between the MAT(α2)2 dimers to form MAT(α2)4 may be a result 
of crystal contacts that only exist due to the packing of the protein molecules in the crystal 
lattice (Carugo 1997). Small angle x-ray scattering was used to examine the oligomeric 
state of MATαβ in solution which supported a hexameric form (Fig 5.7, Table 5.4). 
Moreover, scattering data from MAT(α2)4(βV1Δ16)2 gave a much better fit to the 
crystallographic structure (4NDN) given that the disordered N-terminal were not seen in 
the crystal structure, but they would have contributed to the scattering of the wild type 
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complex (Fig 5.8, Table 5.4).  Also, using the PISA server it suggested that a hexamer 
would be the most energetically favourable state (Table 5.2). Taken together it seems that 
the hexamer, although different from current literature was the correct state for MATαβ 
complexes. The simple schematic in figure 5.20 could be used to visualise the MATαβ 
complexes which are split into MAT(α2)4(βV1)2 and MAT(α2)4(βV2)2 depending on 
which MATβ isoform is involved.  
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Figure 5.20. Schematic drawing of the MATαβ complexes. The MATαβ complexes 
are hetero-hexamers consisting of a tetrameric core of MATα2 flanked by two copies of 
the regulatory protein MATβ. The crystal structure of the MAT(α2)4(βV2)2 has been 
solved through x-ray crystallography and solution scattering data support the idea that 
MATαβ complexes are hexameric.    
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Before solving the structure of MAT(α2)4(βV2)2 there was little insight into the 
interaction site of MATβ with MATα2. Gonzalez et al. proposed, through ClusPro 
modelling, a trimer (MAT(α2)2(β)1) whereby the MATβ subunit binds the central domain, 
close to the active site, through several different regions of MATβ incuding the NADP 
binding site and C-terminal tail. From this model the binding of MATβ would prevent 
oligomerisation of MATα2 into a tetramer. Our model revealed that MATβ interacts with 
MATα2 through the C-terminus which gains secondary structure and this interaction site 
is located in the interface of the MATα2 N-domain and C-domain (Fig 5.9), which is on 
the opposite side to the suggested trimeric model (González et al. 2012). Generation of 
the two stop mutants MATβV2ΔW309 and MATβV1ΔW320, through gel filtration (Fig 
5.10) and ITC (Fig 5.11, Table 5.6), showed that the deletion of the C-terminal prevented 
the formation of the complex and therefore implies that this was the area of interaction. 
To note these stop mutants retained their secondary structure as shown through circular 
dichroism (Fig 5.10) and also the method of purification, though yielding less protein, 
was the same as in the wild types.   
 
In order to probe the interaction site in further detail several mutants were produced with 
the hope of finding the minimum motif required to prevent the binding of MATβ. The 
deletion of the last four residues was enough to inhibit complex formation (Fig 5.12) and 
this motif could be the site of a small inhibitor to block the binding of MATβ in vivo.  
This motif interacts with the loop that recognises the tripolyphosphate of the ATP at the 
active site (Fig 5.13), suggesting a possible allosteric mechanism that could be 
responsible for the observed increase of the kcat of MAT(α2)4(βV116)2 in comparison 
with the catalytic subunit alone (Fig 5.15, Table 5.7). 
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One of the surprising features of the MAT(α2)4(βV2)2 complex is that there is an 
asymmetry in the active sites, two which are in an apo state and two which are in a holo 
state (Fig 5.4). This is a new feature for MAT enzymes as all the structures of MAT 
enzymes deposited in the protein data bank have either all active site empty or all 
occupied (Komoto et al. 2004; Takusagawa et al. 1996; González et al. 2000; González 
et al. 2012; Shafqat et al. 2013). The presence of MATβ has a profound effect on MATα2 
not only effecting the active site occupancy but also the kcat. Kinetic experiments showed 
that the presence of MATβ increased the activity of the enzyme compared to MATα2 (Fig 
5.16, Table 5.7), but from the crystal structure it still remains unclear on how this occurs. 
The position and orientation of MATβ indicates that the N-terminal, which is disordered, 
is in close proximity to the active site such that it could interact with it or influence it. It 
is doubtful that MATβ directly affects the enzymatic mechanism of the MATα2, as SAMe 
synthesis is a fundamental process preserved throughout the kingdoms. It could play a 
role in increasing the turnover and release of the product from the active site either 
through interacting with the gating loop or through MATβ rotation destabilising products 
within the active site causing a quicker release of products. 
 
A comparison of the active site in two different states reveals that loops flanking the 
empty catalytic pockets are disordered, in particular the ‘gating loop’ (residues 113-131) 
that has been proposed to act as a dynamic lid controlling the access to the active site 
(Komoto et al. 2004). In the case of the catalytic subunit MAT1, S-nitrosylation of 
residue C121 in the ‘gating loop’ promotes the inactivation of the enzyme (Pérez-Mato 
et al. 1999) so interaction with the gating loop by MATβ could explain the reasons for 
higher SAMe production in MATαβ complexes. 
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Although MATβ contains a NADP binding domain no interaction between MATαβ 
complexes and NADP was observed by either gel filtration (Fig 5.16) or ITC experiments 
where NADP was titrated against the MATαβ complexes and this produced no heat 
reaction (Fig 5.17, Table 5.9). This shows that NADP is not needed as a co-factor for the 
formation of the MATαβ complexes nor is it needed for SAMe synthesis. This is in 
support of work done by Gonzalez et al. 2012, who mutated the NADP binding pocket, 
preventing NADP binding, and then used these mutant MATβs to form MATαβ 
complexes. We wanted to confirm that the recombinant MATβ was able to be bound by 
NADP, so, NADP was titrated against MATβ and interaction with both isoforms was 
observed with both isoforms showing similar affinity for NADP (Fig 5.17, Table 5.9), 
which is not surprising given the high sequence similarity (94 %) between these proteins 
and that the NADP binding pocket is conserved. It also suggests that the N-termini of 
MATβ, the only part which differs in sequence, do not aid in NADP binding as titration 
of NADP against the N-terminal mutant, MATβΔ16 showed interaction. If NADP did 
interact with the MATαβ complexes, then significantly different kinetic properties should 
be observed in the presence and absence of NADP which they do not (Fig 5.16, Table 
5.8). 
 
The reason why NADP does not bind the MATαβ complex remains unclear. From the 
crystallographic structure of MAT(α2)4(βV2)2 there is no reason why NADP should not 
bind, as the complex formation does not block the binding pocket (Fig 5.18). The dynamic 
movement of MATβ rotating around MATα2 could prevent binding of NADP, if this 
movement caused a structural change in MATβ by compression of the binding site 
inhibiting NADP binding. Furthermore, the observation that MAT(α2)4 does not block 
the binding pocket, suggests that the NADP could bind to MAT(α2)4(βV2)2 complex in 
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the context of the interaction with other proteins such as HuR, GIT1, MEK, ERK, MafK 
(Xia et al. 2010; Peng et al. 2014; Katoh et al. 2011). In fact, there is evidence suggesting 
that MAT enzymes are involved in regulation of many pathways, some of which are 
chromatin-based and some may be independent of SAMe (Katoh et al. 2011).  
 
Whereas resveratrol bound to MATβV2, as shown using differential scanning fluorimetry 
by Shafqat et al we observed no appreciable interaction between MAT2V2 and 
resveratrol by ITC (Fig 5.19A). In addition, we observed that the presence of resveratrol 
had no effect in the complex formation, as observed by gel filtration experiments (Fig 
5.19B). The interaction of resveratrol with MATβ might be relevant for functions other 
than the formation or activity of the MAT2 complexes. Further to this Yang et al. 
reported that resveratrol induced the expression of MATβV1 and MATβV2 in vivo by 
increasing transcription and stabilisation of both, mRNA and protein and proposed that 
resveratrol enhanced the interaction with other proteins that can bind MATβ such as 
SIRT1 and HuR (Yang et al. 2013). 
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Chapter VI. Structural insights into MATα and 
MATβ proteins.  
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6.1 Results  
6.1.1 The effects of sodium chloride concentration on the oligomeric states of MAT 
proteins as determined by gel filtration  
 
Human MATα1 has been known to exist in two oligomeric states, as a dimer or a tetramer, 
but little information was known what drives MATα1 proteins to change oligomeric state. 
Also, little was known regarding the oligomeric state of MATα2 so it was interesting to 
see whether MATα2 had mulitple oligomeric states like MATα1. The concentration of 
sodium chloride was varied to see if simply changing this in the buffer would have an 
effect on the oligomeric state of MAT proteins. Upon dialyzing MATα1 and MATα2 into 
different concentrations of NaCl and injecting into a gel filtration column both proteins 
exhibit two peaks the first of ~13 mL and the second of ~15.4 mL (Fig 6.1A, B). Buffer 
exchanging the proteins into different concentrations of sodium chloride had no effect on 
the equilibrium between the two peaks. The regulatory proteins MATβV1 and MATβV2 
could only be eluted as single peaks (~16 mL) with molecular mass close to their 
predicted molecular mass (Fig 6.2A, Table 6.1). A calibration curve of known proteins 
(Fig 6.2B) was used to determine the mass of MAT proteins based on the elution volume 
(Table 6.1). For MATα1 and MATα2 the second peak (Fig 6.1A, B) corresponded to a 
molecular mass close to a monomeric species (~45 kDa) whilst the first peak correspond 
to a larger mass of ~124 kDa. This larger weight would suggest a trimeric state, but based 
on the crystallographic structure monomeric and trimeric states will not be stable in 
solution. As gel filtration is not the best technique for estimating the mass of non-globular 
proteins, the only clear information that can be inferred from MATα chromatograms is 
the presence of different oligomeric states. For MATβV1 and MATβV2 the elution 
volumes corresponded to a molecular weight that was around ~32 kDa, which is close to 
their estimated molecular weight of ~37 kDa.  
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Table 6.1. Molecular weight estimates of MAT proteins based on elution volume of gel 
filtration. Molecular weights were calculated using the elution volume to work out 
phase distribution coefficient (Kav) and then using this value in the equation Kav=-
0.2760Log (Mw)+1.774. Proteins were injected into a Superdex 200 10/300 column 
with a buffer containing 25 mM HEPES pH 7.5, 200 mM NaCl and 1 mM TCEP.  
Protein  Elution 
volume (mL) 
Molecular weight (kDa) 
from elution volume  
Estimated molecular 
weight (kDa) from 
sequence  
MAT(α1)2 15.37 43.07 87.00 
MAT(α1)4 13.36 123.2 172.0 
MAT(α2)2 15.48 45.48 90.00 
MAT(α2)4 13.34 124.4 180.0 
MATβV1 16.06 32.79 37.50 
MATβV2 16.09 32.31 36.40 
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Figure 6.1 Sodium chloride concentration-dependence of MAT oligomeric state. A. 
MATα1 elution profiles, colour coded according to concentration of used NaCl. 
Absorbance was measured at 280 nm which was used as an indication of the presence of 
protein. Two peaks correspond to tetramer and dimer from left to right. Elution buffer 25 
mM HEPES pH 7.5, 0-1 M NaCl and 1 mM TCEP B. As in A, but with MATα2. 100 μM 
of MATα protein were used for each NaCl concentration. 
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Figure 6.2. A. MATβ proteins elute as single peaks. A. Both MATβV1 (in blue) and 
MATβV2 (in red) elute as one peak. Elution buffer HEPES pH 7.5, 200 mM NaCl and 1 
mM TCEP. B. Calibration curve made using known protein standards shown as red dots 
on the graph. From right to left: ferritin (440 kDa), gamma-globulin (158 kDa), BSA (67 
kDa), ovalbumin (43 kDa), carbonic anhydrase (29 kDa), ribonuclease (13.7 kDa) and 
aprotinin (6.5 kDa).  Phase distribution coefficient, Kav, was calculated based on elution 
volume of protein standards and plotted against Log of their molecular weight.  
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6.1.2 The effects of protein concentration on the oligomeric states of MAT proteins 
as determined by gel filtration. 
 
Changing the concentration of either MATα1 or MATα2 had an apparent effect of the 
equilibrium of the two populations. For MATα1 a lower concentration (0.3-1.5 mg/mL) 
caused the majority of the protein to be in the second population (~15.4 mL), but as the 
concentration increased the proportion of the larger oligomeric state (~13 mL) also 
increased. Regardless of concentration of MATα1, the smaller oligomeric state is in 
greater proportion (Fig 6.3A). Taking multiple fractions of MATα1 at different protein 
concentrations from either the higher molecular weight peak and the lower molecular 
peak and then running them on a native gel showed that each peak splits into two 
populations highlighting the dynamic nature of MATα1 (Fig 6.3B).  
 
For MATα2, concentration also has a great impact on the equilibrium between the two 
populations. At a low concentration (0.3-1.5 mg/mL) the smaller oligomeric population 
is in favour, but as the concentration is increased this changes. At 3 mg/mL the amount 
of the higher oligomeric state increases so that the two states are almost equal with a slight 
favour for the higher oligomeric state. Above 6 mg/mL the second population decreases 
and the higher oligomeric state is the majority of the protein (Fig 6.4A). According to 
native gel, MATα2 proteins, just like MATα1, exist in a dynamic equilibrium and show 
multiple bands and only at 1.5 mg/mL (Lane 2) does it seem to mainly run as a single 
population (Fig 6.4B)  
 
134 
 
 
Figure 6.3 Protein concentration dependence of Methionine Adenosyltransferases 
on oligomeric state. A. MATα1 elution profiles, colour coded according to concentration 
of protein used. Absorbance was measured at 280 nm which was used as an indication of 
the presence of protein. Two peaks correspond to tetramer and dimer from left to right. 
Elution buffer 25 mM HEPES pH 7.5, 200 mM NaCl and 1 mM TCEP. B. Native gel of 
MATα1 at different protein concentrations. C1 refers to the first peak whilst C3 and C4 
refer to the second peak. Although protein fractions were taken from different peaks in 
the gel filtration two bands can be seen indicating the dynamic nature of MATα1. 
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Figure 6.4 Protein concentration dependence of Methionine Adenosyltransferases 
on oligomeric state. A. MATα2 elution profiles, colour coded according to concentration 
of protein used. Absorbance was measured at 280 nm which was used as an indication of 
the presence of protein. Two peaks correspond to tetramer and dimer from left to right. 
Elution buffer 25 mM HEPES pH 7.5, 200 mM NaCl and 1 mM TCEP. B. Native gel of 
MATα2 at different protein concentration. Although protein fractions were taken from 
different peaks in the gel filtration multiple bands can be seen indicating the dynamic 
nature of MATα2. 
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6.1.3 Solution scattering of MAT proteins. 
  
In order to determine oligomeric states of MAT proteins small angle X-ray scattering was 
performed and structural parameters are presented in Table 6.2. The experiment 
suggested that MATα1 exists in dimeric (~90 kDa) and tetrameric (~162 kDa) forms in 
close agreement with predicted molecular weight (93 kDa and 164 kDa, respectively), as 
expected, different from molecular weight determined by gel filtration. MATα2 only 
showed one population during SAXS experimentation which corresponded to a tetrameric 
state (162 kDa). Alignment of SAXS DAMMIN models with crystallographic structures 
of human MATα1 and MATα2 show a good fit (Fig 6.5A-C). Extra space can be seen for 
the MATα1 dimer, MATα1 tetramer and MATα2 tetramer which, is due to the flexible 
nature of the N-terminus that is disordered in the crystal structures. 
 
 Both MATβ isoforms, MATβV1 and MATβV2 data were collected through static-SAXS 
experiments, in the presence and absence of the co-factor NADP, and the proteins appear 
to be monomers, which is consistent with gel filtration experiments (Table 6.2). Although 
NADP does not cause a change in oligomeric state it does create a tighter protein as the 
maximum particle distance (Dmax) decreases for both MATβ isoforms.  Aligning the 
DAMMIN model to the crystal structure of human MATβ (2YDY) gave a good 
agreement, but clearly indicating the presence of C-terminal region and the N-terminal 
region that had not been observed in the high resolution crystallographic structure of 
MATβ (Fig 6.6). Modelling both the N and C-terminals of MATβ using CORAL 
produced a model that satisfied the density obtained from SAXS data (Fig. 6.7A) and 
produced a predicted one dimensional (1D) scatter that shows an excellent agreement 
with the SAXS data of MATβV2 (2=3.3) (Fig. 6.7B). The C-terminus becomes ordered 
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during interaction with MATα2 (section 5.1.7. Fig 5.9), but why the N-terminus is not 
observed in any crystal structure remains an open and intriguing question. 
 
Table 6.2 Structural parameters of MAT proteins as determined by Small angle X-ray 
scattering. Radius of gyration (Rg), maximum particle distance (Dmax) and I(0) were 
calculated using Primus and Scatter whilst molecular weight was calculated using SAXS 
MoW server (Fischer et al, 2010). 
 Rg (Å) Dmax (Å) I(o) Expected 
Molecular 
weight (kDa) 
Calculated 
Molecular 
weight (kDa) 
MATα1 (dimer) 29.6 89.0 4.54x10-2 
 
~86.0 93.0 
MATα1 (tetramer) 38.5 118 3.62x10-2 
 
~172 164 
MATα2 (tetramer) 37.7 116 2.41x10-1 ~180 162 
MATβV1 30.0 94.0 5.57x10-1 ~37.5 41.9 
MATβV1+NADP 26.0 92.0 2.90x10-1 ~37.5 35.1 
MATβV2 27.9 90.0 4.53x10-1 ~36.4 37.2 
MATβV2+NADP 25.2 88.0 2.93x10-1 ~36.4 36.0 
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Figure 6.5. Alignment of crystallographic structures of MATα proteins with SEC-
SAXS data. Using the P(r) of the solution scattering data, twenty runs of DAMMIN were 
performed before models were aligned and averaged. The average model was then 
subjected to a further run of DAMMIN before being aligned using SUPCOMB against 
the crystal structure of MATα1 (20BV) or MATα2 (2P02) (section 4.2.23). Coot was used 
to generate the tetrameric form of both MATα isoforms. A. MATα1 dimer. B. MATα1 
tetramer. C. MATα2 tetramer. Extra space can be seen in the models where the N-termini 
of the MAT proteins are not present in the crystal structure, but they would have 
contributed to the overall scattering and, therefore, the DAMMIN model. Proteins were 
purified as described in section 4.2.11. Protein concentrations and data analysis is 
described in section 4.2.23. 
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Figure 6.6. Alignment of crystallographic structure of MATβ proteins with Static 
SAXS data. Using the P(r) of the solution scattering data, twenty runs of DAMMIN were 
performed before models were aligned and averaged. The average model was then 
subjected to a further run of DAMMIN before being aligned using SUPCOMB against 
the crystal structure of MATβ (2YDY) (section 4.2.23). A. MATβV1 dimer. B. 
MATβV1+NADP. C. MATβV2. D. MATβV2+NADP. Extra space can be seen in the 
models where the N-termini of the MAT proteins are not present in the crystal structure, 
but they would have contributed to the overall scattering and, therefore, the DAMMIN 
model. Proteins were purified as described in section 4.2.11. Protein concentrations and 
data analysis is described in section 4.2.23. 
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Figure 6.7. SAXS modelling of MATβV2. A. The ab initio shape reconstruction of 
MATV2 by DAMMIN using P1 symmetry (light blue mesh), showing the fit with the 
crystallographic structure of the monomer (PDB:2YDY), the orange balls correspond to 
the flexible N-terminus whilst the purple balls are the modelled C-terminal. Extra residues 
were modelled with CORAL(Petoukhov et al. 2012) (section 4.2.23). B. Experimental 
spectrum (blue) of the small angle scattering of MAT and the simulated fit (red) obtained 
from the modified crystal structure (PDB=2YDY) that contained both the C and N-
terminal regions modelled using CORAL  (qmax = 0.30 Å
-1) (2 =3.3). qmax is the maximum 
scattering angle that data was measured. 
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6.1.4 MATβV1 and MATβV2 are monomers that do not interact in vitro. 
 
Using MATβ proteins that contained a N-terminal histidine tag, pull down experiments 
were performed whereby either MATβV1_HIS or MATβV2_HIS proteins were 
immoblised on nickel resin and the other isoform wild type protein containing no histidine 
tag was passed through the resin (Fig 6.8). This was done in order to evaluate whether or 
not the different isoforms of MATβ interact with each other.  MATβV1_HIS and 
MATβV2 do not interact (lanes 2-6) as MATβV2 was eluted from the nickel resin (lane 
5) whilst the immoblised MATβV1_HIS remained (lane 6). For MATβV2_HIS versus 
MATβV1 both proteins ran at the same molecular weight (lanes 7 & 9) so from SDS gel 
it was not possible to tell if they eluted as separate proteins (lanes 11-15).  
 
Gel filtration experiments were performed using the wild type MATβ isoforms to see if a 
shift in elution would occour upon mixing the isoforms and this was done in the presence 
and absence of NADP. It was clear that MATβV1 and MATβV2 do not interact, as both 
proteins eluted at ~16 mL and that the MATβV1+ MATβV2 peak is just a combination 
of the two individual proteins with the same elution volume (Fig 6.9A). The same pattern 
can be observed in the presence of NADP where binding of NADP does not cause 
interaction between the two isoforms. Excess NADP can be seen at 20.5 mL (Fig 6.9B). 
Running the peak of MATβV1+MATβV2 on SDS gel shows that in the absence of NADP 
(lanes 6-10) or presence (lanes 10-13) that both proteins are present in similar levels (Fig 
6.10).  
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Figure 6.8. Pull down experiments showing that MATβ isoforms do not interact.  
MATβV1_HIS or MATβV2_HIS proteins (50 μM) were incubated with nickel resin, that 
had be equilibrated with 25 mM HEPES pH 7.5, for 1 hour before being loaded into 2 
mL flow column. Next, the opposing wild type isoform (50 μM) was passed through the 
column and the flow-through was collected. A low imidazole (25 mM HEPES pH 7.5, 40 
mM imidazole) wash was applied to remove no specific binding. An elution buffer 
containing 25 mM HEPES pH 7.5 and 250 mM imidazole was applied to the column and 
the flow-through was collected.  Lanes 2-6 show MATβV1_HIS versus MATβV2. Lanes 
7-10 show control proteins. Lanes 11-15 show MATβV2_HIS versus MATβV1. The 
flow-through at each step was collected in order to verify if the protein had bound or 
simply passed through the nickel resin. 
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Figure 6.9. MATβ proteins do not interact and elute as single peaks. A. MATβV1 (in 
blue), MATβV2 (in orange) and MATβ1+MATβV2 (green) elute as one peak. Elution 
buffer was 25 mM  HEPES pH 7.5, 200 mM NaCl and 1 mM TCEP. B. As in A but in the 
presence of 250 μM NADP. 100 μM of each protein was applied to the column. 50 μM of 
each protein was incubated together for 1 hour at 4 °C, prior to gel filtration (See section 
4.2.13).  
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Figure 6.10. SDS page of fractions from gel filtration, of incubating MATβV1 with 
MATβV2 in the presence and absence of NADP. MATβV1 (100 μM) and MATβV2 
(100 μM) were mixed together for one hour at 4°C before being injected into a gel 
filtration Superdex 200 10/300 in the presence and absence of NADP. C6-C9 refer to the 
fractions of the gel filtration and have the elution volume of 15-18 mL (Fig 6.9). 
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6.1.5 Novel position of methionine in MATα2: from Substrate binding to formation 
of SAMe.  
 
The atomic resolution structure (SAMe+ADO+MET+PPNP bound) at 1.1 Å (Table 6.3), 
which had been incubated with AMP-PNP and methionine shows multiple occupancies 
of ligands in different subunits including substrates and products within the active site: 
Methionine (occupancy 0.3), adenosine (occupancy 0.5), SAMe (occupancy 0.5) and 
PPNP (occupancy 0.8) can be seen. The omit map clearly shows the substrate methionine 
in a novel position which sits within the active site so that its functional group directed 
away from its final place as part of the product SAMe (Fig 6.11A). In order to observe 
the mixed active site in a clearer way two snapshots of intermediate reactions were created 
(Fig 6.11B,C). The main chain of methionine is stabilized through a host of hydrogen 
bonding between residues of different MATα2 monomers (grey and dark grey), which 
include OD1 of Glu70 (2.8 Å), Asp258 (2.7 Å), NE2 of Gln113 (2.9 Å) and water 
molecules.  The position of adenosine  is maintained through π-π stacking between the 
purine base adenine and Phe250, as well as several hydrogen bonds with the OG of 
Ser247 (2.8 Å), main chain oxygen of Arg249 (2.9 Å) and waters (Fig 6.11B). One water 
forms a hydrogen bond with another water and the O4 of adenosine, and occupies the 
position where later the sulphur of SAMe lies (Fig 6.11B).  
 
The substrate methionine forms a hydrogen bond via its nitrogen with OD1 atoms of both 
Glu70 (2.8 Å) and Asp258 (2.7 Å) and via its two terminal oxygens with NE2 atom of 
Gln113 (3.0 Å) and water ligands (Fig 6.11B). The triphosphate can be modeled precisely 
due to high quality of the omit map at atomic resolution (Fig 6.11, 6.13A). The PPNP is 
secured in place through multiple interactions with residues His29, Lys181, Lys265, 
Ap291 and Ala281, waters, two hexacoordinated magnesium ions and a pentacoordinated 
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potassium ion (Fig 6.12). The high resolution of this structure allows for the observation 
of three snapshots of the reaction:  the hydrolysis of the AMP-PNP into adenosine and 
PPNP, and the orientation of methionine before SAMe formation (Fig 6.11B-C) is 
observed whilst, the formation of SAMe and the placement of PPNP before its hydrolysis 
into pyrophosphate (PPi) and orthophosphate (Pi) (Fig 6.11D) is seen. SAMe lies within 
the active site interacting with the same residues that secure the methionine main chain 
and the adenosine molecule, identical to those in the first step, whilst the SD atom 
occupies the position previously occupied by a water molecule.    
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Figure 6.11 SAMe synthesis in human methionine Adenosyltranferases. A. Active 
site of SAMe+ADO+MET+PPNP bound MATα2 showing low occupancy substrate 
methionine (0.3), adenosine (0.5), SAMe (0.5) and PPNP (0.8). B. Novel position of 
substrate methionine, adenosine and PPNP all hydrogen bonded to MATα2 residues and 
water molecules. C. Adenosine and PPNP within the active site. D. Product SAMe and 
PPNP shown hydrogen bonded by the same residues that secure both substrates. Omit 
map (Fo-Fc) is coloured green around and contoured at 3σ level. Two MATα2 monomers 
form a dimer coloured grey and dark grey. Substrates and residues are shown as sticks, 
colour corded according to the nature of the atom, where blue corresponds to nitrogen, 
red to oxygen. Hydrogen bonds are shown as black dotted lines, green and purple dotted 
lines show magnesium and potassium ions coordination, respectively. Water molecules, 
magnesium and potassium ions are represented as red, green and purple spheres 
respectively.  
148 
 
6.1.6 Coordination of Ions within the MATα2 active site. 
 
The high resolution data has enabled the identification of ions and their co-ordination 
within the active site (Fig 6.12A). Both magnesium ions are hexacoordinated whilst the 
single potassium ion is pentacoordinated. The first magnesium (Fig 6.12B) interacts with 
four water molecules and with two atoms, O2A and O3G, of the PPNP moiety. The 
second magnesium ion interacts with two waters, OD2 of Asp31 and three atoms of 
PPNP, O1A, O2B and O2G (Fig 6.12C). The potassium ion interacts with a single water, 
residues from different MATα2 monomers such as OE2 of Glu57, OD1 Asp258 and O of 
Ala259 and also the O2B atom of PPNP (Fig 6.12D). All magnesium bonds are between 
1.9-2.3 Å whilst the potassium bonds are 2.7-2.8 Å (Harding 2006).   
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Figure 6.12. Magnesium and potassium ions coordination in ligand bound MATα2. 
A. Active site of MATα2 (SAMe+ADO+MET+PPNP) showing two magnesium ions 
(green) and one potassium ion (purple). B. Closer view of the first magnesium ion, 
hexacoordinated by 4 waters, and 2 oxygen atoms, O2A and O3G of PPNP. C. Closer 
view of the second magnesium ion, hexacoordinated by two waters, and 4 oxygen atoms, 
OD2 Asp31, O1A, O2B and O2G of PPNP D. Potassium ion is hexacoordinated by water 
and 3 oxygen atoms originating from PPNP (O2B) and residues Asp258 (OD1) and 
Ala259 (O). PPNP and MATα2 residues are shown as sticks colour coded according to 
atom type (C- in grey, O- in red), waters are shown as red balls. Coordination bonds for 
magnesium ions are shown as green dotted lines and for potassium as purple dotted lines.  
150 
 
6.1.7 Mode of PPNP binding in the absence of the regulatory subunit. 
 
Re-examination of the PPNP conformation in the MATα2βV2 complex structure (4NDN) 
using this group from the 1.1Å SAMe+ADO+MET+PPNP structural model suggests that 
the PPNP group was previously not correctly positioned, as lower resolution MATα2β 
structures did not allow the identification of magnesium ions. Positioning of these 
phosphates and the three metal ions from the atomic resolution structure (Fig 6.13A) into 
the lower resolution electron density map of the MATα2β complexes gives a much 
improved electron density fit (Fig 6.13B). The conformation of the triple phosphate is 
preserved in MATα2βV2, SAMe+ADO+MET+PPNP and in the AMP-PNP from E.coli 
MAT (1P7L) in spite of cleavage from the adenosine moiety (Fig. 6.13C).  
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Figure 6.13 Comparison of phosphate moiety conformations in human MAT 
enzymes. A. Omit (Fo-Fc) electron density map, contoured at 3 sigma level around the 
PPNP from SAMe+ADO+MET+PPNP MATα2 structure. B. Coordination of PPNP from 
re-refined MAT(α2)
4
(βV2)
2
 (PDB 4NDN) showing that position of PPNP is the same as 
in SAMe+ADO+MET+PPNP.  Omit map and colour cording is as in A. C. Superposition 
of AMP-PNP from eMAT (PDB accession number 1P7L) and PPNP from 
SAMe+ADO+MET+PPNP MATα2 shown in stick representation. Residues from 
MATα2 monomers shown as sticks in grey or dark grey with hydrogen bonds are black 
dotted lines with magnesium ions as green balls and potassium in purple. Coordination 
of magnesium and potassium ions are shown as green and purple dotted lines respectively.  
All phosphate moieties are shown as sticks, colour corded by atom: P-orange, O-red, N-
blue. 
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6.1.8 PPNP does not provide the energy to open the gating loop. 
  
In the structure of PPNP bound MATα2 it has a disordered gating loop. The complex 
MAT(α2)4(βV2)2 (4NDN) contains 4 active sites, two of these reveal ordered gating loops 
while the other two do not show the gating loop, presumably due to its highly flexible 
disordered nature (Murray et al. 2014). The two ordered sites contain SAMe, PPNP, Mg2+ 
and K+, whist the disordered sites only contain an ethylene glycol molecule from the 
cryoprotectant.  A comparison of three structures (PPNP bound, MAT(α2)4(βV2)2  and 
SAMe+ADO+MET+PPNP bound) shows that gate is open when the active site is 
occupied by PPNP. In contrast the gate is shut like a lid when the active site is occupied 
by SAMe or adenosine. Comparison of the SAMe+ADO+MET+PPNP structure with 
holo re-refined MATα2 from MAT(α2)4(βV2)2  complex (Fig. 6.14A, B) shows that the 
residues in the active site do not differ in position and the mechanism of the active site 
and the catalytic subunit is preserved in the absence of the regulatory subunit MATβ.  The 
gating loop in the (PPNP bound) (Fig. 6.14C) and apo subunit of MAT(α2)4(βV2)2 
complex (Fig. 6.14D) are invisible, suggesting that the opening of the gate to release 
product is not driven by hydrolysis of the triple phosphate. Gln113 is the only residue of 
the gating loop to interact with SAMe directly through its NE2 atom forming a hydrogen 
bond with the O of SAMe. Ser114 interacts with a water molecule that also interacts with 
SAMe (Fig 6.15). What drives the opening of the gate and release of product thus remains 
an open question. 
 
In SAMe+ADO+MET+PPNP structure OE1 atom of Glu70 interacts with the nitrogen 
atoms of Lys61 (NZ) and Ala259 (N), while its OE2 oxygen is hydrogen bonded to the 
substrate methionine or SAMe (2.8 Å).  Glu70 maintains the same position in all holo 
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active sites (Fig. 6.14A-C). In apo MATα2 subunit of MAT(α2)4(βV2)2 complex (Fig. 
6.14D) there are significant movements of the residues. For example Lys61 adopts a 
different conformation compared to those in all other MATs. The change in lysine 
conformation also enables movement of other residues in the active site, for example, 
Gly257 and Asp258 both move away from the active site. Oxygen atom, OD1 Asp258 
can no longer participate in the interaction with the potassium ion coordinated by O2B of 
PPNP, as the distance between the side chain and potassium ion increases to 4.1 Å. Also, 
the movement of Asp258 enables it to interact with N of Ala259. The oxygen, OE1 of 
Glu70 is unable to interact with Lys61 or Ala259, but could do so with the N of Asp258, 
which alters its conformation as a result of Lys61 movement.  
 
In the MATα2 structures, SAMe+ADO+MET+PPNP bound (Fig. 6.14A) the potassium 
ion is present and the interaction with Asp258 and PPNP occurs. In the PPNP bound 
MATα2 (Fig 6.14C) the PPNP adopts a different position whereby the central phosphate 
PB has rotated onto the side. The orientation of the residues around the PPNP remain in 
the same position as in the holo forms and interaction with a magnesium ion occurs but 
interaction with the second magnesium and potassium is lost. Due to the position of Lys61 
and the coordination through the magnesium ion, the PPNP is able to occupy the active 
site whilst the gating loop is disordered, i.e., when it is no longer in the closed position. 
Furthermore, there are movements in residues that interact with the potassium ion, Glu57 
and Ala259 and the PPNP moiety. Three further residues, His29, Lys181 and Asp291, 
which interact with the PPNP, show movement in the absence of PPNP in the empty 
active site.  
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Figure 6.14 Comparison of the holo and apo active sites in MATα2 and MATαβ. A. Holo 
SAMe+ADO+MET+PPNP MATα2 active site. B. Holo MATαβ (PDB accession number 
4NDN) active site. C. Holo PPNP bound MATα2 active site with disordered gating loop. D. 
Apo MATαβ (PDB accession number 4NDN). Gating loop is highlighted in red. Two MATα2 
monomers form a dimer coloured grey and dark grey with residues of interest shown as sticks, 
SAMe can be seen in orange, PPNP as orange sticks, with magnesium ions as green, potassium 
ion in purple and water molecules as red balls. Hydrogen bonds are shown as black dotted lines, 
green dotted lines show interaction with magnesium ions whist purple dotted lines show 
interaction with potassium ion. 
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Figure 6.15. Ordered gating loop of holo MATα2. A. Omit map (Fo-Fc) is coloured 
green around the gating loop from SAMe+ADO+MET+PPNP bound MATα2 structure 
and contoured at 3σ level. B. Interactions between the gating loop and the product SAMe. 
Gating loop residues are shown in stick representation. Two MATα2 monomers form a 
dimer coloured in cartoon representation. Substrates and residues are shown as sticks, 
colour corded according to the nature of the atom, where blue corresponds to nitrogen, 
red to oxygen. Hydrogen bonds are shown as black dotted lines whilst water molecules 
are represented as red spheres. 
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6.1.9 Catalytic steps captured for human MAT. 
 
Using the following structures, SAMe+ADO+MET+PPNP, PPNP bound, MATα2βV2 
complex and MAT from E.coli (eMAT, 1P7L) a clearer picture of SAMe synthesis can 
be provided from structural snapshots starting from the substrate methionine. In the initial 
position the functional group of methionine (SH) forms hydrophobic interactions with the 
phosphate groups of ATP (here AMP-PNP, 1P7L) and the nitrogen on the methionine is 
at a suitable distance to form two strong hydrogen bonds with OD1 of Asp258 (2.7 Å), 
and OD1 of Glu70 (2.8 Å) (Fig 6.16A). The conformation of AMP-PNP is stabilized by 
two magnesium ions, one of which interacts with O1A and O2B of the triple phosphate 
(PPNP) whilst the other interacts with its O2A, O2G and O3G. In order for the sulphur 
atom of methionine to bond with the C5’ atom of the AMP-PNP, the methionine has to 
move its side chain from its initial position towards the C5’ of AMP-PNP (Fig 6.16B) 
while, the nitrogen of methionine still interacts with OD1 of Asp258 (2.7 Å), and OD1 of 
Glu70 (2.8 Å) to aid in its stabilisation and rotation.  
 
Once the methionine is in position its electron rich sulphur reacts with the positively 
polarized C5’ of AMP-PNP in a nucleophilic substitution to produce adenosine and PPNP 
(Fig 6.16C) before the final SAMe and PPNP (Fig 6.16D) is synthesized. MATα2 (PPNP 
bound) shows a pre-apo state that after the product has been formed, SAMe, it is able to 
leave the active site leaving the triple phosphate moiety within the active site that still 
contains a magnesium and potassium ions (Fig. 6.16E) The loss of one of the magnesium 
ions causes a re-orientation of the PPNP moiety losing the interaction with the potassium 
ion. In order for the active site to cycle and be ready to receive the substrates again, the 
triple phosphate must be broken down before exiting the active site. The triphosphatase 
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activity of MATα2 causes the breakdown of the triple phosphate, which results in the loss 
of all ion coordination. Movement of Glu57, Glu70, Asp258 and Ala259 occurs after all 
products have left the active site (Fig. 6.16F) (4NDN) all of which are able to hydrogen 
bond to water molecules. 
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Figure 6.16. Insights into SAMe synthesis in human methionine adenosyltransferase. A. 
Methionine from SAMe+ADO+MET+PPNP and ATP analog AMP-PNP drawn as ineMAT 1P7L. 
The methionine is in a position where its nitrogen is hydrogen bonded to Asp258 and Glu70. B. 
Movement of substrate methionine as it moves towards C5’ bond of AMP-PNP (ligands modelled 
from 1P7L). C. Cleavage of AMP-PNP producing ADO and PPNP from SAMe+ADO+MET+PPNP 
with methionine (1P7L). D. Formation of SAMe from ADO and methionine with PPNP present 
(SAMe+ADO+MET+PPNP). E. Active site after product SAMe has left the active site leaving PPNP 
(PPNP bound). F. On breakdown of the triple phosphate, Glu70 and Asp258 change conformations 
and magnesium ions no longer coordinate the PPNP. Substrates and residues are shown as sticks with 
hydrogen bonds shown as black dotted lines. Green and purple dotted lines show magnesium and 
potassium ions coordination, respectively. Water molecules, magnesium and potassium ions are 
represented as red, green and purple spheres respectively.  
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6.1.10 Incorporation of non-native methionine analogs. 
 
The S-adenosylethionine  structure is the first non-archaea MAT enzyme structure to 
contain a nonnative reaction product, S-adenosylethionine. Overall there was no 
structural rearrangement in the main chain and secondary structure is maintained 
((RMSD) 0.185 Å) (Fig 6.17A), when compared to SAMe+ADO+MET+PPNP.  S-
adenosylethionine occupies the active site in a similar way to SAMe, there is little 
movement of the residues involved in the stabilization of both SAMe and S-
adenosylethionine, including residues Ser247, Arg249 and Asp258 (Fig 6.17B). The extra 
CH3 group is able to be accommodated within the active site without causing clashes with 
residues near the methyl/ethyl group (Fig 6.17B) specifically Ile117, Ile322, Gly133 and 
Asp134. Omit map shows clear positions for all atoms of S-adenosylethionine molecule 
(Fig 6.17C). 
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Figure 6.17. Structure of S-adenosylethionine bound MATα2. A. Superposition of 
MAT(α2)2 with S-adenosylethionine bound (in purple) and SAMe bound (in silver) displayed 
as lines showing no change in folding (0.185 Å RMSD). B. Superposition of SAMe (green) 
and S-adenosylethionine (light blue) within the active site of MATα2 showing no change in 
position of surrounding residues. Residues from SAMe bound structure are shown as silver 
sticks whilst S-adenosylethionine bound as purple sticks. Hydrogen bonds are shown as black 
dotted lines. C. Omit map (Fo-Fc) electron density map and stick representation of SAE from 
MATα2, the map is contoured at 3 σ level around S-adenosylethionine molecule. 
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Table 6.3. Data collection and refinement statistics of MATα2 structures. Values in 
parentheses are for the highest resolution shell. 
 
 
SAME+ADO+MET+PPNP 
bound 
SAE bound PPNP bound 
Data collection 
Wavelength Å 
0.92 0.92 0.92 
Detector Pilatus Pilatus Pilatus 
Space group I222 I222 I222 
Unit-cell 
dimensions (a,b,c) 
(Å) 
67.92, 94.07, 117.22 68.39, 94.39, 117.39 66.11, 95.33, 117.51 
Resolution (Å) 50-1.10 58.7-2.0 74.04-2.33 
Rmerge % (last 
shell) 
8.9  (9.1) 10.3 (8.14) 13.6 (7.46) 
I/σ (last shell) 24.5 (3.4) 21.3 (3.4) 20.7 (3.9) 
Completeness (%) 99.1 (99.0) 99.5 (97.5) 99.9 (99.9) 
Redundancy 12.3 (9.7) 13.3 (12.5) 13.0 (13.7) 
No. of reflections 176512 33901 16225 
Rwork/Rfree 12.9/15.2 13.4/17.7 14.4/20.1 
No. of atoms  
Protein 3290 2972 2876 
Ligand/ion 68/3 41/3 13/3 
water 552 265 170 
B factor (Å2)   
Protein 11.2 20.0 29.1 
Ligands/ions SAMe/ADO/MET/PPNP/
Mg/K 
7.5/13.3/14.5/10.3/8.5/10 
SAE/PPNP/Mg/K 
22.5/22/21/27 
PPNP/Mg/K 
32.8/28.5/62 
Waters 24.0 29.1 32.4 
Ramachandran 
statistics 
 
Residues in 
preferred regions 
413 (97%) 369 (97%) 358 (98%) 
Residues in allowed 
regions 
14 (3%) 12 (3%) 9 (2%) 
Outliers 0 (0%) 0 (0%) 0 (0%) 
R.M.S deviations  
Bond length (Å) 0.002 0.002 0.014 
Bond angles (°) 1.14 1.94 1.66 
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6.1.11 Binding of molecules into the MATβ binding tunnel of MATα2. 
 
Crystallisation of MATα2 has not only provided insights into how the synthesis of SAMe 
may proceed, but has also revealed that molecules, such as PEG and imidazole,  are able 
to bind in the tunnel that holds the C-terminal of MATβ. Depending on crystallisation 
conditions different ligands were seen within this pocket. Crystallising with 0.1 M 
imidazole or  20 % PEG600 resulted in these molecules co-crystallising with MATα2 
(Fig 6.18A, B). Both ligands sit within the beta binding pocket, hydrogen bonded to water 
molecules. SAMe and PPNP are shown to highlight the position of the active site of 
MATα2. 
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Figure 6.18 Binding of ligands to the MATβ binding tunnel of MATα2. A. When 
MATα2 was crystallised with 0.1 imidazole pH 7.0, 50 % (w/v) MPD and two imidazole 
molecules sit within the tunnel. B. When MATα2 was crystallised in 0.1 M HEPES pH 7.5, 
20 % (v/v) PEG600 and a PEG (PG4) molecule sit within the tunnel. Residues from MATα2 
monomers shown as sticks in grey or dark grey with hydrogen bonds are black dotted lines, 
ligands are shown as stick coloured by atom.  
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6.1.12 Exploitation of differential scanning fluorimetry (DSF) for analysis of MATα2 
ligand binding. 
 
Differential scanning fluorimetry was used to examine whether the presence of ligands 
affected the stabilisation of MATα2. A range of MATα2 concentrations were tested to 
see if protein concentration affected the melting temperature (Tm) of the protein. As the 
protein concentration increased the amount of fluorescence increased (Fig 6.19A). Small 
differences in melting temperature were observed with changing concentrations, but this 
was not in a concentration dependent manner (Fig 6.19B) and the average melting 
temperature over the range of MATα2 concentrations was 46.0 °C. No change in the 
shape of the unfolding protein was seen over any of the protein concentrations. Fixing the 
protein concentration at 0.4 mg/mL and examining the effect of pre incubation with an 
increasing range of the enzyme product, SAMe, showed a stabilisation of MATα2 (Fig 
6.19C). Compared to the control a slight shift can be seen with the addition of SAMe. 
The melting temperature of MATα2 in the presence of SAMe increased and 
concentrations of 2 mM and above caused similar increases but this was again not in a 
dose dependent manner (Fig 6.19D). Incubation with 10 mM SAMe provided the greatest 
thermal shift (+1.50 °C). 
 
The crystal structures of MATα2, presented in section 6.1.11, showed that compounds 
that were part of the crystallisation conditions could bind to the MATα2 protein. The 
binding of both imidazole and PEG600 were investigated to see if they changed the 
thermal stability of MATα2 using differential scanning fluorimetry. Interestingly, 
incubation with imidazole caused a concentration dependant destabilisation which is 
clearly visible at 100 mM imidazole (Fig 6.20A). Compared to the control (47.0 °C, no 
imidazole) clear changes in the melting temperature can be seen from 20 mM imidazole 
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(46.3 °C).  Decrease in the melting temperature suggests that imidazole caused MATα2 
to become destabilised (Fig 6.20B). This effect is not seen in the crystal structure as the 
temperature of crystallisation was only 25 °C even though the concentration of imidazole 
in crystallisation was 100 mM. Given the protective effect of SAMe it was tested to see 
whether the presence of 5 mM SAMe could stabilise MATα2 in the presence of 
imidazole. SAMe does protect MATα2 against the effects of imidazole but a 
destabilisation still occurs for a concentration over 50 mM imidazole (Fig 6.20C). A 
stabilisation occurs when a concentration of 1-20 mM imidazole is used but this is due to 
the presence of SAMe  but beyond 20 mM a clear destabilisation effect can be seen (Fig 
6.20D). When PEG600 was incubated with MATα2 a concentration dependent 
stabilisation effect was observed (Fig 6.21A) with a clear shift in the position of the 
melting curve of all concentrations of PEG600 compared to the control (Fig 6.21A, 
brown). The melting temperature of MATα2 increased in the presence of all PEG600 
concentrations, but the greatest stabilisation was observed with 20 % (w/v) PEG600  
(+5.95 °C) compared to the control (Fig 6.21B). This effect was further enhanced by the 
addition of 5 mM SAMe where a clear shift in melting temperature is seen (Fig. 6.21C). 
The addition of 5 mM SAMe provided an additional stabilisation effect for the MATα2 
which was the greatest at 20 % (w/v) PEG600 (+7.15 °C) (Fig 6.21D).  The stabilisation 
effect that SAMe provides on the recombinant MATα2 protein is clear, either on its own 
or in the presence of imidazole, and PEG600.  Imidazole caused a concentration 
dependent destabilisation of MATα2 which cannot be recovered with the addition of 5 
mM SAMe (Fig 6.22A), whilst PEG600 caused a concentration dependent stabilisation 
of MATα2 that was further enhanced by the presence of SAMe (6.22B).   
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Figure 6.19.  Thermal stability assay of MATα2. A. Melting curves of MATα2 for a 
range of protein concentrations (0.2-2.0 mg/mL). B. Melting temperatures (°C) of 
MATα2 over a range of protein concentrations (±range, n=2). At 0.4 mg/mL MATα2 the 
melting temperature is greatest and there are small variations over the range of protein 
that were tested. C. Melting curves of MATα2 that was pre-incubated with SAMe (1-10 
mM) prior to the thermal stability assay. D. Melting temperatures (°C) of MATα2 +SAMe 
over a range of protein concentrations (±range, n=2). SAMe increases the melting 
temperature of MATα2. A thermal ramping procedure (0.3 °C/min over a range of 25 °C 
to 94 °C) was employed to denature MATα2 and mean melting temperature (°C) values 
(±range) are shown for each condition. Section 4.2.19 describes the differential scanning 
fluorimetry method. The melting temperature was calculated from the first derivative 
curve of the melting curve and was defined as the maximum peak of the first derivative 
curve (Sun et al. 2015). Figures were produced using GraphPad.  
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Figure 6.20. Thermal stability assay of MATα2 with Imidazole. A. Melting curves of 
MATα2 that was pre-incubated with imidazole (1-200 mM).  B. Melting temperatures 
(°C) of MATα2 pre-incubated with imidazole (1-200 mM) (±range, n=2). C. Melting 
curves of MATα2 that was pre-incubated with imidazole (1-100 mM) and SAMe (5 mM). 
A destabilising effect can be seen with increasing imidazole concentrations D. Melting 
temperatures (°C) of MATα2 pre-incubated with imidazole (1-200 mM) and SAMe (5 
mM) (±range). A destabilising effect can be seen with increasing imidazole 
concentrations which is slightly decreased by the presence of SAMe. A thermal ramping 
procedure (0.3 °C/min over a range of 25 °C to 94 °C) was employed to denature MATα2 
and mean melting temperature (°C)  (±range, n=2) are shown for each condition. Section 
4.2.19 describes the differential scanning fluorimetry method. The melting temperature 
was calculated from the first derivative curve of the melting curve and was defined as the 
maximum peak of the first derivative curve (Sun et al. 2015). Figures were produced 
using GraphPad.  
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Figure 6.21. Thermal stability assay of MATα2 with PEG600. A. Melting curves of 
MATα2 that was pre-incubated with PEG600 (0-20 % w/v).  B. Melting temperatures 
(°C) of MATα2 pre-incubated with PEG600 (0-20 % w/v) (±range, n=2). C. Melting 
curves of MATα2 that was pre-incubated with PEG600 (0-20 % w/v) and SAMe (5 mM). 
A stabilising effect can be seen with increasing PEG600 concentration D. Melting 
temperatures (°C) of MATα2 pre-incubated with PEG600 (0-20 % w/v) and SAMe (5 
mM) (±range, n=2). A destabilising effect can be seen with increasing PEG600 
concentration which is further enhanced by the presence of SAMe. A thermal ramping 
procedure (0.3 °C/min over a range of 25 °C to 94 °C) was employed to denature MATα2 
and mean Tm values (±range) are shown for each condition. Section 4.2.19 describes the 
differential scanning fluorimetry method. The melting temperature was calculated from 
the first derivative curve of the melting curve and was defined as the maximum peak of 
the first derivative curve (Sun et al. 2015). Figures were produced using GraphPad. 
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Figure 6.22. Thermal stability of MATα2 in the presence of SAMe, PEG600, and 
imidazole. A. Imidazole (1-100 mM) decreases the stability of MATα2 which is partially 
protected by incubation with SAMe (5 mM). B. PEG600 (2.5-20 % w/v) provided a 
stabilising effect for MATα2 that is concentration dependent. This can be further 
enhanced by SAMe (5 mM). Data is displayed with range (n=2). Section 4.2.19 describes 
the differential scanning fluorimetry method. The melting temperature was calculated 
from the first derivative curve of the melting curve and was defined as the maximum peak 
of the first derivative curve (Sun et al. 2015). Figures were produced using GraphPad. 
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6.2 Discussion  
Even though there was a great effort to make a consensus nomenclature for mammalian 
MAT enzymes by Kotb et al in 1997 there still remains discussion regarding the 
oligomeric states of human MAT enzymes. MATα1 has long been regarded as being able 
to associate into both a dimer and tetramer (Varela-Rey et al. 2011), whilst on the other 
hand MATα2 has not been well characterized and no agreement has been reached as to 
the oligomeric state of this protein.  In order to function as an enzyme, MATα2 must be 
at least a dimer and when MATαβ was purified from human chronic lymphocytic cells it 
was suggested that this was the case (Kotb & Kredich 1985). The crystallographic 
structure of MATα2 solved by Shafqat et al. shows that it is a dimer of dimers and in our 
previous publication  we showed that MATα2 can function as a tetramer in the context of 
the MAT(α2)4(βV2)2 complex (Murray et al. 2014). Using the PISA (Krissinel & Henrick 
2007) server the protein assembly of the MATα2 structures, containing 
SAMe+ADN+MET+PPNP bound and PPNP bound were checked, which suggested that 
both dimers and tetramers are energetically favourable. For the reasons above MATα2 
was used to investigate whether, in solution, it can assemble into dimers and/or tetramers.  
 
Just like MATα1, gel filtration experiments of MATα2 showed multiple peaks (Fig 6.1A, 
B) but when molecular mass was determined using a standard curve of known protein 
standards these peaks did not correspond to dimers or tetramers. Gel filtration 
experiments suggested that the first peak would correspond to a trimeric species of ~124 
kDa, which seemed very unlikely, as in order to function two MATα monomers must 
dimerize to create functional active sites. Due to the equilibrium between oligomeric 
states for both MATα1 and MATα2, SAXS-Size exclusion chromatography (SEC) was 
chosen to ensure that both peaks were separated enough to collect reliable data. For 
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MATα1 the first peak corresponded to a tetramer with a molecular weight of ~160 kDa 
whilst the second peak gave a molecular mass of ~93 kDa (Table 6.2). For MATα2 only 
data corresponding to a tetrameric mass were collected, as the protein became unstable 
from purification to experimentation and precipitated, limiting the amount for data 
collection. Further data collections would have allowed for the dimeric population to be 
measured. Considering the high sequence identity between MATα1 and MATα2 (84 %) 
it is not difficult to see that MATα2 can oligomerise in a similar way.  
 
Of the two human MATβ structures deposited in the PDB, one is a monomer (2YDY) 
and the other is a dimer (2YDX) (Shafqat et al. 2013). Using both SAXS and gel filtration 
MATβV1 and MATβV2 correspond to monomers (Fig 6.2A 6.6A-D, Table 6.1 & Table 
6.2). NADP binding reduced the flexibility of the MATβ proteins, as overall maximum 
particle distance (Dmax) of the protein decreased compared to MATβ without NADP 
(Table 6.2). Although 2YDX is shown as a dimer, this dimerisation may only exist due 
to the co-crystallization ligand, resveratrol, which binds at the dimer interface. 
Resveratrol is a naturally occurring polyphenol commonly found in grapes, peanuts, and 
other plant sources, which has been reported to possess both chemotherapeutic and 
chemopreventive activities in certain types of cancer including liver cancer (Mbimba et 
al. 2012). When resveratrol was incubated with MATβ isoforms no shift was observed in 
the UV spectrum of gel filtration suggesting no oligomerisation occurred in solution. In 
fact, we investigated what function this molecule had in the context of the MAT2 
complexes (section 5.1.13) and saw no interaction between the complex and resveratrol. 
It was reported that resveratrol induces the expression of MAT2B by multiple mechanisms 
and leads to the stabilisation of the protein, though resveratrol was not directly responsible 
for the stabilisation of MATβ proteins (Yang et al. 2013). The results from ITC and gel 
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filtration experiments showed that resveratrol does not bind to MATβ. Comparing the 
crystallographic structure of MATβ to the solution X-ray scattering data provided a good 
fit, which could be further improved by taking the missing N and C-terminal residues in 
the crystal structure into account (Fig. 6.6). Furthermore MATβ isoforms do not interact 
to form heterodimers, as both pull down and gel filtration experiments suggested that they 
do not interact with each other (Fig 6.8 & 6.9). The schematic in figure 6.23 provides a 
summary of the oligomeric states of the MAT family of proteins whereby the two 
catalytic isoforms, MATα1 and MATα2, can form both dimers and tetramers. The 
regulatory subunit, MATβ, shows no evidence of forming higher oligomeric forms and 
has only been seen as monomer.  
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Figure 6.23. Summary of the oligomeric states of MATα1, MATα2 and MATβ 
proteins. The mammalian genes MAT1A, MAT2A and MAT2B encode the catalytic 
subunits MAT1, MAT2 and the regulatory subunit MAT respectively. MAT1 and 
MAT2 subunits can be organised as dimers and tetramers and can be referred to as 
MAT(α1)2, MAT(α1)4, MAT(α2)2  and MAT(α2)4. The regulatory subunits MATβV1 
and MATβV2 are monomeric in solution.  
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Despite a plethora of MAT structures that have been published (González et al. 2003; 
Komoto et al. 2004; Fua et al. 1996; Takusagawa et al. 1996; González et al. 2000) or 
deposited in the protein data bank, to date, only one human MATα2 (Shafqat et al. 2013) 
(1.2 Å resolution) and three MAT(α2)4(βV2)2 complexes (Murray et al. 2014) (2.35 to 
3.3 Å resolution) have been published. Mechanisms of how MAT enzymes function have 
been described for E.coli MAT (González et al. 2003) which is the accepted mechanism 
for MAT enzymes. Here, several high resolution crystallographic structures are presented 
that support the E.coli MAT’s reaction mechanism, but defining the movements of 
methionine within the active site during catalysis from its initial position within the active 
to its final position as part of SAMe. We see that methionine initially occupies the active 
site (Fig 6.11B, 6.16A) in a different manner to E.coli MAT (1P7L) (Fig 6.15B). A direct 
attack by the sulphur of methionine on the C5’ atom of the ATP molecule was proposed 
to form SAMe (Parry et al. 1982), which was confirmed with kinetic isotope studies 
(Markham et al. 1987). With SAMe+ADO+MET+PPNP the initial position (Fig 6.11B) 
of methionine can be seen which is stabilized through hydrogen bonds between the main 
chain nitrogen of methionine with Asp258 and Glu70, conserved in mammals and E.coli 
(Fig 6.24) and through the terminal oxygen and Gln113. The distance between the 
methionine functional group and PPNP is large enough that would allow it to rotate into 
a position to attack the C5’ atom of ATP without encountering steric hindrance.  
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Figure 6.24 Sequence alignment of MATα2 from homo sapiens, rMAT from rattus norvegicus and eMAT from E.coli. Fully conserved 
residues between three sequences are shown in blue, conservation only between human and rat are in light blue, only between human and E.coli in 
orange and in pink for those conserved between E.coli and rat. Red boxes show residues involved in catalysis. Gating loop is highlighted by yellow 
box.
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PPNP is a non-hydrolysable triple phosphate moiety that is particularly useful when studying 
MAT enzymes, as it cannot be cleaved to pyro and orthophosphate. The high resolution 
structure SAMe+ADO+MET+PPNP has shown not only the position of the PPNP, but also 
positions of magnesium and potassium ions within the active site (Fig 6.12 & 6.13) which were 
previously difficult to model. Interestingly, the positions of the three ions within the active site 
share high similarity to those in E.coli (Fig 6.13C). The high resolution data 
(SAMe+ADO+MET+PPNP bound) clearly show that all three active site ions are highly 
coordinated either hexacoordinated or pentacoordinated (Fig 6.12). Orientation of the PPNP is 
the same as in AMP-PNP from E.coli, which demonstrates that as the AMP-PNP is cleaved, 
the newly formed PPNP does not cause a change in orientation or change the residues that were 
initially anchoring the AMP-PNP in the active site. Refining MAT(α2)4(βV2)2 complex 
(4NDN) using the high resolution position of the PPNP satisfies electron density to a greater 
extent. PPNP is stabilized through interactions with magnesium and potassium ions, as well as 
a number of residues (Fig 6.12 & 6.13). These interaction would become destabilised upon the 
cleavage of the triple phosphate to pyro and orthophosphate, allowing them to exit the active 
site. Only a small structural movement within the region close to the active site is needed to 
aid in the anchoring of ATP initially and stabilization of the cleaved triple phosphate moiety in 
order to allow the triple phosphate to be broken down into pyro and orthophosphate.  It is 
difficult to say whether this pre-apo structure (Fig 6.16E) is set up for hydrolysis, because the 
mechanisms of how MAT enzymes hydrolysize the triple phosphate remains unclear. From a 
recent MAT review by Pajares & Markham in 2012 they summarize this: "The mechanism of 
hydrolysis of the triple phosphate intermediate appears to be similar to that of the myriad of 
metal ion dependent ATPases and other phosphatases. However the chemical means by which 
water is activated to react with the triple phosphate and thus split the triple phosphate chain 
into pyrophosphate and orthophosphate is unknown”. 
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The observation that the MATα2 active site can be occupied but have the gating loop disordered 
is new in human MAT enzymes and gives evidence for the exiting order of products from the 
active site (Fig 6.14). SAMe exits the active site upon the gating loop becoming disordered 
followed by the cleaved triple phosphate products, which causes residues (Fig. 6.14) such as 
Lys61, Glu70 and Lys181 to return to their unbound (apo) positions. The non-hydrolysable 
PPNP remains in the active site and position of the highlighted residues remains the same as if 
the active site was occupied and gating loop remains ordered and shut. An interesting 
observation is that in the PPNP bound MATα2 the position of the PPNP is different and this 
may represent a pre-apo structure whereby the central phosphate moves causing a change in 
ion coordination and allowing for the triple phosphatase activity of MATα2 to occur or if it 
could just represent the effect on having a non-hydrolysable PPNP in the active site and that 
its movement may only occur due to non-hydrolysable nature. The data suggests that ATP 
(PPNP) binding will change the conformation of Glu70 from open (Fig 6.14D) to substrate 
bound (Fig 6.14A-C), ready for methionine binding. From a comparison of the 
SAMe+ADO+MET+PPNP bound MATα2 to MAT(α2)4(βV2)2 complex it is clear that the 
presence of MATβ does not directly affect the catalytic site (Figure 16.4A, B). It was 
demonstrated before that recombinant MATαβ complexes have greater activity compared to 
MATα2 alone (Murray et al. 2014) yet it remains unclear as to how MATα2 activity is 
regulated by MATβ.  
 
Although it has been known that human MATα2 can use ethionine as a substrate for many 
years (Smith & Salmon 1965) and the effect that this has within the cell (Rao et al. 1982), no 
human MATα2 structure has been published with this substrate or its product, S-
adenosylethionine. Recently, Wang et al published the structure of sMAT (Wang et al. 2014) 
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from Sulfolobus solfataricus containing SAE within the active site and suggested that moderate 
clashes would occur between the ethyl group and Ile117 and Ile322 of human MATα2. In the 
human MATα2 SAE structure, containing S-adenosylethionine, this is not the case and the 
ethyl group is over 3 Å away from the surrounding residues. S-adenosylethionine, has the same 
orientation as SAMe (Fig 6.17B) with very little noticeable movements. 
 
These results show that SAMe can leave the active site without the breakdown of the PPNP 
which has been presumed to provide the energy for opening of the gating loop.  It is clear that 
the catalytic mechanism of SAMe formation in MATα2 is retained in the absence of the 
regulatory subunit MATβ as residues involved in catalysis are in similar positions (Fig 6.14). 
Both of these unexpected findings have wider implications on the formation and release of 
SAMe. The utilisation of the same catalytic site for substrate ethylene for production of S-
adenosylethionine opens therapeutic possibilities for diseases connected to SAMe and SAE 
utilisation.  
 
Differential scanning fluorimetry provides one of the most simple, yet effective, screening 
method to identify low-molecular-mass ligands that bind and ‘protect’ purified, folded, 
proteins from thermal denaturation as detected by fluorescence of a probe compound (Desantis 
et al. 2012; Mashalidis et al. 2013; Niesen et al. 2007). Reduction in the amount of MATα2β 
complex has shown a decrease in the rate of growth in human liver cancer cells (Wang et al. 
2008) so targeting this complex could provide a treatment of various forms of liver diseases. 
The structure of MATαβ revealed a binding cavity, which is where MATβ interacts with 
MATα2 (Murray et al. 2014), and more recently crystal structures have revealed that other 
molecules, including imidazole and PEG600 can bind within this cavity (Section 6.1.11). 
Screening small molecules that could bind to MATα2, specifically the MATβ binding cavity 
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could provide a starting point in rational drug design and using a rapid and inexpensive 
screening method, such as differential scanning fluorimetry, seemed a suitable methodology to 
use.  
 
Given that MATα2 exists in a dimer/tetramer equilibrium and before molecules were screened 
against it the effect of concentration of MATα2 was examined. This was done to see whether 
an effect of the melting temperature or the shape of the curve, suggesting different unfolding 
rates, would be observed. Neither of these were seen when the protein concentration was 
varied. Small changes in melting temperature were observed but this was not in a concentration 
dependent manner (Fig 6.19A). It is known that binding within the MATα2 active site causes 
several disordered loops to become well ordered (Shafqat et al. 2013; Murray et al. 2014) and 
that if the active site is mutated causing the inactivation of the protein then it cannot function 
then the cell dies which raised the question whether SAMe, the product, could be pre-bound to 
MATα2 before exposure to compounds. When searching for a compound to bind MATα2 we 
wanted to try and reduce the likelihood of compounds binding within the active site.  Incubation 
with SAMe was used to try to lock the active site and prevent other molecules from binding in 
hope of reducing the number of hits that bind to MATα2. SAMe was able to stabilise MATα2 
over a range of concentrations (2-10 mM) (Fig 6.19C). Knowing that ligands such as imidazole 
and PEG600 were able to bind to MATα2 the effect that they had on this protein were 
examined.  Imidazole had a destabilising effect on MATα2 that could be protected against (up 
to 20 mM) by the addition of 5 mM SAMe (Fig 6.20). Imidazole is a small and planar molecule, 
which may be able to fit in and interact with sites on MATα2 monomer or between the 
tetrameric interfaces of the higher oligomeric state that was not revealed by the crystal structure 
which caused  destabilization effect. PEG600 on the other hand had a stabilising effect on 
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MATα2 which may be due to a higher affinity it may have with MATα2 compared to imidazole 
(Fig 6.21). 
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Chapter VII. Interacting partners of MATβ: MATα1 
and GIT1  
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7.1 Results-MATα1 and MATβ  
7.1.1 Interaction of MATβ isoforms with MAT1. 
 
MATα1 is the liver specific isoform of MAT in humans and looking at the structure of the 
MAT(α2)4(βV2)2 complex it is difficult to understand why, in vivo, MATβ has so far been 
found to only interact with MAT2 (Martínez-Chantar et al. 2003; Kotb & Kredich 1985; 
Huang et al. 1998), even though MAT1 and MAT2 have a sequence identity of 84 % and 
share the same fold. The differences between these two isoforms are not restricted to a 
particular part of the protein but rather spread out throughout the sequence, (Fig 7.1). All 
catalytic residue and those residues involved with binding MATβ (green) are conserved, 
suggesting that the catalytic mechanism is the same for MATα1 and MATα2. The largest 
stretch of amino acid substitutions are within the N-terminus of the MATα proteins. The 
observation that the residues involved in MATβ binding are conserved raised the question if 
MATβ could bind to MATα1. For MATβ proteins, the two major isoforms, MATβV1 and 
MATβV2 share over 94 % sequence identity and the interaction region with MATα2 is 
conserved and the only differences arise in the N-terminal region of MATβ (Fig 7.2).  
 
Looking at the surface charge representation of the MAT catalytic subunits no major 
differences can account for MATα1 apparent lack of interaction with MATβ (Fig 7.3A-B). The 
area of interaction with MATβ (Fig 7.3C) as shown by sequence alignment shows that overall 
fold of the MATβ interaction area is equal for both MATα1 and MATα2. 
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Figure 7.1 Sequence alignment of the two catalytic human MAT subunits. A. In blue are residues that are the same in both isoforms. In green are the 
residues of MAT2 that interact with MATβV2, which are also equal in MATα1. In grey are the residues whose side chains are similar in biochemical properties 
and in yellow the residues whose side chains are different in biochemical properties. Proteins were aligned using clustalW server  (Thompson et al. 1994). B. 
Position of all residues that a different between MATα1 and MATα2 located on the structure of MATα2 (2P02). The view of the MATα2 proteins shows the 
side used to form the MAT(α2)2. C. As in B but rotated 180° around and the view of the MATα2 proteins shows the side that would be exposed to the cell. 
MATα2 is shown in cartoon form in slate, whilst highlighted amino acids are shown as spheres.  
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Figure 7.2. Sequence alignment of MATV1 and MATV2. A sequence comparison of the regulatory MAT proteins, MATβV1 and 
MATβV2. Residues that interact with MAT dimer are highlighted by a blue line and the NADP binding motif is also shown as a green box. 
Proteins were aligned using clustalW server  (Thompson et al. 1994).
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Figure 7.3. Structural comparison of MATα proteins.  Electrostatic surface representation 
of A. MAT1 (PDB: 20BV) and B. MAT2 (PDB: 2P02) shows different charge distribution 
at the surface of both proteins. Negative charge is shown in red colour, positive in blue. The 
surface potential has been calculated with Pymol/APBS (Schrödinger, LLC 2010). C. 
Superposition of the MAT1 monomers (PDB: 2OBV in orange) and MAT2 from the 
MAT(α2)4(βV2)2 complex (slate, PDB 4NDN), the green arrow represents the region where 
MAT C-terminal interacts. 
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7.1.2 MATα1 interacts with MATβ isoforms 
 
MATα1 was incubated with MATβV1 for one hour at 4 °C  (Section 4.2.13) before injection 
into a gel filtration column and evidence for complex formation can be seen (Fig 7.4A) with a 
peak around 12 mL (orange) which is typical for MATαβ complexes. UV spectra for MATβV1 
(green) and MATα1 (purple) eluted at different volumes to the complex suggesting different 
masses. Excess MATβV1 that was no incorporated into the MAT(α1)4(βV1)2 complex can be 
seen in orange at 16 mL.  Running fractions of the MAT(α1)4(βV1)2 complex on SDS gel show 
that both proteins are present in similar amounts for the complex peak (lanes 3-8). Lanes 9-15 
show both proteins are in different levels suggesting that some of the MATα1 and MATβV1 
protein did not form a complex (Fig 7.4B).  
 
Incubation with the MATβV2 yielded different results compared to MATβV1. The majority of 
the two proteins, MATα1 and MATβV2, did not form a complex (blue) and were eluted at 
similar volumes to the elution profiles of MATα1 (~14.2 mL, purple) and MATβV2 (~16 mL, 
red) (Fig 7.5A) alone. A small peak appeared at 12 mL which is typical of MATαβ complexes 
although this represents a very small proportion of the proteins. Analysing fractions from this 
gel filtration, 13 mL-17 mL, on SDS page shows that the proteins here are not interacting and 
do not co-elute as the maximum level of protein is different for each protein (Fig 7.5B).  
 
To confirm interaction of MATα1 and MATβV1 ITC was performed (Fig 7.6A) which showed 
that the two proteins interacted and Table 7.1 summarises the thermodynamic properties of 
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their interaction. Compared to MAT(α2)4(βV1)2  complexes (Kd= (3.38 ±0.98)X 10-8, Table 
5.6) MAT(α1)4(βV1)2 had a much weaker interaction together (Kd= (2.96 ±0.21)X 10-6, Table 
7.1). A strong interaction by gel filtration between MATβV2 with MAT1 was not seen (Fig. 
7.5A), indicating a role of the N-terminus of MAT in providing the stability to MAT1β 
complex. Using the truncated version of MATV1, lacking the first 16 amino acids 
(MATV116), complex formation  was tested and showed that this mutant produced much 
smaller amount of complex with MAT1 (Fig 7.6B). Similar results were seen using 
MATβ1Δ16, as when using MATβV2, with most of the two proteins not forming a complex 
and eluting separately. A small population of protein could be seen at 12 mL indicating the 
formation of the MAT(α2)4(βV1Δ16)2 complex. 
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Figure 7.4. Formation of MAT(α1)4(βV1)2 complex analysed by  gel filtration 
chromatography. A. Elution profiles of MATα1, MATβV1 and MAT(α1)4(βV1)2. 100 μM of 
MATα1 was incubated with 50 μM of MATβV1 for one hour at 4 °C (section 4.2.13) prior to 
injection onto a Superdex 200 10/300. For the controls, 100 μM of MATα1 and 50 μM 
MATβV1 were used. The elution buffer was 25 mM HEPES pH 7.5, 200 mM NaCl and 1 mM 
TCEP. Absorbance at 280 nm was used to measure for the presence of proteins. B. SDS PAGE 
of fractions of MAT(α1)4(βV1)2 from 11.0 mL to 17.5 mL.  
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Figure 7.5. Formation of MAT(α1)4(βV2)2 complex analysed by gel filtration 
chromatography. A. Elution profiles of MATα1, MATβV2 and MAT(α1)4(βV2)2. 100 μM of 
MATα1 was incubated with 50 μM of MATβV2 for one hour at 4 °C (section 4.2.13) prior to 
injection onto a Superdex 200 10/300. For the controls, 100 μM of MATα1 and 50 μM 
MATβV2 were used. The elution buffer was 25 mM HEPES pH 7.5, 200 mM NaCl and 1 mM 
TCEP. Absorbance at 280 nm was used to measure for the presence of proteins. B. SDS gel of 
fractions of MAT(α1)4(βV1)2 from 11.5 mL to 18.5 mL.  
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Figure 7.6. Interaction of MATα1, MATβV1 and MATβV1Δ16. A. Isothermal titration 
calorimetry of MAT1 with MATV1.  The top graph represent the differential heat released 
during the titration of MATβV1 (236.8 M) with MAT1 (45.1 M). The bottom graph 
represents the fitted binding isotherm (section 4.2.21). B. Formation of MAT(α1)4(βV1Δ16)2 
complex analysed by gel filtration chromatography. Elution profiles of MATα1, MATβV1Δ16 
and MAT(α1)4(βV1Δ16)2. 100 μM of MATα1 was incubated with 50 μM of MATβV1Δ16 for 
one hour at 4 °C (section 4.2.13) prior to injection onto a Superdex 200 10/300. For the controls, 
100 μM of MATα1 and 50 μM MATβV1Δ16 were used. The elution buffer was 25 mM HEPES 
pH 7.5, 200 mM NaCl and 1 mM TCEP. Absorbance at 280 nm was used to measure for the 
presence of proteins.  
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Table 7.1 Thermodynamic parameters of MAT(α1)4(βV1)2 complex formation. Ka is calculated 
from as 1/Kd and is the binding constant (M
-1). The Kd represents the affinity of the reaction 
(M). H binding enthalpy of the interaction in kcal/mol. N is the stoichiometry indicating the 
ratio of the injected macromolecule-cell macromolecule binding.   
   MATV1   MAT1 
[] 236.8 M    45.1 M 
Ka(M
-1) (3.38  0.24) X 105 
Kd(M) (2.96  0.21) X 10-6 
H kcal/mol -9301  140.9 
N 0.325   0.004 
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7.1.3 Mutations in the gating loop increase formation of MATα1βV2 complexes. 
 
The N-terminus of MATβ plays a role in the regulation of MATα2 increasing the overall 
turnover of the enzyme (Fig 5.15), but it is not clear how this occurs. One possibility is that the 
N-terminus is able to interact with the gating loop of the enzyme increasing the rate of turnover. 
Comparing the gating loop of MATα1 and MATα2 only one residue differs, which is Cys120 
in MATα1 and Gly120 in MATα2. Two mutants were produced, MATα1C120A and 
MATα1C120G to see if this point mutation was sufficient enough to allow formation of a stable 
complex with MATβV2. It was also examined if the presence of a reducing agent, TCEP 
affected the complex formation involving MATα1.  
 
In the presence of the reducing agent TCEP, the two mutants of MATα1 (orange and grey) 
were able to form complexes with MATβV1 (Fig 7.7A) and showed no difference compared 
to wild-type MATα1 (blue). For MATβV2, the MATα1 mutants did not cause the majority of 
the proteins to form a complex, but rather MATα1 and MATβV2 remained as separate proteins 
(Fig 7.7B). The MATα1C120A mutant (red) produced a higher level of complex than either 
the wild-type MATα1 (blue) or the MATα1C120G mutant (green). After dialysis overnight to 
remove the reducing agent TCEP, a similar pattern was observed with regards to formation of 
MATα1β complexes.  For MATβV1 both mutants were able to form MATα1β complexes just 
like the wild-type (Fig 7.8A). However, for MATβ2 the majority of the proteins eluted as 
separate proteins with a small population of protein eluting as a complex. Again the 
MATα1C120A mutant produced a larger proportion of complex than the wild-type or the 
MATα1C120G mutant (Fig 7.8B).  
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Figure 7.7. The effect of the presence of the reducing agent, TCEP, on complex formation 
of wild type and mutant MATα1β complexes. A. Elution profiles of MAT(α1)4(βV1)2, 
MAT(α1C120A)4(βV1)2, MAT(α1C120G)4(βV1)2 and MAT(α2)4(βV1)2. B. Elution profiles 
of MAT(α1)4(βV2)2, MAT(α1C120A)4(βV2)2, MAT(α1C120G)4(βV2)2 and MAT(α2)4(βV2)2 
For all reactions, 100 μM of the catalytic MATα protein (MATα1, MATα1C120A, 
MATαC120G or MATα2) were incubated with 50 μM of either, MATβV1 or MATβV2 for 
one hour at 4 °C (section 4.2.13) prior to injection onto a Superdex 200 10/300. The elution 
buffer was 25 mM HEPES pH 7.5, 200 mM NaCl and 1 mM TCEP. Absorbance at 280 nm 
was used to measure for the presence of proteins. 
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Figure 7.8. The effect of the absence of the reducing agent, TCEP, on complex formation 
of wild type and mutant MATα1β complexes. A. Elution profiles of MAT(α1)4(βV1)2, 
MAT(α1C120A)4(βV1)2, MAT(α1C120G)4(βV1)2 and MAT(α2)4(βV1)2. B. Elution profiles 
of MAT(α1)4(βV2)2, MAT(α1C120A)4(βV2)2, MAT(α1C120G)4(βV2)2 and MAT(α2)4(βV2)2 
Proteins were dialysed overnight into 25 mM HEPES pH 7.5, 200 mM NaCl to remove the 
reducing agent TCEP. For all reactions, 100 μM of the catalytic MATα protein (MATα1, 
MATα1C120A, MATαC120G or  MATα2) were incubated with 50 μM of either, MATβV1 or 
MATβV2 for one hour at 4 °C (section 4.2.13) prior to injection onto a Superdex 200 10/300. 
The elution buffer was 25 mM HEPES pH 7.5, 200 mM NaCl. Absorbance at 280 nm was used 
to measure for the presence of proteins. 
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7.1.4 Attempted crystallisation of MAT(α1)4(βV1)2 
 
In order to try and crystallise MAT(α1)4(βV1)2 crystallisation trials were set up using a number 
of commercial screens. Several different conditions produced crystals including 0.1 M sodium 
HEPES pH 7.5, 0.06 M MgCl2+ CaCl2, 37.5% MPD, PEG 1K and PEG3350 (Fig 7.9A), 0.05 
M HEPES Sodium pH 7.0, 0.005 M magnesium chloride hexahydrate and 25 % (v/v) PEG550 
(Fig 7.9B), 0.01 M zinc chloride, 0.1 M MES pH 6.0 and 20 % (v/v) PEG 6000 (Fig 7.9C). 
Although multiple crystals were produced all were of MATα1 alone and not in complex with 
MATβV1. For the aforementioned crystals a protein concentration of 6.0 mg/mL was used and 
crystals were grown at 25 °C and appeared after 1 day. 
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Figure 7.9. Pictures of MATα1 crystals that appeared in wells contains of 
MAT(α1)4(βV2)1. A. 0.1 M Sodium HEPES pH 7.5, 0.06 M MgCl2+ CaCl2, 37.5% MPD, PEG 
1K and PEG3350. B. 0.05 M HEPES Sodium pH 7.0, 0.005 M magnesium chloride 
hexahydrate and 25 % (v/v) PEG550. C. 0.01 M zinc chloride, 0.1 M MES pH 6.0 and 20 % 
(v/v) PEG 6000.  
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7.2 Discussion  
Looking at the structure of the MAT(α2)4(βV2)2 complex it is difficult to understand why, in 
vivo, MATβ has so far been found to only interact with MATα2, even though MATα1 and 
MATα2 have a sequence identity of 84 % and share the same folding. A plausible explanation 
may be that in in vivo when the expression of MAT1A is switched on MAT2A and MAT2B 
expression is switched off and that MATα1 and MATβ are not expressed in sufficient amounts 
to interact. In adult hepatocytes MAT1A is highly expressed and the expression of MAT2A and 
MAT2B is low. In contrast during hepatocellular carcinoma,  where the expression of MAT2A 
and MAT2B is turned on, as well as the expression of other proteins that interact with MATβ 
such as HuR, GIT1, MEK, ERK or MafK (Xia et al. 2010; Peng et al. 2014; Katoh et al. 2011), 
MAT1A expression is low or absent (Lu & Mato 2012). Accordingly, the formation of the 
MAT(1)4(βV1)2 complex upon incubation of MATβV1 with MAT1 was observed through 
gel filtration and ITC (Fig. 7.4; 7.6A; Table 7.1). The interaction between MATα1 and 
MATβV1 is a lot weaker than the interaction of MATα2 with MATβV1 suggesting the 
differences between MATα1 and MATα2 are sufficient to affect the formation of the MATαβ 
complexes. Also, this would support the lack of MATα1β complexes in vivo if MATβ 
preferentially binds MATα2. Remarkably, we did not observe a strong interaction by gel 
filtration between MATβV2 with MAT1 (Fig. 7.5), indicating a role of the N-terminus of 
MAT in providing the stability of the MAT1β complex. MATβV1 and MATβV2 share high 
sequence identity (95 %) and only differ in the N-terminal region (Fig 7.2), and within this 
region there is no consensus or similarity between the isoforms. MATβV1 has a longer N-
terminal region (21 residues) than MATβV2 (10 residues).  
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 To confirm this hypothesis, a truncated version of MATV1 lacking the first 16 amino acids 
(MATV116) was generated. This mutant produces much smaller amount of complex with 
MAT1, supporting the hypothesis that the MAT N-terminus is indeed important for the 
formation of stable MAT1 complexes (Fig. 7.6B). This is different from the interaction with 
MATα2, where the deletion of the MATβV1 terminus did not reduce the formation of the 
MATαβ complex. 
 
Closer examination of the sequence of human catalytic MATs revealed that the differences 
between these two proteins were spread out throughout the whole sequence (Fig 7.1A). 
Mapping these differences onto the crystal structure of MATα2 (2P02) reveals that these 
mutations are spread out over the protein, with the majority of them being on the exposed 
surface rather than the surface that is used to form the dimer (Fig 7.1B-C).Interestingly, a 
residue in the gating loop, at position 120, is different between the proteins being a cysteine in 
MATα1 and glycine in MATα2. The structure of these two amino acids differ with cysteine 
having a larger functional group containing a methyl and a thiol compared to glycine, whose 
sidechain is a hydrogen. As it was shown that the N-terminus has a role in the activity of 
MATαβ it was hypothesised that the N-terminal could have a direct role in the interaction with 
the gating loop and if this was the case then mutating residue C120 of MATα1 may stabilise 
the formation of the complex. Mutating this cysteine residue to glycine, as it is in MATα2, did 
not have an effect on the amount of complex that was formed with either MATβ isoform (Fig 
7.7). When Cys120 was mutated to an Ala120 the amount of MAT(α1)4(βV2)2 formed was 
increased (Fig 7.7B) supporting the idea that the MATβ N-terminus interacts with the gating 
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loop promoting stability of the complexes and that the small differences in the lengths of the 
MATβ isoforms is sufficient to effect the formation of the MATαβ.   
 
As the MAT(α1)4(βV1)2 complex was able to be formed via gel filtration crystallisation of this 
protein complex was attempted. A wide range of commercial crystallisation screens were 
available to test but in order to try and reduce the number that were initially tried poly-ethylene 
glycol (PEG) based screens were tried first.  Analysis of all the available crystal structures of 
protein-protein complexes by Radaev and Sun revealed that protein-protein complexes seem 
to favour PEG based solutions. In fact 71 % of protein-protein complexes crystallised have 
PEG based conditions (Radaev & Sun 2002; Radaev et al. 2006). Also, through ITC it was 
shown that  MATα1 had a lower affinity for MATβV1 compared to the affinity MATα2 had 
for MATβV1 or MATβV2 (Fig 5.11, 7.6A, Table 5.6 & 7.1) and PEG based screens seemed a 
suitable choice as lower affinity complexes seem to favour PEGs over, salts and organic 
solvents.   
 
Several conditions, which all contained various PEGs, produced protein crystals but upon 
testing them all were revealed to be of MATα1 only. After this, other screens which were not 
PEG based were tried and did not result in crystals, also protein concentration and temperature 
were varied but no crystals containing the complex MAT(α1)4(βV1)2 were ever obtained. From 
the structure of the MAT(α2)4(βV2)2 structures the N-terminal region of MATβV2 was 
disordered highlighting the flexible nature and also, to note, no crystals of MAT(α2)4(βV1)2 
were obtained suggesting that the moving N-terminus of the MATβV1 may be effecting the 
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likelihood of crystal formation. Crystallisation of MAT(α1)4(βV2)2 was not tried as only a 
small amount of protein formed complex upon incubation together showing a very unstable 
and weak interaction. It was interpreted that this protein complex would have destabilised in 
solution and not crystallised as a complex.  
202 
 
 
 
 
7.3 Results-Interaction of GIT1 and MATβ 
7.3.1 Purification of full length GIT1 and analysis by trypsin digest. 
 
Full length human GIT1 was cloned into the pet_SUMO vector as described in section 4.2.8 
and was expressed in E.coli. Full length GIT1 was produced and was present in the soluble 
fraction after cell lysis. It was purified by nickel affinity chromatography, but appeared smaller 
than the predicted molecular weight of 107 kDa (with a sumo and histidine tag) and after 
incubation with SENP2, the protease for the SUMO tag, caused no change in migration on 
SDS-PAGE (Fig 7.10A). Different concentrations of full length GIT1 were run on SDS gel and 
selected bands were analysed for protein identification by peptide mass fingerprinting, which 
was carried out by the proteomic platform of CIC bioGUNE. Two bands, highlighted by red 
boxes were tested and both corresponded to GIT1 protein but of different lengths. Band 1, 
which showed low levels was of full length GIT1 whilst band 2 corresponded to GIT1 which 
had degradation from the C-terminus (661 amino acids).      
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Figure 7.10. SDS gels of full length GIT1 protein. A. SDS-PAGE showing cell lysis and 
purification by nickel affinity chromotography of full-length human GIT1. B. SDS-PAGE 
showing GIT1 purified after incubation with the protease SENP2 loaded with different volumes 
(5-20 μL). Red boxes show bands that were analysed by peptide mass fingerprinting by the 
proteomic platform at CIC bioGUNE. Band 1 corresponded to the full length GIT1 (761 amino 
acids) whilst band 2 corresponded to a 661 amino acid protein that had degraded from the c-
terminal.   
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7.3.2 Production and purification of GIT1_P491stop and GIT1_R413stop. 
 
From analysis by peptide mass fingerprinting and looking at the predicted domain stuctures of 
full length GIT1 (Fig 1.9) two mutants were produced in which a stop codon was introduced 
after a certain residue: GIT1_P491stop and GIT1_R413stop. Again, like full length GIT1 both 
shorter constructs were expressed in E.coli and were soluble upon cell lysis.  GIT1_P491stop 
after incubation with SENP2 shows a shift in size upon SDS-PAGE suggesting that the SUMO 
tag has been removed (Fig 7.11A), but after overnight dialysis and injection into an ion-
exchange coloumn GIT1_P491stop had degraded which may have occurred due to a host 
protease and as a result it could not be seen on the SDS-PAGE (Fig 7.11B, C).  After overnight 
dialysis and injection into an ion-exchange coloumn GIT1_R413stop showed to be stable and 
produced a narrow peak (Fig 7.12A). When fractions corresponding to this peak were run on a 
SDS-PAGEl it showed the presence of GIT1_R413stop protein (Fig 7.12B). These fractions 
were then concentrated and injected into gel filtration coloumn and produced one peak which 
corresponded to a molecular weight of ~49 kDa (Fig 7.12C, D), which was the expected mass 
of GIT1R413_stop.   
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Figure 7.11. Purification of GIT1_P491stop. A. SDS-PAGE of cell lysis, nickel affinity 
chromotography and SENP2 digest of GIT1_P491stop (section 4.2.14). B. UV trace of ion-
exchange of GIT1_P491stop after overnight dialysis into 25 mM Tris pH 8.0, 50 mM NaCl, 
10 mM BME whereby GIT1_P491stop does not seem to present. C. SDS-PAGEof fractions 
from ion exhange showing that GIT1_P491stop is no longer present as no band around 56 kDa 
can be seen.. 
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Figure 7.12. Purification of GIT1_R413stop. A. UV trace of ion-exchange of 
GIT1_R413stop after overnight dialysis into 25 mM Tris pH 8.0, 50 mM NaCl, 10 mM BME. 
B. SDS-PAGE of GIT1_R413stop after ion-exchange showing the presence of the protein in 
fractions 60.0-68.0 mL. C. UV trace from thegel filtation of GIT1_R413stop from fractions 
60.0-68.0 mL that were combined and injected into a superdex 200 10/60.tThe gel filtration of   
GIT1_R413stop showed one peak only. D. Corresponding SDS-PAGE of fractions from 76.0-
90.0 mL  showing purified GIT1_R413stop.Details of purification can be found in section 
4.2.14. 
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7.3.3 Pull down experiments with His_tagged MATβ proteins. 
 
The N-terminal histidine tagged MATβ proteins were  used to perform pulldown experiments. 
Briefly, either MATβV1 or MATβV2 were immoblised by nickel resin and then five times 
excess of GIT1_R413stop was incubated with the resin for one hour. A low imidazole buffer 
(40 mM imidazole, buffer 2) was applied to the resin to remove nonspecific binding. As MATβ 
proteins bind NADP this experiment was performed in the presence and absence of NADP. 
For MATβV1 most of the GIT1_R413stop is removed from the resin upon wash with buffer 2 
(Fig 7.13A, lane 3) and MATβV1 is removed upon washing with 250 mM imidazole (Fig 
7.13A, lane 5). This was the same in the presence of NADP (Fig 7.13A, lanes, 6-9). A small 
band can be seen above MATβV1 (Fig 7.13A Lanes 5 & 9) suggesting the presence of 
GIT1_R413stop, which maybe interact with MATβV1. To see if GIT1_R413stop could stay in 
the resin with the absence of MATβ a control whereby GIT1_R413stop was loaded in the 
absence of MATβ and the elution profile can be view in lanes 10-13. This shows that a small 
amount of GIT1_R413stop is eluted with 250 mM Imidazole and that this suggests that 
MATβV1 and GIT_R413stop do not interact. His_MATβV1 is an unstable protein and this is 
visible by multiple bands (Fig 7.13A, lane 14) which makes it harder to state if the two proteins 
are interacting. The experiment with MATβV1 resulted in the same outcome to that of 
MATβV2 (Fig 7.13B). 
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Figure 7.13. SDS gels of pull down experiments with N-terminally histidine tagged MATβ 
proteins and GIT1_R413stop. Note GIT1 refers to GIT1_R413stop. Experiments were 
performed in the presence and absence of NADP. A. SDS-PAGE of Pull down of 
GIT1_R413stop with His-MATβV1 with and with out NADP. B. As in A but with MATβV2. 
Briefly, 50 μM of His-MATβV1 or MATβV2 ± 100 μM NADP were incubated with nickel 
resin, that had be equilibrated with 25 mM HEPES pH 7.5, for 1 hour before being loaded into 
2 mL flow column. Next, the GIT1_413Stop (50 μM) was passed through the column and the 
flow-through was collected. A low imidazole (25 mM HEPES pH 7.5, 40 mM imidazole) wash 
was applied to remove no specific binding. An elution buffer containing 25 mM HEPES pH 
7.5 and 250 mM imidazole was applied to the column and the flow-through was collected.    
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7.3.4 Complex formation studies of GIT1_R413 and MATβ proteins. 
 
As pulldown experiments were inconclusive another approach was taken to see if 
GIT_R413stop was able to interact with MATβ.  GIT1_R413stop was pre-incubated with 
either MATβV1 or MATβV2 with and without NADP and then injected into a gel filtration 
column. For MATβV1, no interaction with GIT1_R413stop was seen, as the elution profile of 
the mixture of proteins (blue) was equal to the individual proteins (purple and green; Fig 
7.14A). MATβV1 eluted at 15.5 mL which is typical for this protein whilst GIT1_R413stop, 
which is larger than MATβV1 eluted at ~15 mL. The results were the same in the presence of 
NADP, there was no shift in the peak (red) and excess NADP eluted at ~20 mL (Fig 7.14A). 
Fractions of the peaks were run on SDS-PAGE (Fig 7.14B), and show that the two proteins are 
not interacting as the maximum concentration of each protein are in different fractions. The 
same pattern was observed with MATβV2 (Fig 7.15). 
GIT1 is a GTPase activating protein, to see if binding GMPPNP to GIT1_R413stop would 
enable interaction with MATβ, GIT1_R413stop was incubated overnight with EDTA and 
GMPPNP. Before the gel filtration experiments MgCl2 was added. The incubation with 
GMPPNP had no effect on the formation of a complex with either MATβV1 or MATβV2 (Fig 
7.16 & Fig 7.17). With both isoforms of MATβ the proteins eluted in the same volume 
regardless on the presence of GIT_R413stop. Excess GMPPNP eluted at 21 mL slightly after 
NADP. Again, running the peak of the GIT1_R413stop and MATβ on SDS PAGE shows that 
both proteins elute at different volumes with the peak of each protein eluting in separate 
fractions (Fig 7.16B & Fig 7.17B) once again indicating the lack of the formation of a complex.  
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Figure 7.14. Interaction studies between MATβV1 and GIT1_R413stop. A. Gel filtration 
profiles of MATβV1, GIT1_R413stop, MATβV1 and GIT1_R413stop in the presence and 
absence of 100 μM NADP. Proteins were incubated for 1 hour at 4 °C, prior to gel filtration in 
25 mM HEPES pH 7.5, 200 mM NaCl, 10 mM MgCl2, 10 mM KC l± 100 μM NADP.No shift 
was observed when MATβV1 and GIT1_R413stop were incubated together suggesting no 
complex has formed. B. SDS-PAGE of fractions of the MATβV1+GIT1_R413stop showing 
that the proteins eluted at different volumes. GIT1 refers to GIT1_R413stop whist V1 refers to 
MATβV1. C4-C8 refers to 14.5-16.5 mL in fractions of 0.5 mL. All protein concentrations 
were 50 μM.  
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Figure 7.15. Interaction studies between MATβV2 and GIT1_R413stop. A. Gel filtration 
profiles of MATβV2, GIT1_R413stop, MATβV2 and GIT1_R413stop in the presence and 
absence of 100 μM NADP. Proteins were incubated for 1 hour at 4 °C, prior to gel filtration in 
25 mM HEPES pH 7.5, 200 mM NaCl, 10 mM MgCl2, 10 mM KC l± 100 μM NADP. No shift 
was observed when MATβV2 and GIT1_R413stop were incubated together suggesting no 
complex had formed. B. SDS-PAGE of fractions of the MATβV2+GIT1_R413stop showing 
that the proteins eluted at different volumes. GIT1 refers to GIT1_R413stop whist V2 refers to 
MATβV2. C4-C8 refers to 14.5-16.5 mL in fractions of 0.5 mL. All protein concentrations 
were 50 μM. 
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Figure 7.16. Interaction studies between MATβV1 and GIT1_R413stop. A. Gel filtration 
profiles of MATβV1, GIT1_R413stop, MATβV1 and GIT1_R413stop in the presence and 
absence of 100 μM NADP and the presence of 200 μM GMPPNP. Proteins were incubated for 
1 hour at 4 °C, prior to gel filtration in 25 mM HEPES pH 7.5, 200 mM NaCl, 10 mM MgCl2, 
10 mM KCl ± 100 μM NADP and/or 200 μM GMPPNP No shift was observed when MATβV1 
and GIT1_R413stop are incubated together suggesting no complex has formed. B. SDS-PAGE 
of fractions of the MATβV1+GIT1_R413stop showing that the proteins eluted at different 
volumes. GIT1 refers to GIT1_R413stop whist V1 refers to MATβV1. Note all fractions that 
were run on the SDS-PAGE above contained GMPPNP. C4-C8 refers to 14.5-16.5 mL in 
fractions of 0.5 mL. All protein concentration were 50 μM. 
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Figure 7.17. Interaction studies between MATβV2 and GIT1_R413stop. A. Gel filtration 
profiles of MATβV2, GIT1_R413stop, MATβV2 and GIT1_R413stop in the presence and 
absence of 100 μM NADP and the presence of  200 μM GMPPNP. Proteins were incubated for 
1 hour at 4 °C, prior to gel filtration in 25 mM HEPES pH 7.5, 200 mM NaCl, 10 mM MgCl2, 
10 mM KC l± 100 μM NADP and/or 200 μM GMPPNP. No shift was observed when MATβV2 
and GIT1_R413stop are incubated together suggesting no complex has formed. B. SDS-PAGE 
of fractions of the MATβV2+GIT1_R413stop showing that the proteins eluted at different 
volumes. GIT1 refers to GIT1_R413stop whist V2 refers to MATβV2. Note all fractions that 
were run on the SDS gel above contained GMPPNP. C4-C8 refers to 14.5-16.5 mL in fractions 
of 0.5 mL. All protein concentrations were 50 μM. 
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7.3.5 Structural studies of GIT1_R413stop  
 
As GIT1_R413stop was stable and appeared homogeneous in solution HPLC-SAXS was 
performed in order to determine the size of this 3 domain mutant. During data collection the 
radius of gyration remained stable and only a single peak was observed indicating a monomeric 
species (Fig 7.18A). The data collected was averaged from the frames 105-125 and produced 
a scattering curve, which was discrete up till a scattering angle of 0.4 Å-1 (Fig 7.18A).  After 
processing the scattering data to generate a DAMMIN envelope a low resolution model was 
created (Fig 7.18C-D). Using the scattering curve of GIT1_R413stop a predicted molecular 
weight was produced of 47.5 kDa which is very close to the molecular weight of 
GIT1_R413stop of 49 kDa. 
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Figure 7.18. Solution scattering of GIT1_R413stop. A. Data collection of GIT1_R413stop 
showing I(0) and radius of gyration allowing for selection of frames to be used in data 
processing. Frames were chosen for data processing based upon the stability of the radius of 
gyration with frames that had a stable radius of gyration being used. B. Average 1D scattering 
curves of frames 105-125 for GIT1_R413stop up to 0.4 Å-1 scattering angle. C. Average 
DAMMIN model of GIT1_R413stop. D. As in C but with a 90° rotation. Section 4.2.23 has 
further details on SAXS processing.   
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7.3.6 Homology modelling of GIT1_R413stop  
 
There is no structure of the human GIT1 protein known and only two domains, the coiled coil 
and paxillin binding domain, have been individually solved. To find suitable models for the 
three domains of GIT1_R413stop (Fig 7.19A) the sequence of each domain was run in the 
server Homology Detection & Structure Prediction by HMM-HMM comparison (HHPRED) 
(Söding et al. 2005). Three structures were selected (Table 7.2) and used in combination with 
the CORAL programme of the SAXS suite(Petoukhov et al. 2012) . CORAL produced a model 
with which when compared to the scattering data shows close agreement (X2=2.26, Fig 7.19B). 
Linker regions are modelled as spheres which tries to account for the residues between the 
domains and each ball being a protein Cα (Fig 7.19C). Alignment with the envelope generated 
by DAMMIN using SUPCOMB does show a good fit for the domains but not for the linker 
regions (Fig 7.19D).  
 
Table 7.2. List of protein structures used in the modelling of GIT1_R413stop.  
Domain  PDB reference  Protein identity  
GAP 2IQJ GAP domain of SMAP1L (LOC64744) stromal membrane-
associated protein 1-like 
ANK 1N0Q A designed ankyrin repeat protein with three identical 
consensus repeats. 
SHD 2L7K Protein CD1104.2 from Clostridium difficile. Uncharacterised 
protein. 
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Figure 7.19. Modelling of GIT1_R413stop using predicted structural homologs of GIT1. 
A. Schematic of the domains of GIT1_R413stop showing the GTPase-activating domain 
(GAP), ankyrin domain (ANK) and the Spa2-homology domain (SHD). B. Comparative 
representation of 1D scattering data against the predicted 1D scattering curve produced from 
the CORAL model of GIT1_R413stop (X2=2.26). C. CORAL model of GIT1_R413stop with 
domains shown as cartoons and linker regions shown as balls. Forest shows GAP domain, 
purple shows ANK domain and blue shows SHD domains. D. SUPCOMB alignment of 
DAMMIN model and CORAL model of GIT1_R413stop.   
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7.4 Discussion  
MATβ proteins can interact with other proteins, such as HuR and are involved in pathways that 
are independent from SAMe including regulation of growth and apoptosis (Xia et al. 2010; 
Martínez-Chantar et al. 2003; Yang et al. 2008). G protein-coupled receptor kinase interacting 
ArfGAP 1 (GIT1) has been shown to interact with MATβ (Peng et al. 2014; Peng et al. 2015), 
but little information is known about the structure of GIT1 or the functional significance of this 
interaction. 
 
G protein coupled receptors (GPCRs) are among the largest gene families in the mammalian 
genome which when activated by GPCR ligands initiate signal transduction through G proteins. 
One class of G proteins are the GPCR kinases (GRKs), which play a vital role for receptor 
phosphorylation and internalisation (Hoefen & Berk 2006). Proteins known as GRK-
interacting proteins (GITs), a family of scaffolding proteins (Premont et al. 1998), can interact 
with GRKs. GITs can bind paxillin, a focal adhesion protein (Turner et al. 1999) and 
phospholipase Cγ (PLCγ) (Haendeler 2000) amongst others. The GIT family of proteins have 
a complex domain organisation and structure and different domains can bind to different 
proteins. The role of GITs appears to be in the control of cytoskeletal dynamics and membrane 
trafficking between the plasma membrane and recycling endosomes (Hoefen & Berk 2006).  
 
Mammals and birds express two GITs, GIT1 and GIT2, both which are highly conserved across 
both mammals and avians. For example, human and mouse GIT1 have a 98% identity whilst 
human GIT1 and GIT2 have a 65% sequence identity. GITs can form homo and heteroligomers 
and are found at the cell periphery in focal complexes, focal adhesions on the basal surface of 
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the cell and throughout the cell at cytoplasmic structures including lamellipodium (Di Cesare 
et al. 2000; Loo et al. 2004; Manabe et al. 2002; Mazaki et al. 2001; Paris et al. 2003; Turner 
et al. 1999; West et al. 2001; Zhao et al. 2000). GIT1 has one form whilst GIT2 has at least 10 
splice variants giving rise to up to 32 transcripts (Premont et al. 2000). The full length GIT 
proteins have an N-terminal ARF-GTPase activating (ARF-GAP) domain, three ankyrin 
(ANK) repeats, a Spa2-homology domain (SHD), a coiled-coil (CC) domain which is 
important for dimerisation and a paxillin-binding site (PBS) (Figure 7.20).   
 
 
 
Figure 7.20 GIT1 and GIT2 domain structure. The full-length GIT proteins have an N-
terminal ARF GTPase-activating protein (ARF- GAP) domain, three ankyrin (ANK) repeats, 
a Spa2-homology domain (SHD), a coiled-coil (CC) domain and a paxillin-binding site (PBS). 
The truncated GIT2-short protein lacks the CC domain and PBS. Figure taken from Hoefen & 
Berk 2006. 
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As MAT2β is known to interact with other proteins apart from MATα2 including GIT1 and 
RAS (Peng et al. 2014; Peng et al. 2015) producing recombinant GIT1 protein in order to 
characterise this interaction seemed like a logical step, but unfortunately there were problems 
in producing the full length protein. GIT1 full length expressed in bacterial system but the 
histidine tag was unable to be cleaved. Peptide mass fingerprinting revealed that the full length 
protein was unstable and a majority of the protein degraded from the C-terminal to around a 
75 kDa protein. In the PET_Sumo vector there is an N-terminal histidine tag and SUMO tag 
which relies on specific folding to be cleaved by the protease SENP2. SENP2 binds to specific 
secondary structure to cleave so if the cleavage site has not folded correctly or it is not 
accessible, it cannot cleave. This was the case for full length GIT1. A possible reason for this 
is that full length GIT1 contains 5 domains, as shown in Fig 1.9, including a coiled coil region 
important for dimerisation and a C-terminal paxillin-binding domain, which both may prevent 
cleavage. Peptide mass fingerprinting of full length GIT1 after nickel affinity chromatography 
revealed degradation of the protein from the C-terminus. The two C-terminal stop mutants, 
GIT1_P491stop and GIT1_R413stop, which again like the wild-type overexpressed in E.coli, 
but unlike the wild type the tag was able to be removed. Both mutants lack the C-terminal 
paxillin-binding domain, which may have caused prevention of cleavage.  
 
All experiments were done in both the presence and absence of NADP as MATβ contains a 
NADP binding domain (Shafqat et al. 2013). NADP is not needed in terms of the MATαβ 
complex as shown by ITC, kinetic and gel filtration (Fig 5.16; 5.17; Table 5.9) (Murray et al. 
2014; Pajares et al. 2013) but it may be needed to form GIT1_MATβ complexes. The pull 
down experiments were inconclusive as a small band could be seen at the molecular mass of 
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GIT1_R413stop in the elution with His-MATβV1, but this band also appeared when the His-
MATβV1 was run alone and also in the GIT1_R413stop control where MATβ was absence 
from the pull down. From this it could mean a small amount of GIT1_R413stop was pulled 
down, or it was just His-MATβV1 alone or even some GIT1_R413stop bound non-specifically 
to the nickel resin. Whether GIT1_R413stop and MATβ were able to interact remains a 
question. Another approach to answering this question was to use gel filtration, but this did not 
show evidence of  complex formation.  With GIT1_R413stop no complex was observed and 
incubation with NADP had no effect.  It cannot be ruled out that NADP is needed to aid binding 
of MATβ to GIT1, as the truncated construct lacks two domains, which may be important for 
complex formation. The MATβ binding site may only be created upon oligomerisation of GIT1 
via its coiled coil domain or it may bind to the paxillin-binding domain. Expression and 
purification of a stable full length GIT1may be able to help answer these questions.  
 
SEC-SAXS showed that GIT1_R413stop was a homogeneous species as radius of gyration  
remained constant during data collection and the only one peak appeared on gel filtration (Fig 
7.18A). As GIT1_R413stop lacks the dimerisation domain this is consistent with the protein 
being monomeric. The molecular mass generated from SAXS experimentation was 47 kDa, 
which is extremely close to the molecular weight of the protein at 49 kDa. HHPRED (Söding 
et al. 2005) allowed for the identification of structures that share structural homology with the 
predicted structure of GIT1. Having three protein domain structures enabled the possibility of 
modelling GIT1_R413stop against the SAXS data that were collected. Linker regions were 
added during the modelling to take into account the spaces between each domain. Each ball 
represents a protein Cα but they do not take into account any secondary structure that might 
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form making the model larger and more spaced out than it may be (Fig 7.19C). The selected 
protein structures do not share high sequence identity (20-30 %)to that of GIT1_R413stop, but 
they were selected as they shared high predicted structural homology. ANK domains mediate 
protein-protein interactions and show no consensus in binding motifs, but share high structural 
homology (Turner et al. 1999). The SHD domain is a tandem repeat present in orthologs of 
yeast Spa1 and Spa2 proteins (Arkowitz & Lowe 1997; Gehrung & Snyder 1990) but here, the 
two SHD domains were modelled using an uncharacterised protein from Clostridium difficile 
because it showed a better agreement with the target sequence.  
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Chapter VIII: Conclusions and future directions  
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8.1 New nomenclature for Methionine Adenosyltransferases  
 
The research from this PhD thesis has led to the discovery of several new MAT complexes that 
had not been described previously as well as evidence supporting that the catalytic proteins 
have several oligomeric states. Kotb et al in 1997 gave a rational to nomenclature of MAT 
enzymes. This has been updated in view of new discoveries presented in this thesis and those 
recently reported by others (Murray et al. 2014; Yang et al. 2008). In mammals the three genes 
MAT1A, MAT2A and MAT2B encode the catalytic subunits MAT1, MAT2 and the 
regulatory subunit MAT respectively. MAT1 and MAT2 subunits can self oligomerise to 
form either dimers or tetramers and can be simply and correctly be referred to referring to their 
oligomeric state. For example MATα2 can be referred as MAT(2)2 and MAT(2)4 to 
represent the dimeric and tetrameric forms of the same enzyme (Fig. 8.1A). On the other hand, 
MAT2B encodes four isoforms, MATV1, MATV2, MATV2a and MATV2b. Although 
only MATV1 and MATV2 have been studied in detail the other two isoforms MATV2a 
and MATV2b should be monomeric too, as MATV2a shares a 94.7 % sequence identity 
with MATβV2, and MATβV2b is a truncated version of MATβV2a (Fig. 8.1A). The catalytic 
subunits can form complexes with the regulatory subunits forming hexameric complexes and 
giving rise to the MATαβ complexes. This group of complexes can be split into MATα1β and 
MATα2β complexes based on which catalytic subunit is involved. Both MATα1β and 
MATα2β complexes can be further divided by which MATβ they bind to give 
MAT(1)4(V1)2, MAT(1)4(V2)2, MAT(2)4(V1)2 and MAT(2)4(V2)2 (Fig. 8.1B). To 
date, no evidence exists for the formation of complexes involving MATV2a and MATV2b. 
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Figure 8.1. Consensus nomenclature of MAT proteins. A. The mammalian genes MAT1A, 
MAT2A and MAT2B encode the catalytic subunits MAT1, MAT2 and the regulatory subunit 
MAT respectively. MAT1 and MAT2 subunits can be organised as dimers and tetramers. 
We propose to use MAT(2)2 and MAT(2)4 notation. On the other hand, MAT2B encodes for 
four isoforms, MATV1, MATV2, MATV2a, MATV2b. B. The catalytic subunits could 
form complexes with the regulatory subunits. The crystallographic structure of 
MAT(2)4(V2)2 complex consists of a MAT2 tetramer flanked by two MATV2 subunits. 
MAT(2)4(V1)2 has been described in vivo (Yang et al. 2008). The other two MAT 
complexes, MAT(1)4(V1)2 and MAT(1)4(V2)2, have been described in vitro (Murray et 
al. 2014). 
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8.2 Future directions 
8.2.1 What small molecules can bind to MATα2?  
 
In sections 6.1.11 and 6.1.12 it was shown that small molecules are able to bind to MATα2 so 
using screening libraries and differential scanning fluorimetry (DSF), a wealth of small, cell 
permeable molecules can be tested against MATα2 to screen for binding. Initial hits would be 
screened further to ensure binding followed by crystallisation with MATα2. MATα2 could be 
crystallised to a very high resolution (~1 Å) as shown in section 6.1.5. Of the molecules that 
bind to the MATβ binding site of MATα2 the effect of these molecules in cell would be 
evaluated in terms of cell growth, formation of the MATαβ complex, levels of the product, 
SAMe, within the cell and protein expression levels. Given the high sequence identity between 
MATα1 and MATα2 successful candidates could be tested on MATα1 to check for binding to 
ensure that catalytic function is unaffected. Kinetic experiments can evaluate whether the rate 
of SAMe production is effected by the presence of the small molecules for both MATα 
isoforms. This would allow for the identification of molecules that both bind the MATβ binding 
cavity of MATα2 and which do not affect the overall kinetics of the enzymes, which then these 
molecules could be used as starting point for structure based drug design.  
 
8.2.2 What are the interactomes of the MAT proteins?  
 
There is increasing evidence that MAT proteins have a wider interactome than just other MAT 
proteins (Yang et al. 2013; Peng et al. 2014; Peng et al. 2015; Katoh et al. 2011). Recombinant 
MAT proteins that contain N-terminal tags could be produced that could be used as a pull down 
tool. These proteins will be immoblised in nickel resin and cell lysate from a range of cell 
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types, including disease and healthy cell lines can be passed through to look for binding 
partners. Mass spectrometry can be used to identify initial hits and then these can be confirmed 
by co-immunoprecipitation. Furthermore, the MAT proteins can be cloned into vectors that 
contain C-terminal tags and once purified subjected to the same procedure as the N-terminal 
tagged proteins. Once a selection of targets has been identified literature searches can be 
performed to evaluate the role of the binding targets within the cell to look for disease related 
proteins. Selected hits can be produced recombinantly, used to form complexes with their 
respective MAT protein and finally their structure determined. 
 
8.2.3 Is there a back gate to the active site of MAT proteins?  
 
 A characteristic of MAT proteins is that the active site contains a ‘gating loop’ that closes the 
active site preventing products and substrates from leaving the active site during catalysis. 
However, during my PhD a number of data sets were collected which contained compounds 
within the active site that were only added during the crystal freezing process. Upon analysis, 
the structures contained a closed gating loop with products of SAMe synthesis and also 
molecules of compounds added after crystallisation e.g., glycerol. If the gate is closed how can 
these compounds enter? The MATβ binding tunnel of MATα2 provides a point of contact 
where the active site has access to the outside of the MATα2 protein, as there is a loop which 
connects the active and this channel. Mutation of this loop could reveal if products can enter 
or leave the active site through this loop. Mutants can be purified, crystallised and molecular 
modelling could be done to look if the size of this ‘back gate’ is changed and if so how it relates 
to the production of SAMe, which can be evaluated by LC-MS (Murray et al 2014).  
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8.2.4 What prompts the release of products from the active site?  
 
It was previously believed that the breakdown of the triple phosphate provided the energy to 
open the closed gating loop, allowing the release of products. In section 6.1.8 it was shown that 
using a modified ATP analogue,  containing a triple phosphate that is unable to be hydrolyzed, 
that it can sit within the active site without have a closed gating loop. Further modelling could 
be done to investigate how substrates are able to leave the active site and to see how the flexible 
gating loop is regulated. The high resolution allows for the placement of many waters within 
the active site and analysis may reveal if these waters are able to aid in the breakdown of the 
triphosphate, which would be consistent with other phosphatases.   
 
8.2.5 Does the interaction site of GIT1 and MATβ lie in the coiled coil domain or the 
Paxillin binding domain? 
 
In section 7.3 it was shown that GIT1, containing only 3 domains, is unable to interact with 
either of the MATβ proteins. In order to explore the site of interaction a full length GIT1 will 
need to be purified and subsequent complex formation with MATβ isoforms. Size-exclusion 
chromatography and isothermal titration calorimetry (ITC) will be used to access formation of 
the complexes. GIT1_MATβ complexes will be structurally characterised by crystallisation 
and SAXS experimentation. There is no structure of GIT1 published so either Single-
wavelength anomalous diffraction (SAD) experimentation will need to be done on the GIT1 or 
if data of the GIT1_MATβ complex is collected then molecular replacement can be attempted 
using MATβ as a search model. As GIT1_R413stop has been purified previously crystallisation 
of this construct can be further tested. The GIT1_413stop plasmid will be transformed into a 
methionine auxotrophic strain of E.coli followed by expression in commercial SelenoMet 
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media. This will be done in order to replace methionine side chains with the selenomethionine 
which will allow for multi-wavelength anomalous scattering to be done to solve the structure 
without a search model (Hendrickson et al. 1990).  
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